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ABSTRACT 
Critical illness increases blood coagulation and therefore patients in the intensive 
care unit (ICU) are prone to venous thromboembolism (VTE), including deep vein 
thrombosis (DVT) and pulmonary embolism (PE). It is recommended to use 
thromboprophylaxis, most commonly with low-molecular-weight heparins 
(LMWHs), as a part of critical care. Nonetheless, despite pharmacological 
thromboprophylaxis, the incidence of DVT is still 5–15%. The guidelines for 
thromboprophylaxis are based on studies conducted in medical and surgical patients 
whereas much less data are available from ICU patients. However, standard 
thromboprophylaxis in critically ill patients may lead to ineffective anticoagulation.  
The main objective of this thesis was to study how to make thromboprophylaxis 
safer and more effective in critically ill patients. In addition, the association of critical 
illness with blood coagulation was investigated. The coagulation status was mainly 
evaluated in patients with aneurysmal subarachnoid hemorrhage (aSAH) who are 
considered high-risk patients for VTE. At the same time, the risk of bleeding persists, 
which makes the delivery of anticoagulation particularly challenging. 
This thesis consists of four studies. Study I was a systematic review of the 
literature, examining 18 original publications where LMWH thromboprophylaxis 
had been monitored with an anti-Xa level measurement in critically ill patients. The 
anti-Xa levels in critically ill patients were lower in comparison with ward patients. 
However, no association was seen with clinical adverse events, e.g., bleeding or VTE.  
In Study II and III, the route of anticoagulation administration was investigated 
in a randomized controlled study. Forty ICU patients were randomized to receive 40 
mg of enoxaparin thromboprophylaxis either as a continuous intravenous infusion 
(CII) over 24 hours or as a subcutaneous bolus (SCB) every 24 hours for 72 hours. 
In Study II, the maximum concentration of anti-Xa was higher with SCB dosing of 
enoxaparin at 0–24 and 0–72 hours than attained with CII. However, at the final 
trough level at 72 hours, the anti-Xa level was higher with CII.  
In Study III, additional blood clotting parameters were analyzed; these included 
prothrombin fragment 1+2 (F1+2), antithrombin, fibrinogen, and D-dimer. 
Moreover, the formation of thrombin was assessed with a calibrated automated 
thrombogram from a subset of patients. The F1+2 levels were lower when CII 
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thromboprophylaxis was used than with SCB.  These results may indicate a more 
pronounced anticoagulation with CII thromboprophylaxis.  
In Study IV, coagulation changes after aSAH were examined by rotational 
thromboelastometry (ROTEM). This study was a prospective observational study 
conducted in 17 aSAH patients and 16 elective neurosurgical patients as controls. 
The main result was that after aSAH, the blood coagulation increased, and this could 
be measured by ROTEM. The increment in blood coagulation seemed to be further 
associated with a worse neurological outcome.  
In conclusion, the reported anti-Xa levels with LMWH thromboprophylaxis were 
not related to clinical events in ICU patients.  When LMWH thromboprophylaxis 
was given as an SCB, the maximum anti-Xa concentrations were higher than with 
CII. However, the CII led to a higher final trough level of anti-Xa and to more 
pronounced factor Xa inhibition. These effects of CII suggest that it results in more 
continuous anticoagulation in ICU patients than can be attained with SCB. Blood 
coagulation increased after aSAH and associated with worse neurological outcomes. 
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TIIVISTELMÄ 
Useimmat tehohoitoon johtaneet sairaustilat lisäävät veren hyytymistaipumusta ja 
altistavat potilaat laskimotukoksille ja keuhkoveritulpille. Tämän vuoksi 
tehohoitopotilailla suositellaan käytettäväksi laskimotukoksia ehkäisevänä 
lääkityksenä pienimolekyylisiä hepariineja (LMWH). Käytetystä estolääkityksestä 
huolimatta laskimotukoksia ilmaantuu 5–15 %:lle potilaista tehohoidon aikana. 
Tämän hetkiset hoitosuositukset pohjautuvat lähinnä vuodeosastopotilailla tehtyihin 
tutkimuksiin ja näyttöä LMWH-valmisteiden käytöstä tehopotilailla on vähän. 
Alustavissa tutkimuksissa on saatu viitteitä, että käytettäessä LMWH-valmisteita 
muilla potilasryhmillä sopiviksi havaituilla annoksilla, saattaa niiden veritulppia 
ehkäisevä vaikutus jäädä tehohoitopotilailla odotettua heikommaksi. 
Väitöskirjatutkimuksen tavoitteena on selvittää, miten laskimotukoksia ehkäisevä 
hoito voitaisiin toteuttaa nykyisiä hoitomuotoja tehokkaammin ja turvallisemmin. 
Lisäksi tutkitaan miten kriittinen sairaus vaikuttaa veren hyytymiseen ja miten tätä 
muutosta voitaisiin monitoroida parhaiten. Tätä tarkastellaan erityisesti äkilliseen 
lukinkalvonalaisen verenvuotoon (subraknoidaalivuoto, SA-vuoto) sairastuneilla 
tehohoitopotilailla, joiden laskimotukoksia ehkäisevän hoidon toteuttaminen on 
haastavaa samanaikaisesti ilmenevän kohonneen verenvuotoriskin vuoksi.  
Väitöskirja koostuu neljästä osatyöstä, joista ensimmäisessä tutkittiin 
systemaattisen kirjallisuuskatsauksen avulla, osoittaako veren hyytymistekijä X:n 
aktiivisuuden estovaikutus LMWH-estolääkityksen tehoa. Tutkimuksessa todettiin, 
että anti-Xa pitoisuudet olivat tehopotilailla suositeltuja matalammat, mutta nämä 
eivät olleet yhteydessä lisääntyneeseen tukostaipumukseen.  
Toinen ja kolmas osatyö perustuivat satunnaistettuun ja kontrolloituun 
tutkimukseen tehohoitopotilailla, jossa selvitettiin, voidaanko laskimotukoksia 
ehkäisevä hoito LMWH-valmiste enoksapariinilla toteuttaa tehokkaammin jatkuvalla 
suonensisäisellä tiputuksella kuin tavanomaisella ihonalaisella annostelulla. Aiempaa 
tutkimustietoa jatkuvan suonensisäisen enoksapariinihoidon soveltuvuudesta 
tehohoitopotilaiden laskimotukosten ehkäisyyn ei ole. Tutkimukseen osallistui 
yhteensä 40 tehohoitopotilasta. Tutkimuksessa todettiin, että ensimmäisen 
vuorokauden aikana veren anti-Xa:n huippupitoisuus oli suurempi ihonalaista 
annostelua saaneilla. Suonensisäistä annostelua saaneilla pitoisuudet pysyivät 
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kuitenkin tasaisempina tutkimuksen ajan ja 72 tunnin kohdalla suuremmalla osalla 
oli havaittavissa veren hyytymisen estovaikutusta vertailuryhmään nähden.  
Kolmatta osatyötä varten potilailta kerättiin pakasteverinäytteitä, joista 
määritettiin tarkempia veren hyytymistä kuvaavia verikokeita, kuten 
protrombiinifragmentti (F1+2), D-dimeeri ja trombiinin muodostuminen. 
Annettaessa enoksapariinia jatkuvana suonensisäisenä tiputuksena veren 
hyytymistaipumus väheni merkitsevästi ihonalaiseen annosteluun verrattuna.  
Neljännessä osatyössä tarkasteltiin prospektiivisella seurantatutkimuksella SA-
vuodon aiheuttamia muutoksia veren hyytymiseen kokoverestä tehtävillä 
trombolelastometria-analyyseillä (ROTEM). SA-vuodon jälkeistä 
hyytymistaipumusta ei ole aiemmin tutkittu ROTEM:n avulla. Tutkimukseen 
osallistui 17 SA-vuotoon sairastunutta tehohoitopotilasta ja vertailuryhmän 
muodostivat 16 elektiivistä aivoleikkauspotilasta. Päälöydöksenä todettiin, että SA-
vuoto lisää veren hyytymistaipumusta, joka on havaittavissa ROTEM-mittauksella. 
Lisääntynyt hyytymistaipumus oli myös yhteydessä myöhäisen aivoiskemian 
ilmaantuvuuteen ja sen seurauksena huonompaan neurologiseen selviytymiseen.  
Väitöskirjatutkimuksen ensimmäinen osatyö osoitti, ettei tavanomainen 
laskimotukoksia ehkäisevä hoito saavuta riittävää estovaikutusta tehohoitopotilailla. 
Osatöiden kaksi ja kolme perusteella näyttäisi siltä, että laskimotukosten estohoitoon 
jatkuvalla suonensisäisellä annostelulla liittyy tehohoitopotilailla tasaisempi 
lääkevaikutus. Tällöin myös veren hyytymisen aktivoituminen vähenee 
tehokkaammin ihonalaiseen annosteluun verrattuna. Osatyön neljä perusteella 
voidaan todeta ROTEM-analyysin soveltuvan lisääntyneen hyytymistaipumuksen 
tunnistamiseen. Kokonaisuutena tutkimustulosten avulla voidaan parantaa 
tehohoitopotilaan hyytymistaipumuksen tunnistamista ja estolääkitykseen liittyviä 
hoitokäytänteitä.  
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1 INTRODUCTION 
Critically ill patients have a high risk of venous thromboembolism (VTE), i.e., deep 
vein thrombosis (DVT) and pulmonary embolism (PE). Without 
thromboprophylaxis, the incidence of DVT is around 30% (Cade, 1982; Fraisse et 
al., 2000; Hirsch et al., 1995). VTE increases morbidity (Cook et al., 2005a; Cook et 
al., 2005b), and in-hospital mortality is relatively high (Bahloul et al., 2010; Patel et 
al., 2005). 
Pharmacological thromboprophylaxis either with low-molecular-weight heparin 
(LMWH) or unfractionated heparin (UFH) is recommended for all patients in the 
intensive care units (ICUs) to prevent VTE unless contraindicated (Gould et al., 
2012; Kahn et al., 2012; Lassila et al., 2016). However, with the recommended 
prophylaxis, the risk of DVT is not completely eliminated but only decreased to 5–
15% (Cook et al., 2011; Fraisse et al., 2000). 
There are multifactorial reasons for the persistent risk for VTE in critically ill 
patients (Cook et al., 2005b). First, thromboprophylaxis might be omitted because 
of the surgical procedure or the concomitant bleeding risk (Lauzier et al., 2014). 
Second, the bioavailability of subcutaneously administered thromboprophylaxis 
might be impaired (Dörffler-Melly et al., 2002; Haas et al., 2005; Priglinger et al., 
2003). Third, it has been claimed that the current thromboprophylaxis regimens 
might be inadequate (Robinson et al., 2013) to overcome the hypercoagulable state 
caused by critical illness (Sivula et al., 2009). 
Monitoring anticoagulation achieved by LMWH thromboprophylaxis is not 
generally advised (Garcia et al., 2012). In some clinical situations, e.g., renal failure 
or obese patients, it is suggested that plasma anti-Xa activity (anti-Xa) should be 
assayed. However, the ability of anti-Xa to predict the bleeding or thrombotic risk is 
limited (Bara et al., 1992). This could partly be explained by the principle of anti-Xa 
measurement method. The anti-Xa level reflects only the inhibitory effect of 
activated coagulation factor X, and for example the direct inhibition of thrombin is 
ignored. Thus, there could be discrepancy between anti-Xa levels and clinical events 
(Walenga et al., 1991). However, there is a lack of evidence to support monitoring 
LMWH anticoagulation with anti-Xa in critically ill patients.  
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Aneurysmal subarachnoid hemorrhage (aSAH) patients are one of the most 
challenging populations for implementing thromboprophylaxis. The risk of VTE is 
high, but at the same time, the bleeding risk persists with potentially life-threatening 
consequences (Fujii et al., 1996; Ray et al., 2009). After the initial bleeding, it is 
known that a hypercoagulation state is present almost immediately (Ettinger, 1970). 
It is not known, however, if these changes can be detected by rotational 
thromboelastometry (ROTEM).  
The primary purpose of the present study was to assess the pharmacokinetics of 
one of the most common LMWHs, enoxaparin, after continuous intravenous 
infusion (CII) in comparison with standard subcutaneous thromboprophylaxis 
dosing in critically ill patients. The measurement of the anti-Xa level, as well as other 
coagulation parameters, were used. Second, the current literature of the anti-Xa 
levels after LMWH thromboprophylaxis were systematically reviewed. Third, the 
coagulation changes after aSAH were prospectively evaluated by ROTEM. 
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2 REVIEW OF THE LITERATURE 
2.1 Overview of the blood coagulation  
Under physiological conditions, blood coagulation is activated when hemostasis is 
needed. This process, however, can be extreme or happen at the wrong location, 
resulting in either venous or arterial thrombosis. These blood clots can further travel 
through the bloodstream as an embolus.  
The process of blood coagulation was previously described either as a waterfall 
(Hoffman et al., 2001) or as an enzymatic cascade (Macfarlane, 1964). These models 
were protein-centric, and they further were refined as the understanding of the 
biochemistry of the coagulation factors improved. Typically, the coagulation process 
has been divided into three pathways. First, the extrinsic pathway, where coagulation 
is initiated by tissue factor (TF) that is located outside of the bloodstream, second, 
the intrinsic pathway where all components of coagulation are in the blood and third, 
the final common pathway where these two pathways interact (Figure 1). 
 
Figure 1.  Coagulation cascade, the classical interpretation. Abbreviations: fXII, coagulation factor 
XII; HMK, high-molecular-weight kininogen; PK, pre-kallikrein; PL, phospholipid; TF, tissue 
factor. Modified from (Hoffman et al., 2001).  
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In the 1990s, this classification was challenged since it did not correlate with in vivo 
observations (Roberts et al., 1992). For example, why does the extrinsic activation 
of factor X (fX) not compensate for the lack of fVIII or fIX in hemophiliacs? 
Furthermore, the extrinsic and intrinsic pathways overlap in several situations. For 
example, the fVIIa/TF-complex can also active fIX (Osterud et al., 1977), thrombin 
can directly activate fXI (Gailani et al., 1993) and activated platelets can provide a 
surface for the activation of fXI (Oliver et al., 1999). Moreover, fXII, high-
molecular-weight kininogen, and pre-kallikrein might not be needed for the 
activation of coagulation (Baglia et al., 1998). Instead, the primary coagulation 
activator seems to be TF (Hoffman et al., 1996). 
 
 
 
Figure 2.  Coagulation cascade, the cell-based interpretation. Abbreviations: TF, tissue factor; vWF, 
von Willebrand factor. Modified from (Hoffman et al., 2001) .  
At the moment the most prevalent model for coagulation is a cell-based system 
(Hoffman et al., 2001). In contrast to the previous models, it emphasizes the role of 
the cellular environment in the clotting. In this model, the coagulation does not 
occur linearly but in the three parallel phases on different cell surfaces, complicating 
the binary classification into extrinsic and intrinsic pathways. Here, the blood 
coagulation is divided into three phases. The first phase is called initiation, where the 
release of TF starts the coagulation process. Under normal conditions, TF is located 
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on most types of extravascular cells, and it does not make any contacts with plasma 
coagulation factors (Banner et al., 1996). During inflammatory states, however, TF 
can be detected in blood by monocytes and endothelial cells. Typically, hemostasis 
is activated when vascular injury allows coagulation factors in plasma to contact with 
extravascular TF-bearing cells. Here fVII binds to TF, and the formed complex 
activates both coagulation, namely fX and fIX, and anticoagulation proteins, e.g. 
proteins C and S (Wildgoose et al., 1989).  Activated fX (fXa) activates fV, and 
together, they can produce a small amount of thrombin from plasma prothrombin 
(Monkovic et al., 1990). However, the majority of the FXa-fV complex is readily 
inhibited by tissue factor pathway inhibitor (TFPI) terminating the thrombin 
formation.  
The second phase involves amplification which takes place on the surface of the 
platelets. Subsequently, the small amount of thrombin formed during the initiation 
phase activates the platelets, fV, fVIII, and fXI (Díaz-Ricart et al., 2000; Monroe et 
al., 1996). This results in the formation of activated platelets with activated cofactors, 
fVa, and fVIIIa bound to their surfaces (Hung et al., 1992). 
The third phase is a propagation on the activated platelets. It begins when the 
fVIIIa/fIXa complex (called “tenase”) activates fX on the platelet surface. FXa is 
now able to form a complex with its cofactor V, which is bound to the platelet 
surface. Together they form a complex (called “prothrombinase”) that eventually 
catalyzes the enzymatic reaction where prothrombin is converted into thrombin 
(Oliver et al., 1999). The propagation phase results in the large-scale formation on 
thrombin. The amount of formed thrombin is proportional to the clot strength. 
During this process, prothrombin fragments 1+2 (F1+2) are formed (Figure 3), and 
the level of F1+2 is an indirect sign of thrombin formation (Schutgens et al., 2004). 
 
Figure 3.  Formation of prothrombin fragments. Abbreviations: fXa, activated coagulation factor X; 
F1+2, prothrombin fragment 1+2. 
Thrombin cleaves fibrinogen, originally called fI, into insoluble fibrin monomer 
(Riedel et al., 2011). These monomers form first oligomers that aggregate forming 
protofibrils. The protofibrils interact with each other, building longer fibrin chains 
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and eventually polymerized fibrin (Weisel et al., 2013). The polymerized fibrin 
completes the blood clot formation together with platelet adhesion and aggregation. 
2.1.1 Regulation of the blood coagulation 
As important as it is to have coagulation initiated, it is as crucial to prevent 
unnecessary clotting.  The vascular endothelium is an essential element in the 
inhibition of blood clotting (Bombeli et al., 1997). It releases anticoagulants such as 
protein S and TFPI and acts as a source of surface-bound proteoglycans, such as 
thrombomodulin (TM) and heparan sulfate proteoglycans. The main action is to 
inactivate thrombin, either inhibiting its function by antithrombin (AT) or binding 
to TM (Cadroy et al., 1997). When the hemostasis is achieved, the formation of blood 
clot is further controlled by fibrinolysis (Marder et al., 2013). During fibrinolysis the 
fibrinolytic system is activated, and fibrin is converted into soluble fibrin degradation 
products, such as D-dimer (Figure 4). The process is activated by proteases, mainly 
tissue-type and urinary-type plasminogen activators, that convert plasminogen into 
active plasmin, which further dissolves fibrine. The main inhibitors of the fibrinolytic 
system are plasminogen activator inhibitor 1, α2-antiplasmin and thrombin-
activatable fibrinolysis inhibitor.  
 
Figure 4.  Degradation of fibrin by plasmin. Abbreviations: fXIIa, activated coagulation factor XII, 
HMK, high-molecular-weight kininogen; PK, pre-kallikrein; tPA, tissue-type plasminogen 
activator; uPA, urinary-type plasminogen activator.  
2.1.1.1 Thrombomodulin-activated Protein C 
TM is a specific receptor for thrombin located on intact endothelial cells. When 
thrombin is bound to TM, its specificity changes and it no longer cleaves fibrinogen 
or activates platelets (Ye et al., 1991). Instead, it becomes a more efficient protein C 
activator. Activated protein C (APC) forms a complex with protein S. This complex 
inactivates fVa and fVIIIa (Fulcher et al., 1984; Walker et al., 1979). Thus, when 
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thrombin acts via APC it is anti-thrombotic when it is localized on healthy, intact 
endothelial cells, preventing unnecessary clot formation. In inflammatory states, the 
expression of TM decreases and this can lead to unnecessary coagulation (Moore et 
al., 1987). 
2.1.1.2 Antithrombin 
AT is a powerful endogenous anticoagulant protein in plasma (Murano et al., 1980). 
It downregulates blood clotting by inhibiting thrombin and other coagulation 
factors, namely fXa and fIXa, (Biggs et al., 1970; Olds et al., 1994). The native 
conformation of AT molecule has only a limited inhibitory activity in coagulation, 
but it is greatly accelerated by heparan sulfate proteoglycans under physiological 
conditions (Damus et al., 1973). Heparan sulfate proteoglycans are located on the 
vascular endothelium and in the underlying matrix, and when they interact with AT, 
conformational changes are induced (Marcum et al., 1984). The pharmaceutical 
principle of the heparins is their ability to induce a similar conformational change in 
the AT molecule (Beeler et al., 1979; Lin et al., 2001). 
Inherited deficiencies in AT increase the risk for venous thrombosis (Egeberg, 
1965). The prevalence is around 0.02 to 0.05%, and disease severity depends on the 
genetic properties of the deficiency (Patnaik et al., 2008; Tait et al., 1994). An 
acquired AT deficiency is more common, a phenomenon occurring in association 
with severe sepsis, trauma, and extracorporeal circulation (White et al., 2001). In 
general, these conditions lead to consumption coagulopathy, resulting in a decline in 
AT levels (Harper et al., 1996). AT levels below 60% of normal have been associated 
with VTE, but supplementation with AT concentrate is controversial or may be even 
detrimental (Warren et al., 2001). 
2.1.1.3 Heparin co-factor 
Heparin cofactor II (HcII) is another type of serpine produced in liver (Tollefsen et 
al., 1981). HcII inhibits thrombin but no other coagulation factors. Both inherited 
and acquired HcII deficiencies have been described (Tollefsen, 2002). However, the 
association of low HcII levels with VTE is unclear and no routine testing is advised 
(Olson, 2002).  
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2.1.1.4 Tissue factor pathway inhibitor 
TFPI can be found mainly from the microvascular endothelium. In plasma, TFPI is 
bound to lipoproteins; it inhibits fXa directly and produces feedback inhibition of 
the fVIIa-TF complex (Broze et al., 1988). The anticoagulant properties of TFPI can 
be further enhanced with heparins (Ho et al., 1997). 
2.2 Natural history of venous thromboembolism   
 
“Phenomena due to the irritation of the vessel and its surroundings;  
Phenomena due to blood coagulation;  
Phenomena due to the interruption of the blood-stream.” 
(Virchow, 1856) 
 
Virchow’s Triad– endothelial damage, hypercoagulability, and venous stasis is the 
classic foundation of the pathophysiology of VTE. It is a vicious circle that activates 
the coagulation cascade and leads further to thrombus formation and propagation.  
Venous thromboembolism presents either as a DVT or a PE. DVTs can be 
further subdivided by the location in which they occur i.e. proximal or distal (Kearon, 
2003). In lower extremities the divider is the knee and in the upper extremities the 
elbow. In addition, classifications into upper and lower extremity DVTs and 
symptomatic versus asymptomatic DVTs have been used.  
The natural history of venous thrombosis typically originates from the calf veins, 
where it might embolize into proximal veins and further to the pulmonary arteries 
causing a PE (Kakkar et al., 1969). The PE, which has been referred to as ”sudden 
breathless sleep”, is the most feared and potentially fatal complication of VTE (Bell 
et al., 1982). In addition, the natural progression from DVT, PEs can arise from 
various sources, e.g. thrombi in the right atrium, amniotic fluid, bone marrow, or 
tumors (BellSimon et al., 1982). Furthermore, there is a rare entity called in situ 
pulmonary artery thrombosis that usually results from blood stasis in the pulmonary 
vasculature (Cha et al., 2015). 
Without adequate treatment, 28% of symptomatic distal DVT will recur within 
90 days’ follow-up, 17% with a proximal extension, and 13% with PE (Lagerstedt et 
al., 1985). Similar results have been observed in postoperative patients in whom 
nearly 30% experienced a distal DVT in the early postoperative period (Kakkar et 
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al., 1969). Without treatment, the thrombosis persisted in 20% of patients, from 
which nearly every fourth had extended into proximal DVT after only 72 hours.   
In medical and surgical patients, the presence of DVT is known to associate with 
coincidental PE in 40 to 50% of cases. Thus, they are often considered as one entity 
(Kakkar et al., 1969; Moser et al., 1994; Nielsen et al., 1994). Especially with proximal 
DVT, there is a severe risk for subsequent PE (Moser et al., 1981a). Majority of these 
PEs are asymptomatic (Moser et al., 1994; Nielsen et al., 1994). In mechanically 
ventilated ICU patients who required a chest CT scan, the prevalence of PE was 
19% with a concurrent DVT rate of 33% (Minet et al., 2012). Though the lower 
extremity DVTs are strongly associated with PE, it is not precisely known how many 
of the proximal DVTs embolize from the lower extremity veins into the pulmonary 
arteries to form a PE.  
2.3 Prevalence and incidence of venous thromboembolism in 
critically ill patients  
 
ICU patients have a higher risk of DVT than other hospitalized patients (Attia et al., 
2001; Cade, 1982). The used definition of prevalent DVT in critically ill patients has 
varied from 6 hours to two days after the ICU admission (Cook et al., 2005b; Cook 
et al., 2011; Schönhofer et al., 1998). When an ultrasonography screening protocol 
has been used, the DVT prevalence within 48 hours of ICU admission has been 
around 3% in the medical-surgical ICU population (Cook et al., 2005b; Cook et al., 
2011). In specific ICU patient groups, the prevalence of DVT has been somewhat 
higher; 8% in surgical patients (Harris et al., 1997) and 11% in patients with acute 
exacerbation of chronic obstructive pulmonary disease (COPD) requiring ICU 
admission (Schönhofer et al., 1998).  
The incidence of DVT has been about 30% (9–32%), when no 
thromboprophylaxis has been used (Cade, 1982; Fraisse et al., 2000; Hirsch et al., 
1995; Moser et al., 1981b). The study designs are presented in more detailed in Table 
1. 
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Table 1.  The incidence of DVT without thromboprophylaxis in critically ill patients. 
Abbreviations: COPD, chronic obstructive pulmonary disease; DVT, deep venous 
thrombosis; ICU, intensive care unit; MICU, medical intensive care unit; NS, not 
specified; PE, pulmonary embolism; RCT, randomized controlled trial; US, 
ultrasonography. 
 
In historical studies, the incidence of DVT has been up to 40% despite 
pharmacological prophylaxis (Hirsch et al., 1995). In more recent trials, the incidence 
of proximal DVT during the ICU stay is lower, 5–10%, in the medical-surgical ICU 
population when pharmacological prophylaxis has been used (Cook et al., 2005a; 
Cook et al., 2011). In selective ICU patients, DVT rates have varied from 16% in a 
COPD exacerbation (Fraisse et al., 2000), to 21% in a cohort over-represented with 
CRRT patients, (Beitland et al., 2019) to 23% in patients with prolonged mechanical 
ventilation (Ibrahim et al., 2002).  In patients with either severe sepsis or septic 
shock, the incidence of VTE has been the highest – up to 37%, despite of guideline-
recommended thromboprophylaxis (Kaplan et al., 2015). Moreover, in severe septic 
patients, early asymptomatic VTE is common; nevertheless, prophylaxis is used or 
not (Shorr et al., 2009). The incidence of DVT varies depending on which screening 
method is used. If the upper extremity DVTs have also been screened, the incidental 
rate of DVT has been higher (Beitland et al., 2019; Hirsch et al., 1995; Kaplan et al., 
2015). The designs of studies where thromboprophylaxis has been used are 
presented in Table 2.  
  
Author ICU type Study design Screening method Timing of 
screening
No of 
patients
DVT  
(%)
PE 
(%)
Moser et 
al. (1982)
Respiratory Prospective 
cohort
Lower extremity 125I-labeled 
fibrinogen scanning
Twice weekly 34 9 6
Cade et al. 
(1982)
General RCT Lower extremity 125I-labeled 
fibrinogen scanning
8 d (4–10 d) 119 29 NS
Hirsch et 
al. (1995)
MICU Prospective 
cohort
Lower and upper extremity 
Doppler US
Within 48 hours 
and twice weekly
NS 32 1
Fraisse et 
al. (2000)
COPD RCT Lower extremitiy Doppler US 
and venography
At inclusion and 
weekly
85 28 None
Joynt et al. 
(2009)
MICU Prospective 
cohort
Lower extremity compression 
and Doppler US
Within 24 hours 
and twice weekly
80 19 None
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Table 2.  The incidence of DVT with thromboprophylaxis in critically ill patients. Abbreviations: 
COPD, chronic obstructive pulmonary disease; DVT, deep venous thrombosis, GCS, 
graduated compression stockings; ICU, intensive care unit; IPC, intermittent 
pneumatic compression; LMWH, low-molecular-weight heparin; MICU, medical 
intensive care unit; NS, not specified; RCT, randomized controlled trial; PE, pulmonary 
embolism; UFH, unfractionated heparin; US; ultrasonography. 
 
The incidence of PE in critically ill patients is less clear and no studies could be 
identified where the frequency has been studied with screening protocols.  In general, 
in hospitalized patients, the estimated prevalence of PE is around 1% (Stein et al., 
1995). In critically ill patients, the PE rate varies between 0 and 6% when no 
thromboprophylaxis has been used (Fraisse et al., 2000; Moser et al., 1981b; Shorr 
et al., 2009). In a mixed ICU population, the symptomatic PE rate has been reported 
as 1% with LMWH and 2 to 4% with UFH prophylaxis (Cook et al., 2011; Marik et 
al., 1997). 
Screening for DVT in critically ill patients is not currently advised (Kahn et al., 
2012). However, only a minority of the proximal DVTs are clinically suspected 
(Cook et al., 2005a). Furthermore, the definition of symptomatic DVT is not useful 
in critically ill patients (Crowther et al., 2005). In the past, the gold standard of DVT 
diagnosis was the venous angiogram. This has been replaced with a compression and 
Doppler ultrasonography in medical-surgical patients. The ultrasonography is a non-
invasive procedure, but it has not been compared with venography in ICU patients 
(Crowther et al., 2005).  
Furthermore, the sensitivity of ultrasonography in asymptomatic patients has 
been questioned previously (Marik et al., 1997). It has been speculated that screening 
for significant occult DVT should be conducted before initiating a mechanical 
Author ICU type Study 
Design 
Screening method Timing of screening Phramacological prophylaxis Mechanical 
prophylaxis
No of 
patients
DVT  
(%)
PE 
(%)
Cade et al. 
(1982)
General RCT Lower extremity 125I-labeled 
fibrinogen scanning
8 d (4–10 Day) UFH 5000 IU x 2 or placebo NS 119 13 vs. 
29 
ns
Hirsch et al. 
(1995)
MICU Prospective 
cohort
Lower and upper extremity 
Doppler US
Within 48 hours and twice 
weekly
43% UHF 18% IPC 100 33 1
Marik et al. 
(1997)
Mixed Prospective 
cohort
Lower extremitiy Duplex US 4–7th ICU Day UFH If pharmocological 
contraindicated 
(26/102)
102 12 4
Fraisse et 
al. (2000)
COPD RCT Lower extremitiy Doppler US  
and venography
At inclusion and weekly Nadroparin 3800–5700 IU vs. 
placebo
NS 223/167 16 vs. 
28
None
Cook et al. 
(2005)
Mixed Prospective 
cohort
Lower extremity compression 
US
Within 48 hours and twice 
weekly
UFH (81.7%), LMWH ( 4%), 
UFH intravenously (6.8%)
If pharmocological 
contraindicated
261
Cook et al. 
(2005)
Mixed RCT, pilot Lower extremity compression 
US
Within 48 hours and twice 
weekly
UFH vs. dalteparin 5000 IU NS 129 9 1.6
Cook et al. 
(2011)
Mixed RCT Lower extremity compression 
US
Within 48 hours and twice 
weekly
UFH vs. dalteparin 5000 IU GCS or IPC 3746 5.1 vs. 
5.8
1.3 vs. 
2.3
Kaplan et al. 
(2015)
Septic Prospective 
cohort
Lower and upper extremity 
Doppler US
Prior ICU discharge and on 
request
43% UFH, 34% LMWH, 3% 
warfarin
20% GCS 113 37 4
Beitland et 
al. (2019)
Mixed Prospective 
cohort
Lower and upper extremity 
Doppler US
Within 48 hours and twice 
weekly
Dalteparin 5000 IU 63 % GCS 70 21 6
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thromboprophylaxis, especially with a compression device. The rationale behind this 
approach is to minimize the risk of embolization from DVT. Though this reasoning 
seems logical, there is no published evidence to support this practice. However, the 
screening has been proposed before initiation of a mechanical prophylaxis, if the 
patient has one of the following risk factors: age over 65 years, Acute Physiology and 
Chronic Health Evaluation (APACHE) II over 12 points or a recent emergence 
procedure (Harris et al., 1997). 
2.4 Risk factors for venous thromboembolism in critically ill 
patients  
The pathophysiology of VTE is complex, and thus the risk of developing a VTE is 
multifactorial. Commonly, all known risk factors affect at least one of the three 
components of the Virchow triad.  
Thrombotic risk factors are typically divided either into inherited or acquired 
factors. In the ICUs, the risk factors may be further classified as prior to the current 
critical illness or directly related to the reason requiring ICU care or the patient’s 
treatment in that unit. The main risk factors before initiating ICU care include age, 
obesity (Stein et al., 2005), malignancy (Heit et al., 2002), smoking, inherited 
thrombophilia, and family/personal history of VTE (Cook et al., 2005b; Lim et al., 
2015). In critically ill patients, an increasing BMI seems to be associated with VTE 
risk (Lee et al., 2017; Lim et al., 2015). 
The ICU-acquired risk factors include immobilization, central venous catheters 
(CVCs), and platelet transfusions (Cook et al., 2005a). Furthermore, the duration of 
mechanical ventilation (Fraisse et al., 2000; Kaplan et al., 2015) as well as the duration 
of CVC (Ibrahim et al., 2002), seem to be associated with VTE. 
Hypercoagulation with accumulation of tissue factor plays a crucial role in the 
pathophysiology of VTE (Day et al., 2005). Though patients in the ICU are known 
to be hypercoagulable (Sivula et al., 2009), the association with hypercoagulable state 
and VTE in critically ill patients has not been proven (Van Haren et al., 2014).  
The risk factors for PE are typically similar to those for DVT, as the most 
common risk factors for PE are male sex, obesity, history of cancer, patient’s history 
of DVT, coma, thrombocytosis (Lim et al., 2015; Minet et al., 2012). In addition, the 
vasopressor use has been described to increase the risk of PE (Lim et al., 2015). In 
trauma ICU patients, the main predictive factors for PE are age over 40 years, 
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Simplified Acute Physiology Score (SAPS) over 25, and hypoxemia (Bahloul et al., 
2011). 
2.4.1 Catheter-related thrombosis 
The introduction of polyurethane catheters diminished the risk of intravascular 
catheter-related thrombosis (CRT) (Borow et al., 1985). Nevertheless, asymptomatic 
CRTs are still relatively common in ICU patients (Durbec et al., 1997; Merrer et al., 
2001; Timsit et al., 1998). The risk of catheter-related thrombosis varies according 
to the insertion site, and it seems to highest among femoral catheters (Merrer et al., 
2001; Trottier et al., 1995). When upper extremity CVCs were evaluated for CRT, 
the subclavian route was preferable over an internal jugular vein (Hrdy et al., 2017; 
Timsit et al., 1998). As well as the insertion site, increasing age, and the absence of 
therapeutic heparinization seem to be independent risk factors for CRT (Timsit et 
al., 1998). The results on whether the duration of CVC increases the risk of VTE are 
conflicting. Some investigators detected no association with CRTs and the length of 
cannulation (Joynt et al., 2000; Trottier et al., 1995) while others found a positive 
association (Beitland et al., 2019; Ibrahim et al., 2002). These differences may be at 
least partly explained by different screening protocols and methods.  
The clinical relevance of CRTs is uncertain. It appears to vary according to the 
size of thrombus and the level of venous occlusion; a smaller thrombus might even 
dissolve spontaneously (Trottier et al., 1995). However, in one study, CRTs increased 
the risk of catheter-related sepsis (Timsit et al., 1998). 
2.4.2 Clinical outcomes after venous thromboembolism  
In patients with either severe sepsis or septic shock, a clinically significant VTE 
increased the length of ICU stay but did not affect mortality (Kaplan et al., 2015). 
Similar results have been reported in patients requiring prolonged mechanical 
ventilation where VTE lengthened both the ICU and hospital stay (Ibrahim et al., 
2002). 
In a meta-analysis published in 2015, also an incidental DVT prolonged the ICU 
and hospital stay, as well as the duration of mechanical ventilation (Malato et al., 
2015). Hospital or ICU mortality did not reach statistical significance.  
Depending on the size and the location of PE, it can cause acute respiratory 
symptoms, even cardiovascular collapse. In medical patients, PE is known to 
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increase morbidity and mortality (Heit et al., 1999; Pengo et al., 2004). In ICU 
patients, the consequences are less evident. The in-hospital mortality among ICU-
acquired PE patients has been reported to be over 50% despite recommended 
thromboprophylaxis and therapeutic anticoagulation after PE diagnosis (Bahloul et 
al., 2010). On the other hand, if treated early with anticoagulation, the PE does not 
seem to increase the ICU or hospital stay, nor does it elevate mortality (Minet et al., 
2012). 
2.5 Overview of indirect parenteral anticoagulants 
2.5.1 Heparin 
Heparin was initially discovered over 100 years ago from a dog’s liver (Greek for 
liver ”Heparin”) (McLean, 1959). It belongs to the class of linear acidic 
polysaccharides, known as glycosaminoglycans (GAG). Heparin consists of a 
mixture of GAG chains made from disaccharide subunits. These subunits are highly 
sulfated and therefore, negatively charged. Natural heparin is produced by the mast 
cells and can be identified in almost all mammalians. The commercial UFHs are 
usually isolated either from porcine intestinal mucosa or bovine lung.  
2.5.1.1 Structure and effects on coagulation  
The mean molecular weight of heparin is 15 000 daltons (Da), but the molecular 
weight of individual polysaccharide chain ranges from 3000 to 30 000 Da (Andersson 
et al., 1976). The main anticoagulant activity of heparin is mediated through the 
heparin-AT interaction (Andersson et al., 1976). AT is a weak anticoagulant as such, 
but with increasing heparin concentrations, the anticoagulant efficacy increases 
exponentially from 300 to 2000-fold (Beeler et al., 1979). AT forms a covalent bond 
with the coagulation enzymes, and thereby the procoagulant activity is irreversibly 
inhibited.  Heparin dissociates and inhibits the activities of other procoagulant 
enzymes.  
The formed heparin-AT complex inhibits several coagulation factors, including 
fIIa (thrombin), fXa, fIXa, fXIa, and fXIIa (Hirsh et al., 2001); with the most 
sensitive to inhibition being against thrombin and fXa. The heparin molecule needs 
to have a specific pentasaccharide unit to allow it to bind AT and an additional 
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saccharide unit with a minimum of 13 chains for binding to the coagulation fIIa 
(Figure 5A) (Lindahl et al., 1984; Rosenberg et al., 1979). The inhibition of fXa only 
requires binding to AT at the unique pentasaccharide unit of heparin molecule 
(Figure 5B) (Casu et al., 1981). Thus, short heparin chains can only inhibit fXa.  
 
Figure 5.  The interaction of heparin chain, AT, fXa, and thrombin. Abbreviations: AT, antithrombin; 
fIIa, activated coagulation factor II, Da, dalton; MW, molecular weight.  
Even heparin chains without the pentasaccharide unit and the capability to interact 
with AT, can catalyze thrombin inhibition by HcII at high concentrations 
(TollefsenBlank et al., 1981). The chain length needs to be at least 24 saccharides 
long. Thus, LMWHs are less effective in the activation of HcII.  
In addition to AT mediated actions, heparin possesses numerous other effects, 
e.g. it releases TFPI, inhibits platelet function (Fernandez et al., 1986), has anti-
inflammatory properties (Young, 2008) and enhances the antithrombotic and 
fibrinolytic function of the vascular endothelium (Blajchman et al., 1989).  
In whole blood, the anticoagulation effect of heparin is inhibited by at least two 
mechanisms. First, platelet factor 4 (PF4) released from activated platelets during 
coagulation is a potent heparin but not an LMWH inhibitor (Lane et al., 1984). This 
difference can be explained by different length of polysaccharide chains. Second, 
when fXa is bound into the prothrombinase complex, it is resistant to heparin 
inactivation but not to LMWHs (Teitel et al., 1983). 
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2.5.1.2 Pharmacokinetics 
UFH needs to be administered parenterally since its oral absorption is very limited 
(Arbit et al., 2006).  It is usually given either as a CII or as a subcutaneous bolus 
(SCB). The bioavailability of heparin is 50% when given subcutaneously, and a 
higher initial dose or an additional IV bolus is often required (Hull et al., 1986). Once 
it gains access to the bloodstream, heparin binds not only to AT but also to 
numerous other plasma proteins, endothelial cells, macrophages, and von 
Willebrand factor (Bârzu et al., 1985). Thus, the pharmacokinetics of heparin is 
complex, and its anticoagulant effect is unpredictable (Hirsh et al., 2001). 
Heparin is cleared by two mechanisms (Bjornsson et al., 1982). First, there is a 
rapid saturable phase that is due to binding to receptors on endothelial cells 
(Glimelius et al., 1978) and macrophages (Friedman et al., 1974). Bound heparin is 
subsequently internalized and depolymerized. Second, there is a slower non-
saturable phase when the clearance is mainly renal (de Swart et al., 1982). Because of 
this dual mechanism of clearance, heparin accumulation in renal insufficiency is less 
evident.  
2.5.1.3 Monitoring anticoagulation 
The dose of heparin administered is associated with both its efficacy (Turpie et al., 
1989) and safety (Epilog, 1997). While the anticoagulant response displays a wide 
individual variation, monitoring the effect of heparin is usually advised, especially 
with therapeutic doses (Garcia et al., 2012). The anticoagulation is generally 
controlled using the activated partial thromboplastin time, aPTT, a measure of the 
lag time of thrombin formation in the intrinsic system (Béguin et al., 1988). The 
suggested aPTT ratio for therapeutic anticoagulation has been between 1.5- and 2.5-
times the control value which corresponds to the anti-Xa activity of 0.3–0.7 IU/ml 
(Basu et al., 1972). However, these targets have not been confirmed in randomized 
controlled trials (RCTs).  
2.5.1.4 Heparin resistance 
Heparin resistance is a clinical situation where a patient requires unusually high doses 
to achieve the targeted aPTT (Hull et al., 1986). This phenomenon has several 
potential explanations, e.g. AT deficiency, increased heparin clearance (Whitfield et 
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al., 1983), elevations of heparin-binding proteins (Lijnen et al., 1983) and high levels 
of factor VIII and/or fibrinogen (Edson et al., 1967)  and PF4 (Levine et al., 1984). 
In the ICU, unusually large UFH doses are sometimes needed to reach the 
targeted aPTT. In some patients, this could be acquired (or congenital) contact factor 
deficiency. In these patients, monitoring of anti-Xa might be useful (Levine et al., 
1994). 
2.5.1.5 Adverse events 
The most common adverse event related to UFH is hemorrhage. The mechanism 
includes the anticoagulant effect of heparin but also the interaction with platelets 
and endothelial cells (Blajchman et al., 1989; Fernandez et al., 1986).  The risk is 
proportional to the UFH dose (Morabia, 1986) and with therapeutic dose the risk of 
major bleeding is around 4% (Costantino et al., 2012). In critically ill patients the 
major bleeding rate with UFH thromboprophylaxis is around 6% and any bleeding 
rate 13% (Cook et al., 2011). The anticoagulant effect can be reliably neutralized with 
protamine sulfate. The neutralization can be verified with a decrease in the aPTT 
level. Because of the mechanism of action, fresh frozen plasma infusion is ineffective 
for anticoagulant reversal.  
The main non-hemorrhagic adverse events are heparin-induced 
thrombocytopenia (HIT) (Greinacher et al., 1994) and after long-term use 
osteoporosis (Shaughnessy et al., 1995). Uncommon reactions include necrotizing 
skin reactions, hypersensitization, alopecia, hyperkalemia, and transient transaminase 
elevations.  
HIT is a potentially life-threatening disorder where the reaction of heparin with 
immunoglobulin G type antibodies leads to the activation of platelets (Greinacher, 
2015; Warkentin, 2011). The pathogenesis of typical HIT is complex. In brief, some 
of the heparin molecules form a complex with platelet PF4, a small cytokine that is 
released from activated platelets (Greinacher et al., 1994). This PF4-heparin complex 
acts as an antigen for IgG antibody production, resulting in the formation on PF4 
/heparin-IgG immune complexes on platelet surfaces. This further activates platelets 
and promotes PF 4 release. As a consequence, blood coagulation becomes activated 
in a vicious circle manner. As well as the typical HIT, delayed onset HIT and 
spontaneous HIT have been described (Warkentin et al., 2001; Warkentin et al., 
2014). Their pathophysiology is most likely autoimmune (Warkentin et al., 2016). 
In all types of HIT, activated platelets shed highly thrombogenic microparticles 
that provide a surface for the coagulation cascade to promote the generation of 
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thrombin (WarkentinKelton et al., 2001). The activated platelets themselves are 
removed from the circulation, stimulating thrombocytopenia. As a consequence, 
both venous and arterial thromboses rather than bleeding are triggered. The clinical 
assessment of HIT is conducted with a pretest probability scoring system, the 4 T’s: 
Thrombocytopenia (from 0 to 2 scores), Timing of thrombocytopenia or thrombosis 
(from 0 to 2 scores), Thrombosis (from 0 to 2 scores), and no oTher explanation for 
thrombocytopenia (from 0 to 2 scores) (Lo et al., 2006). A total score is 8 where 
scores 1–3, 4–5, and 6–8 are considered to correspond to a low, intermediate, and 
high probability of HIT, respectively. The diagnosis is confirmed from the blood 
tests (Watson et al., 2012). 
HIT usually develops 5–7 days after the initiation of heparin, and it is more 
common after UFH than after LMWH, especially in surgical patients (Greinacher, 
2015). In the ICU, the rate of HIT is 0.3–0.5%, whereas the overall frequency of 
thrombocytopenia is nearly 100-fold (Cook et al., 2011). 
2.5.2 Low-Molecular-Weight Heparins 
The development of LMWHs was stimulated by two key findings. First, it was 
observed that when the heparin molecule was fractionated, it started to progressively 
lose its ability to prolong aPTT while maintaining the capability to inhibit factor Xa 
(Andersson et al., 1976). Second, LMWHs seemed to cause less bleeding than 
heparin in experimental models (Cade et al., 1984). 
2.5.2.1 Structure and effects on coagulation 
All currently available LMWHs are depolymerized from UFH either chemically (with 
nitrous acid or alkaline hydrolysis) or enzymatically (with heparinase) (Table 3) 
(Hirsh et al., 2001). During the depolymerization process, the saccharide chains of 
UFH are cleaved, resulting in more standardized molecules, with molecular weights 
from 3000 to 6000 Da. The mean molecular weight of LMWHs is around 5000 Da 
corresponding to 15 saccharide units (Lane et al., 1984). Though the molecular 
weight of LMWH is more uniform than in UFH, differences in manufacturing 
methods lead to differences in LMWH’s physical structure, biological, and 
pharmacological properties (Table 3). Therefore, their interchangeability has been 
questioned (Baglin et al., 2006). However, in vivo, the anticoagulant activities of 
different LMWHs seem to be more homogenous.  
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Table 3.  The characteristics of UFH and LMWHs. Abbreviations: Da, dalton; MW, molecular 
weight; Tmax, time to peak plasma anti-Xa level, T ½, half-time; UFH, unfractionated 
heparin (Marder et al., 2013). 
 
The anticoagulant effect of LMWHs, like UFHs, is mainly mediated through AT 
(Figure 5) (Casu et al., 1981). Because of the depolymerization, the number of 
saccharide units is lower than in UHF (Andersson et al., 1976). Thus, the capability 
of LMWHs to catalyze thrombin inhibition is reduced (Figure 5A), and the majority 
of LMWH molecules can only inactivate fXa (Figure 5B) (Lane et al., 1984). 
Therefore, the anti-Xa activity of all LMWHs is superior to their anti-IIa activity. To 
a lesser extent, LMWHs also have AT-independent anticoagulation properties by 
HcII. However, the clinical relevance is less clear. 
2.5.2.2 Pharmacokinetics 
The LMWHs pharmacokinetics and the anticoagulant response are more predictable 
than UFH (Bratt et al., 1986; Frydman et al., 1988; Handeland et al., 1990). The 
bioavailability after subcutaneous injection is 90% (Hirsh et al., 1992). The 
elimination half-life of LMWHs is dose-independent, varying between 3 to 7 h. The 
peak level is 3 to 5 h after SCB. All LMWHs are predominately cleared through the 
kidneys, which means that their biological half-life is prolonged in patients with renal 
failure (Palm et al., 1987). 
The pharmacokinetic properties of LMWHs and UFH are shown in more detail 
in Table 3. The anti-Xa-anti-IIa ratio of LMWHs varies from 1.8 (tinzaparin) to 3.9 
(enoxaparin) (Baglin et al., 2006). There is no clinical evidence that these ratios reflect 
their in vivo anticoagulation activities since they are based on assays performed in 
vitro using platelet-poor plasma (Garcia et al., 2012).   
Product MW (Da) Method of 
depolymerization
Anti-Xa 
(IU/mg)
Anti-fIIa 
(IU/mg)
Ratio Tmax T1/2 (h)
UFH 15 000 None 1 minutes 0.5–1.5
Enoxaparin 4034 Alkaline 105 27 3.9 3-5 h 4.5–7
Dalteparin 5663 Nitrous acid 130 58 2.2 3–5 h 3.5–4
Nadroparin 4279 Nitrous acid 95 27 3.5 3–5 h 3.5
Tinzaparin 4500 Heparinase 83 45 1.8 3–4 h 3
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2.5.2.3 Monitoring anticoagulation  
LMWHs are typically administered in fixed doses for thromboprophylaxis and 
weight-adjusted doses for therapeutic situations (Garcia et al., 2012). In general, 
routine monitoring of LMWH anticoagulation is not advised. In specific conditions, 
e.g. in morbid obesity and renal insufficiency, monitoring might be beneficial (Garcia 
et al., 2012; Samama, 1995). In cases of chronic renal insufficiency, anti-Xa levels 
have a positive correlation with the creatinine clearance (Goudable et al., 1991). 
The prolongation of aPTT is only seen significantly with therapeutic doses of 
LMWH, although the degree varies with different reagents. The recommended test 
for LMWH monitoring is the chromogenic anti-Xa assay where results are expressed 
in IU of anti-Xa, accordingly to a LMWH reference preparation for assay calibration. 
The suggested targets for therapeutic anticoagulation administered BID of 
enoxaparin are 0.6–1.0 IU/ml assayed at 4 h after SCB representing the peak level 
(Bara et al., 1985).  
There are no anti-Xa targets with fixed doses of LMWH thromboprophylaxis 
(Garcia et al., 2012), however, in research a peak target of 0.2–0.4 IU/ml is often 
used (Levine et al., 1989). In general, the anti-Xa levels after LMWH 
thromboprophylaxis have been lower in critically ill than in ward patients. The exact 
reason is not known, but a reduced bioavailability of subcutaneously administered 
LMWH because of a concomitantly administered vasoconstrictor infusion has been 
suggested (Dörffler-Melly et al., 2002).  
2.5.2.4 Adverse events 
The affinity of LMWHs for plasma proteins and cells is reduced in comparison with 
UFH. This leads to more desirable safety profile. The most common side effect of 
LMWHs is also bleeding, but the risk is lower compared to UFH. In critically ill 
patients, no difference was seen in major bleeding rates when thromboprophylaxis 
doses of UFH was compared with dalteparin (Cook et al., 2011). However, since all 
LMWHs are cleared by the kidneys, in patients with renal failure, there is a risk of 
accumulation and thus an increased risk of bleeding. This was shown in a meta-
analysis by Lim et al., where creatine clearance < 30 ml/min increased the bleeding 
risk by more than 2-fold after a therapeutic dose of LMWH, but not after a 
prophylactic dose. The reversal of anticoagulant effects of LMWH is yet to proven. 
Protamine neutralizes the anticoagulant effect only party, since it mainly neutralizes 
the anti-IIa activity.  
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Other possible side effects of LMWHs are similar to UFH, including HIT, 
transient increase in transaminase levels, osteoporosis, skin reactions, and 
hyperkalemia (Shaughnessy et al., 1995). Their incidence is lower since LMWHs 
interact with plasma proteins to a lesser extent. e.g. the incidence of HIT is threefold 
lower with LMWHs than with heparin (Hirsh et al., 1992). 
2.6 Current guidelines for pharmacological thromboprophylaxis 
in critically ill patients 
The Finnish “Deep venous thrombosis and pulmonary embolism: The Current Care 
Guideline” recommends using thromboprophylaxis in critically ill patients (Lassila 
et al., 2016). The proposed method of thromboprophylaxis is not specified for 
critically ill patients, but for high-risk (the overall risk for VTE 4-10%) surgical and 
medical patients, LMWH is recommended. In high-risk surgical patients, it is 
recommended to provide supplemental graduated compression stockings (GCS).  
The most detailed recommendation for preventions of VTE in critically ill 
patients can be found in the 9th edition of the American College of Chest Physicians 
Guidelines (ACCP), especially for non-surgical patients (Kahn et al., 2012) and non-
orthopedic surgical patients (Gould et al., 2012). The ACCP guidelines use the 
GRADE (Grading of Recommendations Assessment, Development, and 
Evaluation) system for categorizing the quality of evidence (high, moderate, low, and 
very low) and the strength of recommendations (Guyatt et al., 2008).  
2.6.1 Critically ill non-surgical patients 
The current ACCP guideline for non-surgical critically ill patients recommends using 
pharmacological thromboprophylaxis, either LMWH or UFH, in favor of no 
prophylaxis (GRADE 2C, weak recommendation, low-quality evidence) (Kahn et 
al., 2012). This recommendation is based on 5 RCTs, one  of UFH vs. placebo (Cade, 
1982), one of LMWH vs. placebo (Fraisse et al., 2000), and three of UFH vs. LMWH 
(Cook et al., 2011; De et al., 2010; Shorr et al., 2009). Despite the classification one 
of the included RCTs was done in surgical patients (De et al., 2010). 
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2.6.1.1 Unfractionated heparin vs. placebo 
Cade et al. studied 119 critically ill patients randomized to receive either UFH 5000 
BID or placebo (Cade, 1982).  The incidence of lower extremity DVT was evaluated 
daily by 125I-labeled fibrinogen scanning. The total risk of DVT was reduced when 
UFH was compared with placebo (13% vs. 29%, respectively; RR, 0.46; 95% CI, 
0.22–0.99, p<0.05). The rates of proximal DVT, PE, bleeding, or mortality were not 
reported. 
2.6.1.2 Low-molecular-weight heparin vs. placebo  
In the study by Fraisse et al., nadroparin was compared to placebo in 223 in COPD 
patients requiring mechanical ventilation (Fraisse et al., 2000). The nadroparin dose 
was adjusted for body weight, 3800, or 5700 IU SC OD. The incidence of lower 
extremity DVT was assessed by venography at planned study completion, early 
permanent discontinuation or during the study to confirm Doppler ultrasonography 
diagnosis of DVT.  A slight reduction in all DVT was found with nadroparin, 16 vs. 
28%, respectively (RR 0.55; 95% CI, 0.30–1.00, p <0.05). No difference was detected 
in proximal DVT, major bleeding or mortality rates.  
2.6.1.3 Unfractionated heparin vs. low-molecular-weight heparin  
Two of the studies investigated UFH in comparison with enoxaparin (De et al., 2010; 
ShorrWilliams et al., 2009) and one with dalteparin (Cook et al., 2011). All studies 
were done using subcutaneous administration of heparin and LMWHs. 
The RCT of De et al. examined 154 surgical ICU patients undergoing major 
elective surgery who received either UFH 5000 IU BID or enoxaparin 40 mg OD 
(De et al., 2010). The major surgery was defined as any surgical procedure that was 
assumed to require at least 6 days hospitalization of which at least 24 h in the ICU. 
The DVT rate was assed once between 5th and 7th days by Doppler ultrasonography. 
No difference was observed in either all DVT, 2.7% (2/75 patients) in the UFH 
group vs. 1.2% (1/81 patients) in the enoxaparin group, p=0.51 or the major 
bleeding rate, 2.7% (2/75 patients) vs. 1.2% (1/81 patients), p=0.48, respectively. It 
was reported that UFH increased both minor bleeding 21.3% (16/75 patients) vs. 
8.6% (7/81 patients), p=0.02 and overall bleeding, 24% (18/75 patients) vs. 9.9% 
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(8/81 patients), p=0.01, respectively. The PE rate or the location of DVTs were not 
reported. 
Shorr et al. randomized severe sepsis or septic shock patients to receive either 
UFH 5000 IU BID, enoxaparin 40 mg OD or placebo. In addition, all patients 
received concomitant drotrecogin alfa for 6 days (Levi et al., 2007; et al., 2009). 
Drotrecogin alfa is a recombinant form of APC and has both antithrombotic and 
anti-inflammatory properties. The study included 1935 patients: 498 in UFH, 478 in 
enoxaparin, and 959 in the placebo arm. DVTs were screened with bilateral lower 
extremity compression ultrasonography between day 4 and day 6. Ultrasonography 
was performed earlier if symptomatic DVT was suspected. No difference was seen 
in 28-day mortality, 29.3% (145/495 patients) in the UFH group vs. 27.3% (130/477 
patients) in the enoxaparin group vs. 31.9% (305/955 patients) in the placebo group, 
p= 0.20 (Levi et al., 2007). Neither UFH nor LMWH showed any beneficial or 
detrimental effects within the study days 0–28 when compared to placebo on 
symptomatic DVT : 6.3% (26/498 patients) vs. 5.9% (23/478 patients) vs. 7.0% 
(67/959 patients), PE: 0.4% (2/498 patients) vs. 0.4% (4/478 patients) vs. 0.8% 
(8/959 patients) or any VTE: 5.6% (28/498 patients), 5.9% (28/478 patients), 7.0% 
(67/959 patients), respectively (Shorr et al., 2009). The use of heparin did not 
increase the risk of any bleeding: 12.4% (121/976 patients) vs. 10.9% (105/959 
patients), p=0.06 or serious bleeding: 3.9% (38/976 patients) vs. 5.2% (50/959 
patients), respectively, p=0.16. Interestingly, a withdrawal of anticoagulation seemed 
to be harmful since both the 28-day mortality, 35.6% (p=0.03), and the rate of VTE 
seemed to be highest (8.1%)  in patients who had received any prior heparin before 
randomization and then allocated into the placebo arm (Levi et al., 2007; Shorr et al., 
2009) . One possible explanation could be the so-called “rebound hypercoagulation” 
that has been described in acute coronary syndromes (Granger et al., 1995). 
However, these results should be interpreted with caution since drotrecogin alfa is 
no longer available due to safety and efficacy issues (Ranieri et al., 2012). 
In a large multicenter trial, 3764 medical-surgical ICU patients were randomized 
to receive either UFH 5000 IU BID or dalteparin 5000 IU OD during the ICU stay 
(Cook et al., 2011). A lower extremity compression ultrasonography was performed 
within 2 days after ICU admission and then twice weekly. No difference in proximal 
DVT: 5.1% in the UFH group vs. 5.8% in the dalteparin group (96/1873 patients 
vs. 109/1873 patients, HR 0.92; 95% CI 0.68–1.23, p=0.57) , all DVT: 7.4 vs. 8.6% 
(138/1873 patients vs. 161/1873 patients HR 0.93; 95% CI 0.72–1.19, p=0.54), 
major bleeding: 5.5 vs. 5.6% (103/1873 patients vs. 105/1873 patients, HR 1.00; 
95% CI 0.75–1.34, p=0.98), respectively. Both ICU mortality: 15.2 vs. 16.2% 
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(284/1873 patients vs. 304/1873 patients, HR 0.97; 95% CI 0.82–1.15, p=0.71) and 
hospital mortality: 22.1 vs. 24.5% (414/1873 patients vs. 459/1873 patients, HR 
0.92; 95% CI 0.80–1.05, p=0.21), respectively, remained indifferent.  Dalteparin 
reduced the incidence of any PE: 2.3 vs. 1.3% (43/1873 patients vs. 24/1873 
patients, RR 0.51; 95% CI 0.30–0.88, p<0.01), respectively. 
Overall, when UFH or LMWH has been compared with placebo, the risks of 
symptomatic DVT, symptomatic PE, major bleeding, and mortality have remained 
the same. A reduction in asymptomatic DVT rates has been shown both with UFH 
and LMWH (Cade, 1982; Fraisse et al., 2000). LMWHs seem to have a marginally 
more favorable profile over UFH: less bleeding (De et al., 2010) and more reduction 
in PE rate (Cook et al., 2011). However, ACCP guidelines decided to consider them 
as equivalent since the beneficial treatment effect of PE was only attributable to a 
small difference in events (Cook et al., 2011). Moreover, the treatment effect was 
biased because of screening of DVT and further treating asymptomatic DVT with 
therapeutic anticoagulation (Kahn et al., 2012). 
2.6.2 Critically ill surgical patients 
Surgical patients in the ICU are typically considered as high-risk patients for VTE 
(around 6%) (Gould et al., 2012). Moreover, major surgery seems to be one of the 
main risk factors for VTE (Barsoum et al., 2010). Surgical procedures with an 
especially high VTE incidence of 2 to 3% include lower extremity vascular surgery, 
invasive neurosurgery and total or partial hip arthroplasty major orthopedic surgery, 
and abdominal and urologic cancer surgery (White et al., 2003). In addition to the 
risk of VTE, the risk of bleeding needs to be evaluated when planning 
thromboprophylaxis, especially in the early postoperative period. However, the risk 
of bleeding can only be evaluated indirectly, since in most RCTs, those patients with 
increased risk for bleeding are excluded. Typically risk factors for major bleeding 
complications are active bleeding, previous major bleeding, severe renal or hepatic 
failure, thrombocytopenia, acute stroke, uncontrolled hypertension, and 
concomitant use of anticoagulants (Gould et al., 2012). 
In thoracic, general and abdominal surgery patients at high risk for VTE, but not 
at high risk for bleeding: pharmacological thromboprophylaxis with UFH or LMWH 
(GRADE 1B) is preferable over no prophylaxis (Gould et al., 2012). This is based 
on the meta-analysis performed by Collins et al. where UFH reduced the risk of fatal 
PE from 0.9% (55/6777 patients) to 0.3% (19/7307 patients), p<0.001 (Collins et 
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al., 1988). In LMWHs, the risk reduction was also halved i.e. from 12 per 1000 
patients to 6 (95% CI 3–13) per 1000 patients in comparison with placebo (Mismetti 
et al., 2001). It has been suggested that mechanical prophylaxis with elastic stockings 
or intermittent pneumatic compression (IPC) should be supplemented to 
pharmacological prophylaxis (GRADE 2C) (Kakkar et al., 2010), (Roderick et al., 
2005). If the bleeding risk is considered major, only mechanical prophylaxis is 
advised as long as the risk of bleeding persists (GRADE 2 C) (Eppsteiner et al., 
2010). 
The postoperative risk of VTE seems to be lower in cardiac surgery patients than 
in other ICU patients, approximately 0.5 to 1.0% (White et al., 2003). The risk of 
major postoperative bleeding is 4.7%. Thus, the risk of VTE is considered moderate, 
but the risk for major bleeding is substantial.  In uncomplicated cardiac surgery 
patients, only IPC is preferred to no prophylaxis (GRADE 2C) or pharmacologic 
prophylaxis (GRADE 2C). If hospitalization is prolonged, it is suggested to combine 
pharmacological prophylaxis with mechanical prophylaxis (GRADE 2C).  
2.6.2.1 Critically ill trauma patients 
In major trauma patients, the baseline risk for VTE is approximately 3–5%, but it 
increases up to 8–10% among patients with traumatic brain injury or spinal cord 
injury (Gould et al., 2012). Furthermore, an incidence of proximal DVT as high as 
18% (63/349 patients, from whom only 3 symptomatic) has been reported with 
venography screening when no prophylaxis has been used (Geerts et al., 1994). There 
are limited RCT data supporting interventions involving thromboprophylaxis in 
trauma patients, especially those in ICU. Therefore, the ACCP’s recommendation 
for thromboprophylaxis in trauma patients is based on estimates of the relative risk 
in other populations (Gould et al., 2012). For major trauma patients at high risk for 
VTE but an average risk for bleeding, it is recommended to have a combination of 
pharmacological (either LMWH or UFH) and mechanical prophylaxis (GRADE 
2C). If pharmacological prophylaxis is contraindicated, mechanical prophylaxis, 
preferably with IPC, is suggested (GRADE 2 C). When the risk of bleeding recedes, 
then it is possible to initiate pharmacological prophylaxis (GRADE 2C). 
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2.7 Current guidelines for mechanical thromboprophylaxis in 
critically ill patients 
Mechanical thromboprophylaxis includes GCS and IPC (Limpus et al., 2006). Both 
approaches have a similar mechanism of action as they generate an external pressure 
that reduces the diameter of the venous lumen, and accelerates venous blood flow 
(Stanton et al., 1949) further reducing venous stasis (Agu et al., 1999). The external 
pressure provided by GCS is static, while IPC generates a more dynamic approach 
mimicking the physiological effects of the venous valve system and sustaining 
pulsatile blood flow in the deep veins (MacLellan et al., 2007). 
The mechanical thromboprophylaxis offers two potential benefits. First, it may 
be useful when pharmacological prophylaxis is contraindicated. Second, while 
reducing the venous stasis –one of the three elements of Virchow’s Triad– it might 
confer synergistic benefits with pharmacological prophylaxis. The side effects 
include patient discomfort, skin injury, and reduced mobility (CLOTS, 2009). 
The ACCP guideline for non-surgical ICU patients recommends using 
mechanical thromboprophylaxis, either GCS or IPC, for as long as the risk of 
bleeding persists. Subsequently, mechanical thromboprophylaxis should be replaced 
by pharmacological thromboprophylaxis (GRADE 2C). In major trauma patients 
with a high risk for VTE, it is suggested to supplement mechanical 
thromboprophylaxis, preferable IPC, with pharmacological prophylaxis (GRADE 
2C) (Gould et al., 2012). IPC should be used at least 18 h a day. If GCS are used 
efforts should be made to achieve proper with and ankle pressure of 18 to 22 mmHg. 
When the current ACCP guidelines were released, the RCT data on mechanical 
thromboprophylaxis in critically ill were limited. Thus, the recommendation is based 
on results originating from surgical ward patients where combining IPC with 
pharmacological prophylaxis was found to be beneficial (Kakkos et al., 2016). 
2.7.1 Intermittent pneumatic compression vs. low-molecular-weight heparin 
Four RCTs studying mechanical thromboprophylaxis in ICU patients have been 
published. The thromboprophylaxis study of Ginzburg et al. examined 442 moderate 
to severe trauma patients who were randomized either to an IPC group or to an 
LMWH group (enoxaparin 30 mg BID) (Ginzburg et al., 2003). Doppler 
ultrasonography of lower extremities was performed within 24 hours of ICU 
admission and weekly thereafter.  The rate of all DVT did not differ, 2.7% (6/224 
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patients) in IPC group vs. 0.5% (1/218 patients) in enoxaparin group (p=0.122). No 
difference was seen in the incidence of PE (1/224 patients vs. 1/218 patients), minor 
bleeding (4/224 patients vs. 9/218 patients, p=0.237) or major bleeding rates (4/224 
patients vs. 4/218 patients), respectively. Mortality was not reported.  
Kurtoglu et al. studied 120 severe head or spinal trauma patients who received 
either IPC thromboprophylaxis or LMWH (enoxaparin 40 mg) (Kurtoglu et al., 
2004). The DVTs were screened by lower extremity Doppler ultrasonography on 
admission to the ICU, weekly and one week after discharge. The DVT rate did not 
differ, 6.6% (4/60 patients) in IPC group vs. 5% (3/60 patients) in enoxaparin. No 
difference was seen in PE (2/60 patients vs. 4/60 patients), mortality (7/60 patients 
vs. 8/60 patients) or exacerbation of intracranial hematoma rates (1/60 patients vs. 
1/60 patients), respectively.  
In the study of Serin et al., 259 mechanically ventilated ICU patients received 
either both IPC and GCS or LMWH thromboprophylaxis (enoxaparin 4000 IU) 
(Serin et al., 2010). No difference in asymptomatic DVT rate was seen: 1% (1/94 
patients) in IPC+GCS group vs. 2% (3/152 patients) in enoxaparin group.  
In the largest RCT studying mechanical thromboprophylaxis, 2003 medical, 
surgical or trauma patients were investigated (Arabi et al., 2019). They were 
randomized within 48 hours after ICU admission to receive either IPC with 
pharmacological prophylaxis (UFH or LMWH) or only pharmacological 
prophylaxis. IPC was used a median of 22 hours (interquartile range, IQR, 21–23 
hours) daily for a median of 7 days (IQR 4–13 days). There was no difference in the 
incidence of proximal DVT 3.9% (37/957 patients) vs. 4.2% (41/985 patients) (RR 
0.93, 95% CI 0.60–1.44, p=0.74). Adjunctive IPC did not result in beneficial or 
detrimental effects on PE: 0.8% (8/991 patients) vs. 1.0% (10/1012 patients) (RR 
0.82; 95% CI 0.32–2.06), nor any DVT: 9.6% (95/991 patients) vs. 8.4% (85/1012 
patients), (RR 1.14; 95% CI 0.86–1.51), skin injury: 2.5% (25/991 patients) vs. 2.2% 
(22/1012 patients), (RR 1.16; 95% CI 0.66–2.04), or mortality at 28 days: 14.6% 
(145/990 patients) vs. 16.5% (167/1011 patients), (RR 0.89; 95% CI 0-72–1.09). 
The ACCP guideline gives already a GRADE 2C recommendation of 
pharmacological thromboprophylaxis over mechanical thromboprophylaxis in 
critically ill patients (Kahn et al., 2012). Based on the results of Arabi et al., the 
grading of the recommendation is most likely to be upgraded (Arabi et al., 2019). No 
subgroup analysis has yet been published. In major trauma patients, however, the 
recommendation to combine mechanical prophylaxis to pharmacological 
prophylaxis might also be revised (Gould et al., 2012).  
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In a large observational study including 271 ICUs and nearly 300 000 hospital 
discharge events, the used VTE prophylaxis was evaluated (Lilly et al., 2014).  
Interestingly, only the use of pharmacological prophylaxis was associated with 
reduced in-hospital mortality OR 0.84 (95% CI 0.82–0.86, p<0.0001). Mechanical 
thromboprophylaxis was associated with a higher mortality risk, OR 1.11 (1.09–1.14, 
p<0.001) (Lilly et al., 2014). Furthermore, the risk persisted even when mechanical 
thromboprophylaxis was combined with anticoagulation although the reason for this 
is unknown. 
2.8 Aneurysmal subarachnoid hemorrhage patients  
Despite a decrease in the annual incidence of aSAH (Korja et al., 2016) the 1-year 
mortality after aSAH is still 50% (Korja et al., 2013). In the acute phase of aSAH, 
the blood coagulation and fibrinolytic systems are activated, resulting in increased 
coagulation (Ettinger, 1970). This provokes cerebral microthrombosis, a 
phenomenon that has been suggested to be a part of some clinical entities, such as 
early brain injury (EBI) and delayed cerebral ischemia (DCI) (Macdonald, 2014). An 
overview of the proposed pathophysiology is shown in Figure 6. EBI and DCI are 
both significant risk factors for poor neurological outcomes and increased mortality 
(Ahn et al., 2018; Broderick et al., 1994; Frontera et al., 2009). Moreover, because of 
the increased coagulation, the aSAH patients are considered as high-risk patients for 
VTE.   
 
 
 
Figure 6.  Pathophysiology of delayed cerebral ischemia 
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2.8.1 Overview of the coagulation changes after aneurysmal subarachnoid 
hemorrhage patients 
Managing thromboprophylaxis in aSAH patients is challenging. In the early stage of 
the disease course, the risk of re-bleeding is around 17% (31/179 patients) surpassing 
the risk of thrombosis (Fujii et al., 1996). After the aneurysm has been secured, the 
risk of bleeding varies depending on whether a craniotomy has been performed, 
whether there is an intracerebral hemorrhage, an external ventricular drain, a need 
for antithrombotic medications due to endovascular stenting or a need for further 
neurosurgical procedures. Nevertheless, the concomitant risk of VTE exists.  
In retrospective cohorts, the overall incidence of DVT after aSAH has ranged 
from 3.5% up to 18% (Kshettry et al., 2014; Ray et al., 2009), and the incidence 
seems to be higher than in other neurosurgical populations (Kim et al., 2009). When 
ultrasonography screening has been applied, the incidence of overall DVT is 
somewhat higher, around 9.7 to 24% (Ray et al., 2009; Serrone et al., 2013). On 
average, DVT is detected later if no screening has been conducted (Kim et al., 2009; 
Serrone et al., 2013). The symptomatic PE rate is 1.2 – 2% (Kshettry et al., 2014; Ray 
et al., 2009; Serrone et al., 2013).  
The known independent risk factors for DVT after aSAH are tobacco smoking, 
black race and long hospital stay (Serrone et al., 2013). Furthermore, the severity of 
aSAH correlates with the risk of DVT (Ray et al., 2009). VTE has been associated 
with in-hospital complications (e.g. pulmonary/cardiac and infectious 
complications) and the length of hospital stay (Kshettry et al., 2014). 
2.8.2 Pharmacological thromboprophylaxis in aneurysmal subarachnoid 
hemorrhage patients  
There are very limited RCT data on pharmacological thromboprophylaxis in aSAH 
patients. There is weak evidence that after surgical occlusion of the aneurysm, 
enoxaparin thromboprophylaxis might increase intracranial bleeding (4/85 patients)  
in comparison with placebo (0/85 patients) (Siironen et al., 2003). However, none 
of the four patients required any additional treatment. The incidence of symptomatic 
DVT remained unchanged: 3/85 patients in the placebo group vs. 1/85 patients in 
the enoxaparin group. In a meta-analysis conducted in a mixed neurosurgical 
population, the efficacy of LMWH and IPC was considered to be equal in DVT 
reduction, LMWH vs. GCS RR 0.60; 95% CI 0.44–0.81 and IPC vs. placebo RR 
0.41: 95% CI 0.21–0.78 (Collen et al., 2008). No statistical difference was seen in the 
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numbers of intracerebral hemorrhages, LMWH vs. mechanical prophylaxis RR 1.97; 
95% CI 0.64–6.09. The safety and efficacy profiles of LMWH and UHF were similar.  
2.8.3 Mechanical thromboprophylaxis in aneurysmal subarachnoid 
hemorrhage patients  
No RCT trials have been done investigating the use of mechanical 
thromboprophylaxis in the aSAH population, but the closest surrogates might be 
immobilized stroke patients. In CLOTS-1, 2518 stroke patients were investigated in 
a multicenter RCT and randomized 1:1 to either regular care plus thigh-length GCS 
or routine care without GCS (CLOTS, 2009). No benefit was observed from GCS 
treatment within 30 days of randomization: the incidence of all DVT was 10.0% vs. 
10.5%. More skin breaks, ulcers, and blisters occurred in the study group: 5 vs. 1%, 
OR 4.18 (95% CI 2.40–7.27). Mainly based on these results, the most recent 
Cochrane review does not recommend the routine use of GCS in stroke patients 
(Naccarato et al., 2010). 
In CLOTS-3, 2876 non-ambulatory stroke patients were randomized 1:1 to 
receive IPC care or no IPC (CLOTS, 2013). After randomization clinicians were 
allowed to start both prophylactic and therapeutic dose of UFH/LMWH. The 
incidence of DVT decreased significantly with IPC: 8.5 vs. 12.1%, RR 3.6% (95% 
CI 1.4–5.8). There was no difference in the incidences of either symptomatic DVT 
or PE. Skin breaks were more common in the IPC group (3% vs. 1.5% p=0.002). 
Pharmacological prophylaxis was used only in 17% of patients in both groups.  
2.8.4 Current guidelines for thromboprophylaxis in aneurysmal 
subarachnoid hemorrhage patients 
Both the Neurocritical Care Society and the European Stroke Organization 
guidelines advise starting mechanical thromboprophylaxis prior to occlusion of the 
aneurysm (Diringer et al., 2011; Steiner et al., 2013). After the aneurysm is secured, 
additional pharmacological thromboprophylaxis is recommended. This could be 
started 12–24 h after surgical occlusion and immediately after coiling (Steiner et al., 
2013). While the use of antifibrinolytic therapy prevents rebleeding (Hillman et al., 
2002; Starke et al., 2008), it increases the risk of DVT (Starke et al., 2008). Thus, it is 
considered to be contraindicated in patients with a high risk of thromboembolic 
complications (Diringer et al., 2011). However, an early (<48 h after the onset of 
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aSAH symptoms, short (<72 hours) course of antifibrinolytic treatment with 
tranexamic acid might be beneficial. 
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3 AIMS OF THE STUDY 
The main aim of this thesis was to study how to make thromboprophylaxis safer and 
more effective in critically ill patients.   Furthermore, the association of critical illness 
with blood coagulation was studied. 
 
The more detailed objectives were: 
1. To systematically review the literature of anti-Xa levels in critically ill patients 
receiving LMWH thromboprophylaxis and to evaluate the association of anti-Xa 
levels with clinically meaningful patient-centered endpoints (e.g., VTE or bleeding) 
(I) 
2. To compare the pharmacokinetics of enoxaparin using plasma anti-Xa levels 
when thromboprophylaxis was given either as a CII or a SCB in critically ill patients 
(II) 
3. To study coagulation parameters when enoxaparin thromboprophylaxis was 
given either as a CII or a SCB in critically ill patients (III) 
4. To analyze the coagulation after aSAH using ROTEM measurements in 
comparison with patients undergoing clipping of a non-ruptured aneurysm (IV) 
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4 MATERIALS AND METHODS 
4.1 Study I 
4.1.1 Study design 
Study I was a systematic review of the literature designed to assess anti-Xa levels in 
critically ill patients receiving LMWH thromboprophylaxis. The study design was 
published in PROSPERO (www.crd.york.ac.uk/PROSPERO, number 
CRD42015025744) before data extraction. The Cochrane Collaboration (Higgins et 
al., 2011), PRISMA Statement (Moher et al., 2009), and Meta-analysis Of 
Observational Studies in Epidemiology (MOOSE) reporting (Stroup et al., 2000) 
recommendations were used.  
In data gathering, the following databases were searched: MEDLINE, SCOPUS, 
Cochrane Library, and ClinicalTrials.com in collaboration with a university librarian. 
The following keywords were combined using Boolean Operators: Venous 
Thrombosis/thromboprophylaxis/ Venous Thromboembolism AND Critical 
Care/Intensive Care Unit/Critical Illness AND LMWH. No restriction on language, 
date, or type of publication was applied. The data search was completed in May 2015.  
Studies were selected using predefined inclusion criteria. The inclusion criteria 
were prospective in design, performed in adult (age >18 years) critical care patients, 
included more than ten patients, used any LMWH thromboprophylaxis, and 
included at least one anti-Xa measurement at a known time point after a specified 
LMWH administration. Two reviewers independently evaluated all identified titles 
and abstracts. Inter-rater agreement was calculated, and any disagreements were 
resolved through discussions.  
The studies retrieved for more detailed evaluation were also independently 
evaluated by the same two investigators. The following data were extracted from 
selected studies: study design, patient population, anti-Xa results, and clinical 
outcomes (i.e., DVT, symptomatic DVT, PE, symptomatic PE, and major or minor 
bleeding. The Downs and Black checklist was used for assessing the quality of the 
selected studies (Downs et al., 1998). 
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4.2 Studies II and III 
4.2.1 Study design (II and III) 
Studies II and III were based of a randomized, single-blind, controlled trial 
conducted in 40 critically ill patients who were recruited from ICUs of Tampere and 
Helsinki University hospitals between March 2014 and July 2016.  
Inclusion criteria were: ICU patients age between 18 and 80 years with an 
indication for pharmacological thromboprophylaxis; a BMI between 18–30 kg/m2 
and expected ICU stay over 72 hours. The following exclusion criteria were applied: 
indications for anticoagulant therapy other than thromboprophylaxis; intracranial 
hemorrhage or central neurosurgical operation within 3 months of ICU admission; 
diagnosis of disseminated intravascular coagulation according to International 
Society on Thrombosis and Haemostasis criteria (Taylor et al., 2001); known HIT; 
known hypersensitivity to enoxaparin or heparin; blood platelet count < 20 × 109/l, 
prothrombin time (PT) < 20% or International Normalized Ratio (INR) > 1.7; major 
hemorrhage within the last week unless definitively treated; glomerular filtration rate 
<50 ml/min/1.73 m2 (Cockcroft et al., 1976) or chronic dialysis; known HIV, 
hepatitis B or hepatitis C infection; pregnancy; and known liver disease. If a patient 
had received LMWH thromboprophylaxis within 24–72 hours before inclusion, 
randomization was done if the anti-Xa level was <0.1 IU/ml.  
Block randomization was performed using sequentially numbered and sealed 
envelopes that were stratified according to use of vasopressor. The randomization 
was conducted independently in each study site.  
4.2.2 Study intervention and clinical management (II and III) 
After obtaining consent, patients were randomized to receive 40 mg enoxaparin 
(Klexane, Sanofi, Espoo, Finland) either as a CII or a SCB for 72 hours. The CII 
was prepared by a pharmacist or an ICU nurse. The daily dose of 40 mg of 
enoxaparin sodium was diluted in 100 ml 0.9% sodium chloride solution that was 
divided into two 50 ml syringes and infused intravenously 4.2 ml/h via either a 
central or peripheral venous catheter using an automated pump. The study period 
lasted 72 hours, during which any discontinuations were recorded and if the break 
was over 2 hours, then the patient was excluded. The SCB of enoxaparin was given 
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once daily from a prefilled single-dose syringe containing 40 mg of enoxaparin 
sodium. Mechanical thromboprophylaxis was undertaken according to the regular 
clinical practice of each study site. The dosing of enoxaparin was not allowed to 
change during the study period. After the study period of 72 hours, the 
thromboprophylaxis was continued according to the regular ICU practice.  
4.2.3 Blood sampling (II and III) 
The blood samples for immediate anti-Xa analysis were taken at 0, 3, 6, 9, 12, 15, 18, 
24, 27, 48, 51, and 72 hours after the beginning of the study drug. Additional blood 
samples were obtained at 1.5 and 4.5 hours from patients in the CII group. Complete 
blood count, platelet and leukocyte counts, serum C-reactive protein concentrations 
were checked daily and INR or PT when clinically indicated. All study blood samples 
were taken from a heparin-naïve arterial line.  
In study III, additional blood samples were collected at 0 (presenting the 
baseline), 51 (presenting the final peak level for the SCB group), and 72 (representing 
the final trough level for the SCB group) hours. These were collected into sodium 
citrate anticoagulant (3.2%, 109 nM) tubes. Samples for AT, F1+2, fibrinogen, and 
D-dimer were centrifuged 2500 g for 15 min.  
Further additional samples were collected from patients treated in Helsinki 
University Hospital. These blood samples were first centrifuged at 2000 g for 10 min 
and then at 10 000 g for 10 min to obtain platelet-poor plasma (PPP) for 
thrombogram analysis.  
All plasma was divided into 0.5ml plastic tubes and stored at -80 C in a freezer at 
each study cite until analysis.  
4.2.4 Outcome measures  
4.2.4.1 Study II 
The primary outcome measure was the maximum plasma anti-Xa concentration 
within the 24 hours after the beginning of the study drug (Cmax0–24h). The secondary 
outcomes were the maximum anti-Xa concentration within 72 hours (Cmax0–72 h), area 
under the time-concentration curve (AUC) at 24 (AUC0–24 h), and 72 (AUC0–72 h) 
hours. The influence of vasoconstrictor infusion (yes/no) as well as total 
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vasoconstrictor dose on anti-Xa Cmax0–24h and AUC0–24 h were analyzed in order to 
evaluate the effect on the bioavailability of the SCB of enoxaparin. 
The following clinical adverse events were registered: major bleeding (requiring 
>2 units transfusion of red blood cells, intracranial bleeding or bleeding requiring 
therapeutic intervention or resulting in death), minor bleeding (any other bleeding), 
symptomatic DVT confirmed by compression ultrasound, symptomatic PE 
confirmed by CT pulmonary angiography and HIT (Cuker et al., 2012). 
Asymptomatic VTE events were not screened.   
At baseline, basic patient characteristics, comorbidities and APACHE II score 
were collated.  The daily Sequential Organ Failure Assessment score was calculated 
during the study period of 72 hours. The length of ICU stay, and all-cause mortality 
at day 90 after ICU admission were further registered.  
4.2.4.2 Study III 
The primary outcome measure was F 1+2 levels at 51 and 72 hours after the 
beginning of the study drug. Further markers of coagulation (anti-Xa, AT, D-dimer, 
and fibrinogen) were assessed. From these, the DIC scores were calculated (Taylor 
et al., 2001). Additionally, thrombin generation was analyzed with a calibrated 
automated thrombogram (TGA-CAT) from patients treated in Helsinki University 
Hospital.  
4.3 Study IV 
4.3.1 Study design 
Study IV (ClinicalTrials.gov identifier, NCT02540005) was a prospective, 
observational study conducted in Tampere University Hospital between October 
2015 and June 2016. During the study period of 72 hours, the coagulation status in 
aSAH patients was evaluated and compared with preoperative values in patients 
undergoing clipping of non-ruptured aneurysms.  
All consecutive patients who were admitted to the ICU because of aSAH were 
considered eligible. Inclusion criteria for the study group were age over 18 years, 
aSAH confirmed by brain computed tomography (CT) and confirmed aneurysmatic 
origin either with CT angiography (CTA) or digital subtraction angiography (DSA), 
 53 
the onset of symptoms less than 12 hours, and an expected ICU stay over 72 hours. 
Inclusion criteria for the control group were aged over 18 years, elective craniotomy 
due to a non-ruptured intracranial aneurysm, and expected hospital stay of over 72 
hours. The exclusion criteria for both groups were pregnancy, any long-term 
anticoagulant medication, except for aspirin <150 mg/day and known active cancer.  
4.3.2 Blood sampling  
The overall coagulation was evaluated using ROTEM. Additional blood samples for 
ROTEM analysis were collected at 12, 24, 48, and 72 hours since the onset of aSAH 
symptoms. From the control group, ROTEM samples were taken preoperatively 
(i.e., baseline), and these also served as a local reference range for ROTEM. From 
the aSAH patients, complete blood count, platelet and leukocyte counts, C-reactive 
protein, and international normalized ratio concentrations were measured daily 
during the study period of 72 hours.  
All study blood samples were taken from a heparin-naïve arterial line and 
analyzed immediately.  
4.3.3 Clinical management and outcome measures  
The primary outcome measure was EXTEM-MCF by ROTEM in the aSAH patients 
compared with baseline values from the control group. Secondary outcomes 
included other measured ROTEM parameters: EXTEM-CT, EXTEM-CFT, 
FIBTEM-MCF, INTEM-MCF, INTEM-CT, and INTEM-CFT. To further assess 
the contribution of platelets to the strength of the blood clot, the difference between 
EXTEM-MCF and FIBTEM-MCF was calculated. In addition, the association 
ROTEM parameters with the incidence of EBI and DCI was analyzed.  
During the ICU stay, aSAH patients were treated according to the neurointensive 
care guidelines (Diringer et al., 2011; Steiner et al., 2013). After the aneurysm was 
secured, all patients received pharmacological thromboprophylaxis, 4500 IU 
tinzaparin OD. If the aneurysm was secured by coiling, then the thromboprophylaxis 
was started at the same evening and if by clipping on the following evening. No 
additional mechanical thromboprophylaxis was used. The control patients received 
standard perioperative treatment. 
A bilateral compression ultrasonography of the lower extremity veins was done 
in both study and control patients once within days 3–5 (from the onset of aSAH 
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symptoms or from the operation day). If a DVT was detected, it was treated 
accordingly. If PE was suspected, a CT pulmonary angiography was done.  
The clinical severity of aSAH at admission was evaluated retrospectively to detect 
EBI. For this Hunt-Hess score was applied, scores 4–5 were classified as severe, and 
scores 1–3 as mild (Ahn et al., 2018; Hunt et al., 1968). A Fisher grading scale (grades 
1–4) was used to evaluate the severity of bleeding from the first head CT (Fisher et 
al., 1980). The incidence of symptomatic vasospasm is associated with the Fisher 
scale and being highest in grade 3 (Frontera et al., 2006).  
DCI was evaluated retrospectively using the ICU database (Centricity Critical 
Care Clinisoft; GE Healthcare, Barrington, Illinois, USA) at 24 hours to 14 days from 
the onset of aSAH. Criteria for DCI presented by Vergouwen et al. was used 
(Vergouwen et al., 2010). Accordingly, DCI was defined either clinically or 
radiologically. The clinical criteria included either a neurological deterioration for 
over 1 hour or a new neurological symptom, both of which could not be explained 
by other features. The radiological criterion was a new ischemic lesion on 
neuroimaging data that was not related to the primary aSAH insult or neurosurgery.  
Outcome data were evaluated using the Glasgow outcome scale score on day 90 
(Wilson et al., 1998).  
4.4 Laboratory methods 
4.4.1 Chromogenic Anti-Xa measurement (II)  
Anti-Xa activity was measured in fresh blood samples using a validated chromogenic 
assay without adding AT. The method used in Tampere University Hospital was 
STA-Liquid anti-Xa, Diagnostica Stago, and in Helsinki University Hospital 
HemosIL Liquid Anti-Xa on an ACL TOP 750 Analyzer, Instrumentation Company 
Laboratory/Werfen.  
The chromogenic anti-Xa measurement uses an fXa substrate that has a 
chromophore attached. When it interacts with fXa, the chromophore is cleaved 
(Figure 7) (Walenga et al., 2004). The released chromophore induces a color change 
that can be measured with a spectrophotometer. The magnitude is directly 
proportional to the amount of fXa in the plasma. During the anti-Xa measurement, 
a known amount of fXa is added to the analyzed plasma. If there is heparin or 
LMWH present, they will inhibit fXa by AT.  Thus, less fXa is available to cleave the 
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substrate and render the color change.  The amount of heparin can be further 
calculated using a standard curve with the known heparin concentration (Bates et al., 
2005). The results are presented as IU of anti-fXa.   
 
Figure 7.  The principle of chromogenic anti-Xa measurement. Abbreviations: fXa, activated 
coagulation factor X. 
4.4.2 Other markers of coagulation (III) 
AT levels in plasma samples were analyzed by chromogenic assays using the 
HemosiL (HemosIL Liquid Antithrombin and HemosIL Liquid Anti-Xa reagents 
on an ACL TOP 750 Analyzer) with reagents from Instrumentation Laboratory, 
F1+2 by an enzyme immunoassay (Enzygnost® F1+2, monoclonal, Siemens 
Healthcare Diagnostics, Espoo, Finland), fibrinogen with HemosIL Fibrinogen 
activity (IL QFA Thrombin, Clauss method) on an ACL Top Analyzer and D-dimer 
with an immunoturbidimetric assay (Quantia D-Dimer, Abbot Diagnostics, Espoo, 
Finland) on an Architect –analyzer. All analyses were performed in the core 
laboratory of Helsinki University Hospital.  
4.4.3 Thrombogram (III) 
Thrombin generation was measured by CAT using Thrombinosope software 
(Thrombinoscope, Stago, Asnières-sur-Seine, France) (Dargaud et al., 2012; Helin et 
al., 2015; Hemker et al., 2002). Measurements were done in 96-microtiter plates, 
where 80 μL of PPP was supplemented with 20 μL of either the inner method 
calibrator reagent or TF–containing reagent. Reagents comprised 1–5 pM TF and 4 
µM phospholipids in PPP (PPP Reagent Low). TGA-CAT was initiated by 20 μL of 
FluCa reagent mixture (Thrombinoscope, Stago, Asnières-sur-Seine, France). 
Analysis was conducted for a minimum of 60 min. The following TGA-CAT 
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parameters were registered: lag time, endogenous thrombin potential (ETP), peak 
amount of generated thrombin (Peak), and time-to-Peak (tt-Peak) (Figure 8). 
Additionally, PPP from 11 healthy controls served as a reference range. 
 
Figure 8.  Thrombogram. Abbreviations: A, Lag time; B, Time-to-Peak (tt-Peak); C, Peak amount of 
generated thrombin; D, Endogenous thrombin potential (ETP). 
4.4.4 Rotational thromboelastometry (IV) 
ROTEM analysis was conducted using a ROTEM delta analysis system (TEM 
Innovations GmbH, Munich, Germany). The analysis was performed in the central 
laboratory of Tampere University Hospital immediately after the blood sample was 
drawn.  
Each analysis included EXTEM, INTEM and FIBTEM analysis from which the 
following parameters were measured: clotting time (CT), clot formation time (CFT), 
and maximum clot firmness (MCF) (Figure 9). In brief, CT represents the interval 
to initiation of clot formation, CFT is the duration of 20 mm wide clot formation 
after CT, and it represents increasing polymerization of fibrin and beginning 
interaction between fibrinogen and platelets and MCF represents the overall 
maximum clot strength. The increased MCF is a sign of hypercoagulation (Akay et 
al., 2009). Every analysis was done using single-use reagents, and a more detailed 
description is shown in Table 4. 
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Figure 9.  Basic principle of ROTEM. Abbreviations: CT, clotting time; CFT, clot formation time; MCF, 
maximum clot firmness. 
Table 4.  Description of different ROTEM assays used. Abbreviations: TF, tissue factor. 
 
4.5 Statistical methods 
In study II, the primary endpoint was maximum anti-Xa concentration (Cmax) after 
a SCB of enoxaparin. No data on anti-Xa levels after a CII of enoxaparin were 
available. Thus, based on previous results after a SCB of enoxaparin, a clinically 
meaningful increase in the anti-Xa level was considered as 0.1 IU/ml (standard 
deviation, SD, 0.11 IU/ml).  Accordingly, at least 20 patients in both groups were 
needed to achieve 80% power with a significance level of 5%. A stratification 
according to use of vasoconstrictor was used to further assess the impact of 
vasoconstrictor infusion on anti-Xa levels.  
In study IV, the primary endpoint was MCF (mm) by EXTEM. The sample size 
was calculated using previous results from a non-cardiac population (Hincker et al., 
2014). Accordingly, at least 16 patients in each group were needed to achieve an 80% 
power to detect a clinically meaningful increase from 65mm to 70 mm (SD 5 mm) 
in MCF with a significance level of 5%.  
Data are presented in absolute numbers and percentages (%), in medians with 
IQR or means with SD as appropriate. The threshold for the statistical significance 
Assay Activation method Citration Recalcification Interpretation
EXTEM TF Yes Yes Extrinsic pathway (platelets and fibrinogen)
INTEM Contact Yes Yes Clot formation via the contact phase
FIBTEM TF Yes Yes Clot formation after platelet inhibition with 
cytochalasin D
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level was set at a p-value <0.05. No Bonferroni correction for multiple comparisons 
was done.  
The normality of data was assessed with Shapiro-Wilk test. Comparisons between 
continuous variables were performed using Student’s t-test for normally distributed 
variables and Mann-Whitney U test for non-normally distributed variables. For 
categorical variables, univariate analysis with Fisher’s exact test was performed. 
Spearman’s rank correlation test was used to determine the relationship between two 
continuous variables. Pair-wise comparisons of non-parametric variables were made 
using Wilcoxon signed-rank test. Inter-rater agreement was calculated by Cohen’s 
kappa (k) 
All statistical analyses were performed using the SPSS statistical software, version 
23.0 or 24.0 (IBM Corp., Armonk, New York, USA). 
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5 ETHICAL ASPECTS (STUDIES II–IV) 
All clinical study protocols (II–IV) were independently assessed in the local ethics 
committee of Pirkanmaa. The study protocols II and III were further approved by 
the Finnish Medical Association (FIMEA) and each study hospital. All trials were 
conducted in accordance with the amended Declaration of Helsinki.  Written 
informed consent was obtained from all patients or their next of kin before study 
enrolment.  
5.1 Studies II and III 
The pharmacokinetics of LMWHs in the critically ill is poorly understood. Based on 
two pilot studies, decreased bioavailability after subcutaneous dosing of LMWH has 
been suspected (Dörffler-Melly et al., 2002; Priglinger et al., 2003). Thus, 
investigating enoxaparin pharmacokinetics using a CII was warranted.  
The dosage and modes of administration of enoxaparin were in agreement with 
current recommendations and did not significantly differ from the current guidelines 
for thromboprophylaxis in critically ill patients (Gould et al., 2012; Kahn et al., 2012). 
An intravenous bolus of enoxaparin is generally used e.g. during percutaneous 
coronary intervention (Montalescot et al., 2011). However, intravenous loading dose 
was omitted, since immediately after intravenous bolus anti-Xa levels are known to 
be high before drug distribution (Aiach et al., 1983). Thus, no additional risks for 
bleeding or thromboembolic complications were anticipated when enoxaparin 
thromboprophylaxis was given as a CII. During the study period, a total of 30-34 
samples (total 186-210 ml blood) was taken depending on the study group. The 
amount of blood can be considered insignificant. All blood samples were taken from 
an arterial line already in place.  
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5.2 Study IV  
All patients received routine care in the ICU and the neurosurgical ward. The 
sampling did not influence the treatment, and the treating physician was unaware of 
the results. The total amount of extra blood samples was small (9-14 ml/patient), 
and the samples were drawn from an arterial line already in place. A compression 
ultrasound of the lower extremities was conducted once in all patients on days three 
to five. It is a non-invasive procedure with minimal complication risk. If a DVT was 
detected, the treating physician was informed, and the treatment was started 
accordingly. 
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6 RESULTS 
6.1 Study I 
The literature search revealed 5206 potentially relevant studies, of which 31 were 
retrieved for more detailed evaluation. The number of selected studies was 18, 
including two RCTs and 16 observational studies. A total number of patients was 
1644. Enoxaparin had been studied in 12 publications (Costantini et al., 2013; Gouya 
et al., 2012; Haas et al., 2005; Lim et al., 2013; Malinoski et al., 2010; Mayr et al., 
2002; Priglinger et al., 2003; Robinson et al., 2010; Robinson et al., 2013; Rutherford 
et al., 2005; Vincent et al., 2011; Zenáhlíková et al., 2010), dalteparin in four 
publications (Douketis et al., 2008; Droege et al., 2014; Rabbat et al., 2005; Rommers 
et al., 2006), certoparin in one report (Jochberger et al., 2005) and nadroparin in one 
trial (Dörffler-Melly et al., 2002). The detailed data of selected studies are presented 
in Table 5 and the target values for adequate anticoagulant levels in Table 6.  
The median peak anti-Xa varied from <0.1 (Jochberger et al., 2005) to 0.35 IU/ml 
(Douketis et al., 2008) and the mean peak anti-Xa from 0.09 to 0.40 IU/ml (Dörffler-
Melly et al., 2002; Robinson et al., 2013). Only four studies reported trough anti-Xa 
levels, and the medians were between undetectable and <0.1 IU/ml (Douketis et al., 
2008; Jochberger et al., 2005; Mayr et al., 2002). 
The majority, 12 out of 18 studies, reported clinical events, such as VTE and 
bleeding.  These were not associated with anti-Xa levels. In one study done in 
critically ill trauma and surgical patients, a trough level below 0.1 IU/ml correlated 
with all DVT incidence (37 vs. 11%, p=0.026) when routine screening bilateral lower 
and upper extremity Duplex ultrasonography was used within 48 hours of admission 
and then weekly  (Malinoski et al., 2010).  
The median overall Downs and Black Quality score was 19 (IQR 15–20) of 27 
consisting of the following subscores: 8.5 (IQR 7–10) of 11 for reporting, 1 (IQR 1–
2) of 3 for external validity, 5 (IQR 4–5) of 7 for internal validity-bias, and 3 (IQR 
2–5) of 7 for internal validity-confounding and power. 
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Table 5.  Selected studies for systematic review (I). Abbreviations: BID, twice a day; CrCl, 
creatinine clearance; ICU, intensive care unit; LMWH, low-molecular-weight heparin; 
MICU, medical intensive care unit; NS, not specified; OD, once a day; SICU, surgical 
intensive care unit; TICU, trauma intensive care unit.  
 
 
 
Study Population LMWH dose Peak anti-Xa  IU/ml Trough anti-Xa 
IU/ml 
Certoparin
Jochberger et al. (2005) Mixed ICU (n=30+32) 3000 IU OD or bid <0.1 (<0.1–0.2) vs. <0.1 
(<0.1–0.28)
<0.1 (<0.1–0.17) 
vs. <0.1 
Dalteparin
Douketis et al. (2008) ICU, CrCl <30 ml/min 
(n=138/156)
5000 IU  OD d3:0.29 (0.20–0.42),  
d10:0.35 (0.24–0.43), 
d17:0.34 (0.27–0.45)
<0.1 (<0.1–<0.1) 
Droege  et al. (2014) TICU (n=190/785) 5000 IU OD or bid NS NS
Rabbat et al.   (2005) Mixed ICU, CrCl >30 
ml/min  (n=19)
5000 IU OD 0.3 NS
Rommers et al.   (2006) Mixed ICU (n=7+7) 2500 IU OD 0.15 (±0.05) vs. 0.14 
(±0.06)
 0.05 (± 0.06) vs. 
0.02 (±0.02)
Enoxaparin
Costantini et al.   (2013) TICU  (n=61) 30–60 mg bid NS NS
Gouya et al.   (2012) MICU vs. ward (n=15+16) 40 mg OD 0.16 (0–0.22) vs. 0.2 
(0.15–0.27) 
NS
Haas et al.   (2005) TICU nonedematous 
(n=11/14) vs. edematous 
30 mg  bid  0.27 vs. 0.12 NS
Lim et al. (2013)     MICU (n=55) 40 mg OD 0.22 (0.17–0.26)  0 (0–0.03)
Malinoski et al.  (2010) SICU (n=54), through <0.1 
IU/ml) vs. through > 0.1 
30 mg bid  0.17 (±0.1) vs. 0.27 
(±0.1)
NS
Mayr et al.  (2002)        Mixed ICU (n=89) 40 mg OD  0.18 (<0.1–0.52)  <0.1 (<0.1–0.43)
Priglinger et al. (2003) Mixed ICU vs.  ward  
(n=16+13)
40 mg OD NS NS
Robinson et al. (2010) Mixed ICU 
(n=18+16+20+18)
40, 50, 60 or 70 mg 
OD
0.13, 0.14, 0.27 vs. 0.29 NS
Robinson et al. (2013) Mixed ICU 
(n=20+20+19+19)
40 mg OD, 30 mg  bid, 
40 mg bid or 1 mg/kg 
0.20, 0.08, 0.17 vs. 
0.34, d3: 0.13, 0.15, 
NS
Rutherford et al. (2005) TICU (n=17) 40 mg OD  0.19 (±0.09) 0.04 (±0.04)
Vincent et al.  (2011) Mixed ICU (n=36) 30 mg bid 0.24 (0.19)  0.10 (0.09)
Zenáhlíková et al.  (2009) MICU (n=16) 40 mg OD 0.17 (±0.17) NS
Nadroparin
Dörffler-Melly et al.  (2002) ICU  vs. ward  
(n=15+15+15)
2850 IU OD 0.09  vs. 0.23vs. 0.28 NS
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Table 6.  Target levels for thromboprophylaxis (I) and the used references in selected studies. 
Abbreviations: NS, not specified 
 
 
Study Target for anti-Xa 
IU/ml
Reference
Certoparin
Jochberger et al. (2005) Any time 0.1-0.3 Levine et al. (1989)
Dalteparin
Douketis et al. (2008) Peak 0.2–0.4 Levine et al. (1989)
Droege  et al. (2014) At 12h >0.1 NS
Rabbat et al. (2005) Peak 0.2–0.4 Levine et al. (1989)
Rommers et al. (2006) NS
Enoxaparin
Costantini et al. (2013) Peak  0.2–0.4 Samama et al (1995) 
Nutescu et al. (2009)
Gouya et al. (2012) NS
Haas et al. (2005) Peak >0.1 Mayr et al. (2002), 
Levine et al. (1989)
Lim et al. (2013)     Peak 0.1–0.3 Levine et al. (1989)
Malinoski et al. (2010) Trough >0.1 Levine et al. (1989)
Mayr et al. (2002)        Any time 0.1-0.3 Levine et al. (1989)
Priglinger et al. (2003) NS
Robinson et al. (2010) Any time 0.1–0.3 Mayr et al. (2002), 
Levine et al. (1989)
Robinson et al. (2013) Peak 0.1–0.4 Levine et al. (1989)
Rutherford et al. (2005) Any time 0.1–0.2 NS
Vincent et al. (2011) Any time >0.1 Levine et al. (1989)
Zenáhlíková et al. (2009) Peak 0.2–0.4 Rabbat et al. (2005)
Nadroparin
Dörffler-Melly et al. (2002) Peak 0.3–0.4 Leyvraz et al. (1991)
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6.2 Study II 
Forty patients were randomized but one subject had to be excluded because of an 
infusion pump failure, leaving 39 patients to modified intention-to-treat (ITT) 
analysis. Furthermore, 7 patients were excluded leaving 32 in the per-protocol (PP) 
analysis. The study flowchart is illustrated in Figure 9.  
 
 
Figure 10.  Flowchart of the study enrollment (II). Abbreviations: BMI, body mass index; GFR, 
glomerular filtration rate; ITT, intention-to-treat; PP; per-protocol analysis. 
The baseline characteristics and laboratory values are shown in Table 7. No 
differences existed between the groups. 
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Table 7.  Baseline and laboratory characteristics (II). Data are presented as n (%) or median 
(interquartile range). Abbreviations: APACHE, Acute Physiology and Chronic Health 
Evaluation; BMI, body mass index; Hct, hematocrit; ICU, intensive care unit; LMWH, 
low-molecular-weight heparin; WBC, white blood cell. 
 
Patient characteristics Continuous intravenous 
infusion n=23
Subcutaneous 
bolus n=16
Male sex 13 (57) 14 (88)
Age, years 52 (45–59) 56 (42–64)
BMI, kg/m2 27 (23–30) 27 (24–30)
Active cancer 2 (9) 2 (13)
Diabetes 4 (17) 2 (13)
Smoking 13 (57) 5 (31)
Alcohol abuse 11 (48) 8 (50)
Hypertension 9 (39) 6 (38)
APACHE II 16 (14–20) 18 (11–26)
Creatine Clearance, ml/min 121 (84–152) 122 (94–162)
Norepinephrine 8 (35) 7 (44)
Sepsis 7 (30) 7 (44)
Septic shock 2 (9) 1 (6)
Primary admission diagnosis 
Cardiovascular 1 (4) 0
Respiratory 10 (44) 6 (38)
Gastrointestinal 7 (30) 6 (38)
Neurologic 1 (4) 0
Infection 2 (9) 2 (13)
Trauma 1 (4) 1 (6)
Metabolic 1 (4) 1 (6)
LMWH prior inclusion 11 (48) 5 (31)
Length of ICU stay before
LMWH  (hh:mm)
18:56 (10:18–26:47) 17:33 (13:55–24:55)
Mechanical ventilation 15 (65) 12 (75)
Platelet count, 109/l 195 (153–319) 142 (122–192)
WBC count, 109/l 13 (8–17) 12 (10–21)
C reactive protein mg/l 236 (140–295) 262 (190–393)
Hct % 0.36 (0.30–0.38) 0.34 (0.29–0.43)
Bilirubin µmol/l 12 (7–20) 13 (9–15)
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Within the first 24 hours, the median anti-Xa Cmax0–24h was lower in the CII in 
comparison with the SCB group: 0.05 IU/ml (IQR 0.05–0.18 IU/ml) vs. 0.18 IU/ml 
(IQR 0.12–0.33 IU/ml), respectively (p<0.05), Table 8. Within 72 hours the 
difference was similar: median anti-Xa Cmax0–72 h was 0.14 IU/ml (0.05–0.22 IU/ml) 
in the CII group and 0.23 IU/ml (0.20–0.38 IU/ml) in the SCB group (p<0.05). At 
72 hours the median anti-Xa was higher in the CII than in the SCB group: 0.12 
IU/ml (IQR 0.05–0.17 IU/ml) vs. 0.05 IU/ml (IQR 0.01–0.05), p<0.05.  The AUC 
values did not differ. PP analysis did not affect the results. Norepinephrine infusion 
did not significantly alter plasma anti-Xa levels or AUCs.  
No DVTs were diagnosed. Three patients had PE; two in CII and one in SCB 
groups. Four minor bleedings were seen. The 90-day mortality was 12.8%.  None of 
these adverse events displayed any associations with anti-Xa levels. 
Table 8.  Pharmacokinetic parameters between study groups (II). Data are presented median 
(interquartile range). Abbreviations: anti-Xa, anti-factor Xa; AUC, area under the time- 
concentration curve; Cmax, maximum concentration; ITT, intention-to-treat; PP, per-
protocol  p<0.05. 
 
6.3 Study III 
From 40 initially randomized patients, two patients were excluded (one because of 
infusion pump failure resulting in an erroneous enoxaparin dose and one because of 
missing frozen samples), leaving 22 in the CII and 16 in the SCB group. TGA-CAT 
Pharmacological 
parameters
Continuous 
intravenous infusion
Subcutaneous bolus
ITT Anti-Xa Cmax 0–24 h 0.05 (0.05–0.18) 0.18 (0.12–0.33)
Anti-Xa Cmax 0–72 h 0.14 (0.05–0.22) 0.23 (0.20–0.38)
AUC (0-24 h) 1.2 (1.0–2.9) 1.54 (1.2–4.1)
AUC (0-72 h) 5.4 (3.6–10.9) 7.7 (5.9–11.7)
PP Anti-Xa Cmax 0–24 h 0.05 (0.05–0.16) 0.19 (0.11–0.34)
Anti-Xa Cmax 0–72 h 0.11 (0.05–0.19) 0.22 (0.18–0.34)
AUC (0-24 h) 1.2 (0.8–2.7) 1.6 (1.3–4.8)
AUC (0-72 h) 4.1 (1.8–8.0) 5.7 (3.1–8.0)
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was performed in 18 patients from whom 5 pM TF stimulation triggered thrombin 
generation in 13 (72%) patients: 7 in the CII and 6 in the SCB group (Figure 11). 
Only an ITT analysis was carried since in study II, the results of ITT and PP analyses 
did not differ.  
 
Figure 11.  CONSORT flowchart (III). Abbreviations: CII, continuous intravenous infusion; SCB, 
subcutaneous bolus; TGA-CAT, thrombin generation assay by calibrated automated 
thrombogram. 
At baseline, no difference was seen in coagulation parameters. D-dimer, F 1+2, and 
fibrinogen were markedly above the upper reference level and AT was below the 
lower reference level in all patients. At 51 and 72 hours, F1+2 levels were 
significantly lower in the CII in comparison with the SCB group: 372 pM/l (IQR 
237–627 pM/l) and 374 pM/l (IQR 287–531 pM/l) vs. 634 pM/l (IQR 501–846 
pM/l) and 657 pM/l (IQR 482–880 pM/l), p<0.05 (Figure 12).  AT levels nearly 
normalized in the CII group, but not in the SCB group. The detailed coagulation 
parameters are shown in Table 9.  
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Figure 12.  Comparison between F1+2 levels in study groups (III). Abbreviations: CII, continuous 
intravenous infusion; SCB, subcutaneous bolus. 
Table 9.  The coagulation variable results (III). Data are presented median (interquartile range). 
Abbreviations: Anti-Xa, anti-factor Xa; AT, antithrombin; CII, continuous intravenous 
infusion; DIC, disseminated intravascular coagulation; F1+2, prothrombin fragment 
1+2; NA, not applicable; SCB, subcutaneous bolus.  p <0.05 within groups (baseline 
vs. 51 h or baseline vs. 72 h from the study start. respectively),  p <0.05 between 
groups (CII vs. SCB) 
 
 
At 51 hours, both lag time and time to peak were shorter in the CII group than in 
the SCB group: 4.3 min (IQR 4.0–6.0 min) vs. 7.5 min (IQR 5.8–14.8 min), 
respectively, p <0.05 and 7.7 min (IQR 6.3–8.3 min) vs. 14.3 min (IQR 9.5–27.1min), 
respectively, p <0.05. The peak concentration was lower in the CII than in the SCB 
group at 72 hours 271 vs. 356 nM, respectively (p <0.05) (Table 10). 
 
CII 65 (52–89) 79 (59–94) 83 (64–96) 
SCB 70 (63–81) 70 (54–82) 69 (54–110)
NA CII 0.05 (0–0.05) 0.10 (0.05–0.13) 0.12 (0.05–0.17)
SCB 0.05 (0–0.05) 0.21 (0.09–0.25) 0.05 (0.01–0.05)
CII 3.1 (1.7–6.1) 5.2 (1.8–8.5) 6.1 (2.2–7.1)
SCB 5.4 (1.7–7.0) 5.5 (2.5–9.1) 3.1 (2.7–7.3)
NA CII 3 (2–3) 3 (0–3) 3 (1–3)
SCB 3 (2–3) 3 (2–3) 2 (2–3)
69–229 CII 438 (197–731) 372 (237–627) 374 (287–531)
SCB 413 (300–831) 634 (501–846) 657 (482–880)
CII 6.9 (4.9–8.8) 7.9 (6.8–9.1) 7.5 (6.8–8.7)
SCB 7.9 (5.9–9.3) 8.6 (6.6–9.5) 7.6 (5.9–9.2)
72 h
n=38 (at peak for SCB) (at  trough for SCB )
Variable Reference 
range
Study 
group
0 h 51 h
F 1+2 (pM/l)
Fibrinogen  
(g/l)
2–4
AT (%) 85–125
Anti-Xa 
(IU/ml)
D-dimer 
(mg/l)
<0.5 
DIC-score
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Table 10.  The thrombogram results (III). Data are presented median (interquartile range). 
Abbreviations: ETP, endogenous thrombin potential; CII, continuous intravenous 
infusion; Peak, peak amount of thrombin; SCB, subcutaneous bolus; TGA-CAT, 
thrombin generation assay by calibrated automated thrombogram. values of healthy 
adults p <0.05 within groups (baseline vs. 51 h or baseline vs. 72 h from the study 
start. respectively), p <0.05 between groups (CII vs. SCB) 
 
No correlation was evident with any of the TGA-CAT parameters and anti-Xa levels. 
In the CII group, the lag time (.882) and tt-Peak (.791) correlated significantly with 
AT, but inversely with F 1+2 (-.937) and C-reactive protein (-.847) at 51 hours. At 
the same time, F 1+2 levels and Peak (.929) had a significant correlation in the SCB 
group.  
6.4 Study IV 
The study included 17 aSAH and 16 control patients. The demographics are detailed 
in Table 11. The groups were reasonably balanced; however, the number of smokers 
was higher in the aSAH group, and the aSAH patients were younger than the control 
group. Majority of ruptured aneurysms were secured with coiling (Table 12). Severe 
EBI was diagnosed in four and DCI in 7 of the 17 aSAH patients. However, on day 
90, a majority, 60%, of the patients showed functional neurological recovery (Table 
12). The 90-day mortality was 5.9%. Two aSAH patients had an asymptomatic DVT, 
and in both, a PE was confirmed irrespective of ROTEM analysis results.  
  
2.6 (2.3–2.7) CII 3.7 (3.5–4.7) 4.3 (4.0–6.0)  4.8 (4.5–6.5)
SCB 4.8 (3.5–6.8) 7.5 (5.8–14.8)  4.7 (2.9–8.2)
1278 (1123–1467) CII 1543 (1349–1556) 1448 (1289–1531) 1411 (1219–1471)
SCB 1495 (1244–1543) 1038 (843–1677) 1545 (1326–2293)
210 (161–232) CII 295 (288–302) 303 (225–309) 271 (215–299)
SCB 256 (238–280) 125 (29–180) 364 (287–430) 
6.1 (5.5–7.3) CII 6.2 (6.0–7.0) 7.7 (6.3–8.3)  7.3 (7.2–9.5)
SCB 7.4 (5.7–9.4) 14.3 (9.5–27.1)  6.7 (4.7–10.5)
CII n=8, SCB n=5
Reference range
Lag time,   
min
ETP,    
nM/min
Peak,           
nM
Time to 
peak, min
TGA-CAT 
parameter
Study 
group
0 h 51 h 72 h
CII n=7, SCB n=6  CII n=7, SCB n=7
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Table 11.  The baseline demographics of included patients (IV). Data are presented as n (%) or 
median (interquartile range). Abbreviations: aSAH, aneurysmal subarachnoid 
haemorrhage; ACA, anterior communicating artery; BA, basilar artery; BMI, body mass 
index; HTA, hypertensio arterialis; ICA, internal carotid artery; MCA, middle cerebral 
artery; PCA, posterior cerebral artery; PA, pericallosal artery. p<0.05. 
 
  
Characteristic
aSAH patients 
(n=17)
Control patients 
(n=16)
BMI 30 (25–33) 28 (25–31)
Age 49 (40–60) 62 (56–67)
Sex male 6 (35.3) 7 (43.8)
Smoking 10(58.8) 6 (37.5)
Alcohol abuse 2 (12.5) 0
HTA 7 (41.2) 11 (68.8)
Diabetes 0 3 (18.8)
Known cancer 1 (5.9) 1 (6.3)
Low-dose aspirin 1 (5.9) 5 (31.3)
ACA 6 (35.3)
BA 2 (11.8)
ICA 4 (23.5)
MCA 4 (23.5) 15 (93.8)
PCA 1 (5.9)
PA 0 1 (6.3)
Aneurysm location
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Table 12.  Neurological outcome of aSAH patients (IV). Abbreviations: GOSe, Glasgow outcome 
score extended; LMWH, low-molecular-weight heparin; TXA, tranexamic acid. 
 
The laboratory results and ROTEM assays are in Table 13. At 72 hours EXTEM-
MCF and FIBTEM-MCF were significantly higher in aSAH when compared to the 
baseline values from the control group: 68.0 mm (IQR 66.0–71.0 mm) vs. 64.5 mm 
(IQR 59.5–66.8 mm), p=0.024 and 23.9 mm (IQR 19.0–25.0 mm) vs. 15.4 mm (IQR 
12.5–17.8 mm), p=0.001, respectively.  
 
  
Characteristics Mean (SD) n (%)
Hunt Hess 2.4 (1)
1 2 (11.8)
2 10 (58.8)
3 1 (5.9)
4 4 (23.5)
Fisher scale 3 (0.9)
Fisher 1 0
Fisher 2 6 (35.3)
Fisher 3 5 (29.4)
Fisher 4 6 (35.3)
Treatment
Clipping 4 (23.5)
Coiling 13 (76.5)
TXA 1 (5.9)
LMWH during ICU 15 (88.2)
GOSe score at 90 d 6.7 (1.9)
Death 1 (5.9)
Vegetative state 0
Lower severe disability 0
Upper severe disability 0
1 (5.9)
3 (17.6)
Lower good recovery 3 (17.6)
Upper good recovery 7 (41.2)
Lower moderate disability
Upper moderate disability
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Table 13.  ROTEM results. Data presented as median (interquartile range) or mean (standard 
deviation) (IV). Abbreviations: aSAH, aneurysmal subarachnoid hemorrhage; CFT, clot 
formation time; CRP, C-reactive protein; CT, clotting time; Hb, hemoglobin; MCF, 
maximum clot firmness. p<0.05. 
 
At 72 hours in patients who further developed DCI, FIBTEM-MCF was significantly 
higher in comparison to aSAH patients without DCI: 25.0 mm (IQR 66.8–69.8) vs. 
19.0 mm (IQR 16.5–22.5 mm), p=0.012 (Figure 13). The results were comparable in 
patients with EBI.  
 
Figure 13.  Association with FIBTEM-MCF and the incidence of early brain injury (A) and delayed 
cerebral ischemia (B) (IV). p<0.05. 
Parameter
Reference 
range  Control group 12 24 48 72
EXTEM
MCF (mm) 50–72 64.5 (59.5–66.8) 64 (62.0–69.5) 68 (63.0–70.0) 66 (65.5–69.0) 68.0 (66.0–71.0)
CT (s) 38–79 48 (45–58) 53 (48–57) 54 (45–61) 51 (47–62) 52 (45–61)
CFT (s) 34–159 96.5 (81.3–120.5) 100 (71.5–109.5) 101 (68.5–111.5) 86.0 (69.0–92.0) 74.0 (65.0–89.0)
INTEM
MCF (mm) 50–72 65.5 (61.3–68.0) 65.0 (62.5–71.5) 68 (64.0–71.5) 67 (65.5–70.0) 67.5 (65.8–71.3)
CT (s) 100–240 158 (149–170) 142 (129–167) 145 (129–167) 149 (138–167) 149 (143–159)
CFT (s) 30–110 66 (58.5–78.5) 72 (51.5–82.5) 65 (51.0–74.5) 61 (52.5–79.0) 59 (50.5–66.8)
FIBTEM
MCF (mm) 9–25 15.4 (12.5–17.8) 15 (13.5–21.5) 16 (14.5–22.5) 19 (16.5–23.0) 23.0 (19.0–25.0)
Platelet (109/l) 150–360 244  (88) 240 (50) 217 (66) 221 (66)
Leucocyte (109/l) 3.3–8.2 7.2 (1.6) 13.7 (3.9) 13.5 (3.9) 12.3 (3.5)
Hb(g/l) 134–167 145 (13) 132 (15.2) 124 (12.5) 127 (12.6)
CRP (mg/l) < 10 23.7 (13.0–36.8) 8.3 (3.7–13.2) 19.5 (9.2–45.5) 34 (6.2–88.5)
From the onset of aSAH (h)
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7 DISCUSSION 
7.1 Anti-Xa levels with low-molecular-weight heparin 
thromboprophylaxis in critically ill patients (I) 
In the systematic review, the reported median peak anti-Xa levels were between <0.1 
to 0.35 IU/ml, and the mean peak anti-Xa ranged from 0.09 to 0.40 IU/ml. The 
reported median trough levels were generally low: undetectable to <0.1 IU/ml.  
The interpretation of these results is challenging. Laboratory monitoring of 
prophylactic anticoagulation with anti-Xa level is not generally recommended since 
the association with clinical results – thrombosis or bleeding – is considered weak. 
At the moment, the measurement of anti-Xa is restricted to special cases where the 
anticoagulant effect of LMWHs is thought to be either unpredictable or uncertain, 
such as in obese patients and patients with renal insufficiency (Garcia et al., 2012; 
Nutescu et al., 2009). Nonetheless, in clinical research, the measurement of anti-Xa 
activity is widely used. There are no validated targets for prophylactic range and 
various arbitrary ranges have been implemented, complicating the interpretation of 
the results. Usually, the target levels are given for peak anti-Xa levels (Samama, 1995). 
It has been suggested that the target peak anti-Xa level should be decided based on 
the risk of thrombosis: 0.1–0.25 IU/ml for low risk and 0.2–0.5 IU/ml for high risk 
(Samama, 1995). The more recent trials conducted in postoperative patients 
receiving enoxaparin thromboprophylaxis have implemented higher peak anti-Xa 
targets: 0.2–0.4 IU/ml  BID dosing and 0.3–0.5 IU/ml for OD dosing (Pannucci et 
al., 2017a; Pannucci et al., 2017b). 
In the selected studies, the target levels set for anti-Xa level were most commonly 
given either as a constant target of 0.1–0.3 IU/ml or as peak level of 0.2–0.4 IU/ml 
(Table 6). These targets were reported irrespective of the type of LMWH or dosing. 
Interestingly, these targets were mainly based on the same study by Levine et al 
(Levine et al., 1989). In this substudy of RCT, 163 patients undergoing total hip 
replacement were evaluated. The patients received enoxaparin 40 or 60 mg OD 
subcutaneously. Anti-Xa levels were determined at 12 hours after previous 
enoxaparin injection on days 0, 1, 3, and 6 post-operatively. They observed that the 
cut-off anti-Xa level for hematoma was >0.2 IU/ml and for thrombosis <0.1 IU/ml 
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By using known pharmacokinetic principles of enoxaparin (Aiach et al., 1983), they 
further estimated that peak anti-Xa levels for thromboprophylaxis should be 0.1–0.4 
IU/ml (Levine et al., 1989).   
In a non-inferiority trial conducted by Leyvraz et al., thromboprophylaxis doses 
of UFH and nadroparin (41–62 IU/kg) were as effective in the prevention of 
proximal DVT after total hip replacement (Leyvraz et al., 1991). During the first 
three postoperative days, the mean peak anti-Xa levels after nadroparin were 
between 0.25 IU/ml and 0.29 IU/ml and between 0.33 IU/ml and 0.37 IU/ml 
during the fourth and 10th postoperative days. No association was seen between 
anti-Xa levels and DVT rate. Nevertheless, these results have been used as indirect 
evidence of adequate thromboprophylaxis (Dörffler-Melly et al., 2002). 
However, if using the peak target of 0.2–0.4 IU/ml, only 8 out of 15 studies met 
this target partly, but only 4 out of 15 if it was an ICU cohort investigated (Table 5 
and 6). The highest anti-Xa levels were seen in patients with renal insufficiency 
(Douketis et al., 2008; Rabbat et al., 2005) but also with increasing LMWH dose 
(Robinson et al., 2010; Robinson et al., 2013). 
No sign of LMWH accumulation was seen in any of the studied cohorts. The 
low-anti-Xa levels seemed to be associated with a higher body weight, (Costantini et 
al., 2013; Droege et al., 2014; Mayr et al., 2002) and when weight-based dosing of 
LMWH was used, anti-Xa levels were higher (Robinson et al., 2013). A weak 
association was detected with anti-Xa and low AT level in two studies (Jochberger 
et al., 2005; Zenáhlíková et al., 2010). 
Based on the systematic review, there was no clear association with clinical events 
and the anti-Xa level. In critically ill trauma patients, a low trough anti-Xa level (<0.1 
IU/ml) was associated with an increased risk for VTE (Malinoski et al., 2010). Similar 
results have been observed in retrospective studies. Moreover, there is increasing 
evidence that peak anti-Xa level <0.3 IU/ml might be associated with post-operative 
VTE (Pannucci et al., 2017a). To reach anti-Xa levels > 0.3 IU/ml in critically ill 
patients, increasing the enoxaparin dose up to 40 mg bid or 1 mg/kg OD was 
required (Robinson et al., 2013). 
As stated before, monitoring LMWH thromboprophylaxis is not generally 
recommended in critically ill patients (Garcia et al., 2012). Furthermore, the quality 
of the current literature was fair, and the selected studies were underpowered to 
detect clinical events (Downs et al., 1998; Hooper et al., 2008). Nevertheless, 
increasing dosing of LMWH thromboprophylaxis in critically ill patients might be 
beneficial.    
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7.2 Route for low-molecular-weight heparin anticoagulation (II and 
III)? 
 
In study II, it was found that when enoxaparin thromboprophylaxis was delivered 
as a CII, the maximum concentration of anti-Xa was lower during the first 24 hours 
than was the case with SCB. The same was seen when the pharmacokinetic steady 
state of enoxaparin was reached.  
It seems that administering 40 mg of enoxaparin as a SCB, the most commonly 
referred peak target for thromboprophylaxis in critically ill patients, i.e. 0.2–0.4 
IU/ml (Samama, 1995), was reached within 72 hours. The Cmax0–72 h in the CII group 
remained below this threshold. The most rigorous target for peak anti-Xa level, 0.3–
0.5 IU/ml, was not reached in either of the groups. On the contrary, the constant 
target of anti-Xa 0.1–0.3 IU/ml (Leyvraz et al., 1991) was only reached with CII. 
Low trough levels have been observed by others when OD or BID dosing of 
LMWHs has been used (Lewis et al., 2018; Mayr et al., 2002; Rutherford et al., 2005; 
Vincent et al., 2011). There is also some evidence that low trough levels are 
associated with the incidence of VTE (Malinoski et al., 2010). Though the results 
from Study II imply more constant anticoagulation with CII, the clinical relevance 
remains unclear.  
It has been speculated that low anti-Xa levels in critically ill patients might result 
from a reduced bioavailability of subcutaneously administered LMWH. Indeed, there 
is some evidence that both edema (Haas et al., 2005) and a concomitantly 
administered vasoconstrictor reduce plasma anti-Xa levels (Dörffler-Melly et al., 
2002). In Study II, the used norepinephrine infusion did not affect the anti-Xa levels. 
Others have also failed to duplicate these results (Helviz et al., 2016).  
In Study III, the CII resulted in significantly lower F1+2 levels in vivo at 51 and 
72 hours in contrast to the  SCB dosing. The level of thrombin activity cannot be 
directly measured. However, evaluation indirectly, for example by F1+2 can be used 
as a surrogate. Thus, these results suggest that CII controls the generation and 
activity of thrombin better than SCB. 
At baseline, F1+2 levels were high in both groups as also observed by others 
(Gouya et al., 2012; Hoppensteadt et al., 2014). Within the 72 hours, F1+2 decreased 
in CII group, implying that there had been an improvement in fXa inhibition and 
thus improved anticoagulation. In medical patients, high F 1+2 levels have been 
associated with a risk of VTE, whereas a reduction in the F1+2 level has been 
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considered as a sign of adequate anticoagulation (Schutgens et al., 2004; Tripodi et 
al., 2008). In critically ill septic patients, standard enoxaparin prophylaxis did not 
correct the sustained increased levels of F1+2 (Gouya et al., 2012). Thus, it seems 
plausible that the standard SCB dosing of enoxaparin fails to suppress the high 
formation of F1+2 in critically ill patients. Furthermore, the results of Study III add 
to the previous results obtained in Study II, suggesting that the CII of enoxaparin 
may result in more reliable thromboprophylaxis.  
In study III, the CII, but not the SCB, nearly normalized AT levels. Similar 
observations have been made previously in critically ill patients where low AT levels 
after subcutaneous enoxaparin thromboprophylaxis have been associated with 
reduced biological activity (Haas et al., 2011). Though continuous heparin infusion 
decreases AT concentration (Marciniak et al., 1977), and might be further associated 
with thromboembolic complications (Matthai et al., 1999) no previous data on AT 
concentration after CII of LMWH exist. Thus, the clinical relevance of AT 
concentration after CII remains unknown.  
TGA-CAT is considered to reflect the overall coagulation capacity better than 
plasma anti-Xa level, especially in healthy subjects (Thomas et al., 2015), (Al Dieri et 
al., 2004).  The evidence in critically ill patients is more limited (Gouya et al., 2012; 
Lindström et al., 2011) and it has not been previously investigated at steady state of 
LMWH thromboprophylaxis. In Study III, it was found that TGA-CAT was able to 
detect the anticoagulation response after subcutaneous enoxaparin, seen in 
prolonged lag time and tt-Peak. Gouya et al. previously obtained similar results 
during a shorter monitoring period (Gouya et al., 2012). At the final trough level, the 
peak thrombin activity was significantly lower when the drug was administered as a 
CII than as a SCB. However, the number of responders in the TGA-CAT 
measurement was only moderate. Hence, these results need to be interpreted with 
caution.   
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7.3 Coagulation changes after aneurysmal subarachnoid 
hemorrhage (IV) 
 
In Study IV, it was found that at 72 hours after aSAH onset, the strength of blood 
clotting had increased as the EXTEM-MCF and FIBTEM-MCF increased, 
suggesting enhanced blood coagulability. The increase in FIBTEM-MCF was further 
associated with the incidence of EBI and DCI.  
This is the first study where coagulation changes after aSAH have been evaluated 
with ROTEM. In a more recent study by Lauridsen et al., both EXTEM-MCF and 
FIBTEM-MCF were already elevated at admission (median 3 hours 39 min from the 
onset of aSAH symptoms) in comparison with healthy controls (Lauridsen et al., 
2019). The median modified Fisher Scale was 4, implying a greater magnitude of 
blood on CT than in Study IV. This could explain the earlier detection of 
hypercoagulation.  Similar results have also been obtained in moderate-to-severe 
aSAH patients with thromboelastography (TEG) if the coagulation status has been 
monitored over three days (Ramchand et al., 2016). In TEG trials, no difference has 
been observed (Frontera et al., 2017; Miao et al., 2018) with a monitoring period 
shorter than 72 hours in comparison with healthy controls. Interestingly, in Study 
IV, increased coagulation was observed with EXTEM and FIBTEM, but not with 
INTEM at 72 hours. Similar results have been obtained by others at 24 hours after 
aSAH (Lauridsen et al., 2019). Ramchand et al. found increased maximum amplitude 
with TEG when kaolin was used as an activator of the indirect pathway but only 
after three post-bleed days (Ramchand et al., 2016). The shorter monitoring period 
in Study IV could explain why no change in INTEM parameters was seen.  
FIBTEM-MCF levels increased significantly after 72 hours from the onset of 
aSAH. This suggests that both fibrin formation and polymerization are significant 
contributors to the strength of clotting. To my knowledge, there are no data on fibrin 
function after aSAH. It is known that the plasma fibrinogen concentration with 
FIBTEM-MCF increases during many other critical illnesses (Sivula et al., 2009). 
However, at an early state of aSAH, other investigators have reported fibrinogen 
concentrations within normal limits (Ettinger, 1970; Fujii et al., 1997; Ilveskero et 
al., 2005; Larsen et al., 2012; Miao et al., 2018) or only slightly elevated levels 
(Ramchand et al., 2016), but no trials where changes in fibrinogen concentration 
after aSAH  could be identified.  
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High FIBTEM-MCF at 72 hours after the onset of aSAH was further associated 
with the incidence of severe EBI and DCI. No association was detected with 
EXTEM-MCF. Previously, there has been some evidence that higher fibrinogen 
concentrations might be associated with the incidence of DCI (Fujii et al., 1997). In 
TEG trials, the association with hypercoagulability and DCI are inconsistent 
(Frontera et al., 2017; Ramchand et al., 2016). The pathophysiology of DCI is 
complex and still not fully understood. However, the activation of blood 
coagulation, that further predisposes cerebral microthrombosis is thought to be one 
of the key elements (Macdonald, 2014). Based on the results of study IV, it seems 
plausible that increasing the formation of fibrin and its polymerization might be a 
contributor to the pathophysiology. However, this needs to be confirmed in a larger 
clinical study.  
The incidence of DVT was 11.8% (n=2), which is within the limits of previous 
trials where ultrasonography screening has been applied (Ray et al., 2009). Both 
DVTs were clinically meaningful since, after the diagnosis of DVT, both patients 
were further diagnosed with a PE. No association was detected with any of the 
parameters measured in the ROTEM analysis. This is in contrast, to a single report 
examining aSAH, where hypercoagulation detected with TEG was associated with 
the DVT incidence (Miao et al., 2018). According to a meta-analysis (including nine 
cohort studies and one RCT, with a total of 1056 patients) by Dai et al, TEG is not 
considered accurate enough in to predict post-operative VTE (Dai et al., 2009). In 
the current guidelines starting early pharmacological prophylaxis after aSAH is highly 
addressed (Steiner et al., 2013). This is in line with the results of increased blood 
coagulability after aSAH in Study IV.    
7.4 Limitations 
 
These studies have some limitations which need to be addressed. 
7.4.1 Study I 
First, majority of the included studies were observational studies with small sample 
sizes. Second, the included studies were highly heterogeneous with respect to the 
type of ICU, the patient population and the type, and dose of LMWH limiting the 
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generalization of the results. Finally, methods and designs for anti-Xa monitoring 
were not identical.  
7.4.2 Study II and III 
First, Studies II and III were based on the same population with a small sample size 
and no conclusion on clinical relevance can be drawn. Second, some protocol 
violations were encountered that led to a smaller PP group than expected. 
Nevertheless, the results of the ITT and PP groups did not differ. Third, the stratified 
block randomization independently in each study site meant that there was a 
different number of patients in each study group. Fourth, the study period of 72 
hours was too short to detect the accumulation of enoxaparin (Douketis et al., 2008). 
Fifth, to avoid bias, patients with acute kidney injury and obesity were excluded. This 
was decided due to the preliminary nature of the study design. Sixth, because no 
initiation dose of enoxaparin was given in the CII group, this probably affected the 
results within the first 24 hours. Finally, because of the repeated measures of same 
individuals over the study period, using linear mixed model, not included in the 
predetermined statistical plan, might have improved the reliability of results (Pietrzak 
et al., 2010).  
Some additional limitations concerning Study III. First, because of laboratory 
technical reasons, the TGA-CAT analysis was only conducted in 18 patients. 
Moreover, the number of non-responders in the TGA-CAT measurement was 
surprisingly high due to the preanalytical properties of the blood samples (e.g. shade 
of plasma in pancreatitis) (Lindström et al., 2011).  
7.4.3 Study IV 
First, the study was conducted in an emergent situation without the ability to obtain 
real baseline values from aSAH patients. Therefore, it was decided to use 
neurosurgical patients as a surrogate for the reference range. Though these patients 
represent the same patient population, the aSAH patients were younger, and the 
number of smokers was higher than in control group. It is not known how these 
differences have contributed to the ROTEM results. Second, the ROTEM was 
monitored only for 72 hours. In TEG trials, the hypercoagulability state has 
continued to evolve up to day 10 (Ramchand et al., 2016). Third, a decrease in the 
hemoglobin level (from 145 g/l ±13 to 127 g/l ± 12.6, p<0.05) might have increased 
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the EXTEM-MCF levels. However, the effect is most likely to be minimal (Nagler 
et al., 2013). Fourth, the measurement of fibrinogen level or platelet function testing 
were not done. Thus, the exact contribution of fibrinogen and platelets on increased 
coagulation remains unknown.  Finally, the sample size was too small for clinical 
endpoints that limit the interpretation of these results. Furthermore, the influence of 
other relevant confounders on the incidence of EBI and DCI could not be tested, 
nor was it possible to investigate the role of different operative interventions on 
blood coagulation. 
 
7.5 Clinical implications and future perspectives 
 
The reduced bioavailability of LMWHs in critically ill patients has been suspected 
for over 15 years (Freedman, 2003). Indeed, the risk for VTE has remained in a range 
of 5 to 10% despite the provision of LMWH thromboprophylaxis. When planning 
future studies, there are several aspects that need to be considered. First, the 
association of plasma anti-Xa level and clinical endpoints should be studied in 
critically ill patients. Currently, anti-Xa levels are widely used both in research and 
clinical settings without adequate validation.  Second, it is unsure how best to 
evaluate the incidence of DVT in clinical research. Screening protocols are often 
used, but the clinical guidelines have placed less emphasis on these results because 
of the potential bias on clinical endpoints (i.e. earlier DVT detection might influence 
PE rate). Third, there is a need for a large multicenter RCTs where different 
modalities of LMWH thromboprophylaxis are studied. The study raises some 
questions to be answered:  
1. Should a larger dose of thromboprophylaxis be used in all critically ill 
patients?  
2. Should a weight-based dosing of thromboprophylaxis be applied in critically 
ill patients?  
3. Should LMWH thromboprophylaxis be administrated as a CII administration 
of LWMH instead of a SCB in critically ill patients?  
Nonetheless, in order to answer these questions, a sample size of around 3000 
patients would be warranted.  
 81 
However, the results from Studies II and III are promising about the benefits of 
LMWH thromboprophylaxis delivered as CII in critically ill patients. This should be 
considered especially for patients who have both an increased risk for thrombosis 
and bleeding e.g. in DIC. In the future, because of the known pathophysiology of 
DIC, it would be especially interesting to conduct an in-depth investigation of CII 
thromboprophylaxis in this patient population.  
Neurological impairment after aSAH is a significant contributor to the functional 
recovery. The initial bleeding itself is beyond the scope of critical care, but one of 
the primary reasons for a poor neurological recovery is DCI, which usually develops 
between 3 to 14 days after the onset of aSAH, offering a window for treatment. The 
pathophysiology of DCI is still not fully understood; however, it is reasonable to 
assume that improving the understanding in the pathophysiology would lead to 
interventional clinical trials in the future. In Study IV, it was observed that the 
coagulation changes after aSAH could be detected with ROTEM. Furthermore, this 
increment in overall coagulation seemed to have an association with the incidence 
of DCI. This finding needs to be confirmed in an observational study where the 
sample size would be adequate for evaluation of the incidence of DCI. If one wishes 
to diagnose the coagulation changes more precisely, the study period should also be 
longer and have more specific coagulation markers than only ROTEM.  
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8 CONCLUSIONS 
The following conclusions can be drawn based on this thesis: 
1. When the literature on anti-Xa levels after LMWH thromboprophylaxis in 
critically ill patients was systematically reviewed, the reported median anti-
Xa levels were between <0.1 to 0.35 IU/ml.  No association was detected 
between clinical events and anti-Xa levels. The overall quality of the 
pharmacokinetic studies examining the anti-Xa level with LMWH 
thromboprophylaxis was moderate.  
2. When enoxaparin thromboprophylaxis was given as a continuous 
intravenous infusion, the maximal concentrations of anti-Xa remained 
lower within 24 and 72 hours in comparison with subcutaneous dosing. 
However, the trough level at 72 hours was higher, suggesting more 
constant anticoagulation.  
3. A continuous infusion of enoxaparin thromboprophylaxis reduced 
prothrombin fragment 1+2 levels in plasma significantly more as 
compared with subcutaneous dosing. The continuous infusion of 
enoxaparin normalized the AT levels, whereas this did not occur with the 
subcutaneous dosing of the drug. This novel finding suggests that 
continuous intravenous infusion of enoxaparin might be more beneficial 
than SCB in providing thromboprophylaxis in critically ill patients.  
4. After 72 hours from the onset of aSAH, the blood coagulation was 
activated. The increase in coagulation could be detected with ROTEM 
EXTEM-MCF and FIBTEM-MCF analyses. This suggests that fibrin 
formation and polymerization have significant contributions to the 
strength of clotting.  
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Background: Critical care patients are prone to venous thromboembolism (VTE) and, thus, pharmacological
thromboprophylaxis is generally advised. Low-molecular weight heparins (LMWHs) have become the drug of
choice in ICU patients, since their predictable and reproducible dose response. Monitoring their pharmacological
effect is not usually necessary except in special occasions (i.e. with obese or renal failure patients), where
anti-FXa level measuring is recommended. However, there is neither recommendation of adequate anti-FXa
levels in critically ill patients nor is it known whether peak or trough level should be measured. The aim of this
systematic review was to evaluate the recommended LMWH doses, and the reasons to monitor anti-FXa levels.
Methods:We searchedMEDLINE, Scopus, Cochrane Central Register of Controlled Trials and ClinicalTrials.com to
identify all potentially relevant studies. Prospective studies done in critically ill patients were included if at least
one anti-FXa level (i.e. peak or trough) after any speciﬁed LMWH thromboprophylaxis dose was measured.
Results: Total 18 eligible studies including 1644 patients were included. Therewas awide variation in themedian
peak anti-FXa levels (b0.1–0.35 IU/ml). Trough levels were generally low. Of note, none of the studies detected
any correlation with bleeding events and anti-FXa levels. Low trough level increased incidence of DVT in one
study only.
Conclusion: Based on the current literature, no deﬁnite conclusions can be drawn on targeted anti-FXa level in
critically ill patients when using LMWH thromboprophylaxis.
© 2016 Elsevier Ltd. All rights reserved.
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1. Introduction
Critically ill patients are at increased risk of venous thromboembo-
lism (VTE) because of several additive risk factors [1,2], with the critical
illness itself acting as a hypercoagulable state [3,4]. In addition,
withholding anticoagulant prophylaxis because of an elevated bleeding
risk may predispose to VTE [5]. Therefore, the incidence of deep vein
thrombosis (DVT) varieswidely, from10% to almost 100% [2,6]. Hospital
mortality rates in patients with VTE have been reported to be relatively
high, up to 28% [7]. In addition, VTE has been associated with increased
risks of longer durations of mechanical ventilation and hospitalization
[1].
Current guidelines of the American College of Chest Physicians
(ACCP) recommend the use of low-molecular-weight heparin
(LMWH) or unfractionated heparin (UFH) to prevent VTE in critically
ill patients [8]. However, data supporting the thromboprophylactic
effects of LMWH and UFH are mainly based on studies in medical and
surgical ward patients, in which LMWHs were superior to UFH in
preventing VTE [9]. LMWHs have also become the drug of choice for pa-
tients in the intensive care unit (ICU) owing to their more predictable
and reproducible dose responses without the need for monitoring
[10]. Furthermore, LMWHshave a lower risk of heparin-induced throm-
bocytopenia than UFH [11]. However, despite the almost routine use of
pharmacological prophylaxis, the incidence of VTE has remained
relatively high, between 5% and 16% [11,12], raising questions about
the adequacy of current recommendations in heterogeneous high-risk
groups of ICU patients.
The antithrombotic effects of LMWHs are mainly owing to their en-
hancement of the inhibitory effects of the intrinsic anticoagulant anti-
thrombin III (AT III) on activated factor X (FXa) and thrombin (FIIa).
Each LMWHhas its own pharmacological proﬁle (i.e., molecular weight
distribution and anti-FXa/anti-FIIa activities),whichmust be considered
when interpreting laboratory results [13]. As all LMWHs are predomi-
nantly cleared by the kidneys, patients with renal insufﬁciency may be
predisposed to bleeding. Therefore, monitoring the pharmacological
effects of LMWHs bymeasuring anti-FXa levels has been recommended
only in patients with renal insufﬁciency or with other special circum-
stances (e.g., morbid obesity) [10]. To date, recommendations for ade-
quate anti-FXa levels in critically ill patients have not been proposed,
nor is it known whether the peak or trough level should be measured.
Peak levels are generally regarded as reﬂecting thromboprophylactic ef-
fect, whereas trough levels are regarded as reﬂecting accumulation.
However, it is unclear whether high peak levels predispose to bleeding
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or low trough levels to thrombosis. This systematic review was
designed to determine anti-FXa levels in blood of critically ill patients
after prescribed LMWH thromboprophylaxis and to evaluate whether
clinically relevant events (e.g., VTE or bleeding) correlate with anti-
FXa levels.
2. Methods
This systematic review is based on themethodology recommendedby
the Cochrane Collaboration. PRISMA Statement andMoose reporting rec-
ommendations were used. The protocol was published on the PROSPERO
register (www.crd.york.ac.uk/PROSPERO, number CRD42015025744)
before ﬁnal data extraction.
2.1. Data sources and search strategy
MEDLINE, SCOPUS, the Cochrane Library, and the ClinicalTrials.com
databaseswere searched in collaborationwith a librarian from theUniver-
sity of Helsinki, using the termsVenous Thrombosis/thromboprophylaxis/
Venous ThromboembolismANDCritical Care/Intensive CareUnit/Critical
Illness AND LMWH. Therewere no restrictions on language, date, or type
of publication. The initial search was completed in May 2015. The refer-
ence lists of all retrieved articles weremanually reviewed to identify any
potentially relevant studies. Details of the search strategies are shown in
Supplemen 1.
2.2. Study selection
Predeﬁned inclusion criteria were used. Studies had to be prospec-
tive in design, performed in adult (age N18 years) critical care patients,
include more than 10 patients, use any LMWH thromboprophylaxis,
and include at least one anti-FXa measurement at a known time point
after speciﬁed LMWH administration. All abstracts and titles were
screened independently by two reviewers (AV and AK). The full text
of every identiﬁed article was read. Agreement between the two
reviewers on article inclusion was high (kappa value 0.89), with any
disagreements resolved through discussions.
2.3. Data extraction and quality assessment
The selected studies were independently reviewed by the same two
investigators (AV and AK), and data were extracted using predeﬁned
criteria, including the study design, patient population, anti-FXa results,
and clinical outcomes (i.e., DVT, symptomatic DVT, pulmonary embo-
lism (PE), symptomatic PE, and major or minor bleeding based on the
original trial deﬁnition). The quality of eligible studies was assessed
using theDowns and Black checklist [14], and any disagreementwas re-
solved by consensus. Quality assessment is presented as total Downs
and Black score (maximum, total score 27), as well as by subgroup
scores (reporting, external validity, internal validity-bias, internal
validity-confounding). Because of the high heterogeneity of clinical
outcomes in included studies, quantitative analyses could not be
performed.
3. Results
The initial search identiﬁed 5206 citations, after duplicates were re-
moved. Of these, 31 studieswere retrieved for more detailed evaluation
and 18 studies, including 1644 patients, were included in the ﬁnal
systematic review (Fig. 1). These studies were mainly observational,
with only two randomized clinical trials (RCTs) identiﬁed. Trial charac-
teristics are presented in Table 1. Most of these studies (10 observation-
al studies and two RCTs) tested the effects of different dosages of
enoxaparin [15–26], whereas four observational studies assessed
dalteparin [27–30], and one each tested certoparin [31] and nadroparin
[32]. No studies testing tinzaparin were identiﬁed. The median peak
anti-FXa levels in ICU patients varied widely, from b0.1 IU/mL [31] to
0.35 IU/mL [27]. The median trough anti-FXa levels were reported in
four studies, and they varied between undetectable and b0.1 IU/mL
[27,31,18,20].
The quality of the studies according to the Down and Black score is
shown in Table 2. The median total score (interquartile range, IQR)
was 19 [15–20]/27. The median subscores (IQR) were 8.5 [7–10]/11
for reporting, 1 [1–2]/3 for external validity, 5 [4–5]/7 for internal
validity-bias, and3 [2–5]/7 for internal validity-confounding andpower.
Fig. 1. Flow chart of the study selection.
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3.1. Certoparin
The only observational study of certoparin included 62 critically ill
patients. Treatment with 3000 IU OD certoparin resulted in a median
peak anti-FXa level that was undetectable b0.1 (IQR b0.1–0.2) IU/mL.
Only 28% of patients were within the antithrombotic range using the
study deﬁnition of target value. When the dosage was doubled to
3000 IU bid, the median peak anti-FXa level did not change but 47% pa-
tients were within the recommended range. Median trough levels in
patients administered 3000 IUODand bid certoparinwere undetectable
b0.1 (IQR b0.1–0.17) and b0.1 (IQR b0.1–0.26) IU/mL, respectively. One
patient in the lower dose group experienced severe PE, but the anti-FXa
concentration of this patientwas not reported. Therewas no correlation
between bleeding and high anti-FXa levels (N0.3 IU/mL) [31].
3.2. Dalteparin
Four studieswere identiﬁed. The ﬁrst study, involving patients in the
ICU with renal insufﬁciency (creatinine clearance “CrCl” b 30 mL/min)
administered 5000 IU OD dalteparin, reported median peak anti-FXa
levels 4 h (hrs) after treatment to be 0.29 (IQR 0.20–0.42) IU/mL after
3 days and 0.34 (IQR 0.27–0.45) IU/mL after 17 days. Trough levels
were undetectable. The incidence of major bleeding was 7.2% and two
patients died of bleeding complications. However, there was no correla-
tion between anti-FXa levels and deaths [27]. Similar results were ob-
served in a small observational study of patients with renal
insufﬁciency (CrCl b 30 mL/min) [29].
The third study was a before and after study, in which dalteparin
dosage was doubled if the anti-FXa level at 12 h was below b0.1 IU/
mL. The protocol reduced the total incidence of VTE (12.8% vs. 7.0%,
p = 0.009). Moreover, if the median anti-FXa level was below
b0.1 IU/mL at 12 h, the rates of VTE (14.4% vs. 5.4%, p = 0.05) and
DVT (14.4%. vs. 3.2% p = 0.01) were signiﬁcantly higher [28].
In the fourth study, the pharmacokinetics of dalteparin were
assessed in edematous and non-edematous ICU patients. There were
no between-group differences in mean ± standard deviation (SD)
peak (0.15 ± 0.05 vs. 0.14 ± 0.06 IU/mL) and trough (0.05 ± 0.06 vs.
0.02 ± 0.02 IU/mL) anti-FXa concentrations [30].
3.3. Enoxaparin
Median peak anti-FXa levels tended to be lower in ICU than in med-
ical ward patients: 0.16 (IQR 0–0.22) vs 0.2 (IQR 0.15–0.27) IU/mL [16].
Similar results were observed when the area under curve (AUC)0–12 h
was measured (SD 2.63 ± 1 vs. 4.26 ± 1.7 IU/mL/h) [21]. Two RCTs
also showed positive correlations between enoxaparin dosage and me-
dian peak and mean anti-FXa levels [22,23]. Five studies reported
trough levels, which were generally low (0–0.10 IU/mL) and in one
study the low trough level correlated with the incidence of DVT (37
vs. 11%, p=0.026) [19].Median trough levelswere generally lowor un-
detectable [18,20]. Nine studies reported adverse events, with none of
these studies detecting any correlation between bleeding events and
anti-FXa levels [15,18–20,22,23,24,33,26].
3.4. Nadroparin
Only one observational study was found, in which nadroparin
2850 IU OD was compared in three different patient groups: ICU pa-
tients on vasopressors (n = 15), ICU patients not on vasopressors
(n = 15), and surgical ward patients (n = 15). The mean peak anti-
FXa levels at 3 h were 0.09 (95% conﬁdence interval (CI) 0.05–0.10),
0.23 (95% CI 0.18–0.27), and 0.28 (95%CI 0.23–0.31) IU/mL respectively.
Trough levels were not measured, and clinical outcomes were not re-
ported [32].
4. Discussion
This systematic review,which included 16 observational studies and
two RCTs, found a lack of evidence regarding optimal targeted anti-FXa
levels in critically ill patients. Median peak anti-FXa levels
(b0.1–0.35 IU/mL) [31,27] and mean anti-FXa levels (0.09–0.40 IU/
mL) [32,23] varied widely, depending on the type and dose of LMWH
and on the study population. In addition, the trough levels were consis-
tently low [27,31,18,20,29,30,24,33]. Data on peak and trough anti-FXa
levels after LMWH thromboprophylaxis in ICU patients are sparse, and
more research is certainly needed. Irrespective of LMWH drug and
dose, peak and trough anti-FXa levels were generally low throughout
the studies, but correlations between anti-FXa levels and clinically rele-
vant outcomes, such as DVT, PE, and bleeding, remain uncertain. How-
ever, one study found that a low trough anti-FXa level signiﬁcantly
increased the incidence of DVT (37% vs. 11%, p = 0.026) [19].
These ﬁndings may have several explanations. First, AT III levels in
critically ill patients were consistently low, correlating with low anti-
FXa levels [31,21]. Low AT III levels may be due to elevated levels of
other heparin-binding proteins (e.g., ﬁbronectin and vitronectin), as ob-
served in an animal endotoxin model [34]. Second, the absorption of
subcutaneously administered LMWHmay be reduced in patients treat-
edwith a vasopressor, reducing systemic bioavailability [32]. Third, crit-
ically ill patients often receive excessive amounts of intravenous ﬂuids,
resulting in peripheral edema,whichmay affect LMWHpharmacokinet-
ics and reduce its bioavailability [17].
Administration of a standard prophylactic dosage of LMWH to obese
ICU patients results in lower anti-FXa activity than in non-obese indi-
viduals [28,20]. However, enoxaparin dose may be positively correlated
with anti-FXa levels, with adequate peak anti-FXa levels achieved using
a weight-adjusted dose of enoxaparin (1 mg/kg once daily) [23].
Because of the lack of good quality RCTs [35], evidence of the effec-
tiveness of LMWH thromboprophylaxis in ICU patients is mainly
based on measurements of plasma levels of anti-FXa, as anti-FXa is a
surrogate marker for anticoagulant effects. Correct anti-FXa levels
have been determined only in patients undergoing orthopedic surgery
[36,9]. It has not yet been determined whether peak or trough level
should be measured. The generally recommended peak anti-FXa level
for thromboprophylaxis is 0.1–0.3 IU/mL in medical and surgical pa-
tients [37]. The rates of VTE in patients undergoing hip surgery with
trough (12 h after administration of enoxaparin) anti-FXa activity of
N0.1 IU/mL, b0.1 IU/mL, and b0.05 IU/mL were reported to be 6.3%,
14.6%, and 18.8%, respectively. Anti-FXa levels N0.2 IU/mL were associ-
ated with hematomas [36]. These values are also generally used as ref-
erences for anticoagulant effects in ICU patients in the observational
studies included in this review.
Two of the observational studies were conducted in critically ill pa-
tients with renal insufﬁciency. Administration of a prophylactic dose
of dalteparin to patients with impaired renal function (CrCl b 30 mL/
min) did not altermedian peak anti-FXa levels [29,27] norwas there ev-
idence of an increased risk of bleeding, despite a mean ± SD CrCl of
18.9 ± 6.5 mL/min [27]. Lower serum creatinine and urea levels (not
speciﬁed) were associated with a greater clearance of LMWH
(certoparin), as measured by lower plasma anti-FXa levels [31].
Renal insufﬁciency is one of the most frequent reasons for omission
of pharmacological thromboprophylaxis or for preferring UFH over
LMWH [5]. Current research evidence does not support this practice,
but these data are observational and limited. Moreover, urinary CrCl is
an imprecise estimate of glomerular ﬁltration rate in critically ill pa-
tients [38]. A meta-analysis that included patients with severe renal in-
sufﬁciency (CrCl b 30mL/min) found that only when therapeutic doses
of enoxaparin were administered were anti-FXa levels elevated and the
risk of major bleeding increased [39]. Prophylactic administration of
enoxaparin but not of tinzaparin showed similar accumulation ﬁndings
in elderly medical patients with impaired renal function (CrCl 34 ±
11.4 mL/min) [40].
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The critical illness itself often acts as a hypercoagulable state
(e.g., sepsis or trauma) [3]. In addition, the severity of critical illness
(e.g., multiple organ dysfunction score or severity of burn injury) was
reported to correlate with lower anti-FXa [41,20]. Whether the latter
reﬂects an insufﬁcient anticoagulant effect or the nature of anti-FXa as
a surrogate marker requires further investigations.
Theseﬁndings of low levels of anti-FX activity and several conditions
that can alter LMWH bioavailability in intensive care patients have
raised the question of the adequacy of thromboprophylaxis with dosing
schemas applied to medical and surgical patients. Although VTE events
have decreased with LMWH prophylaxis, thromboembolism has
occurred, despite recommended dosing of LMWHs and even within
recommended anti-FXa levels [19]. In addition to the reasons described
above, uneventful thrombosis may result from a fear of bleeding,
resulting in pauses and delays in thromboprophylaxis [5].
4.1. Strengths and limitations
To our knowledge, this is the ﬁrst systematic review of the role of
anti-FXa monitoring during LMWH thromboprophylaxis in critically ill
patients. However, this study had several limitations. First, all included
studies were relatively small, withmost being observational and under-
powered for clinical endpoints, and of lowquality. Second, as the type of
ICUs varied among studies (i.e., mixed, medical, trauma, and surgical)
and patients had various degrees of renal failure, the study population
was quite heterogeneous. The beneﬁts and adverse effects of LMWH
may vary in different subgroups of ICU patients. Third, the type and
dose of LMWH varied among studies; because LMWHs have different
pharmacological properties, it is unclear whether anti-FXa levels can
be generalized. Fourth, there were methodological limitations
concerning anti-FXa measurements, as the protocols of the included
studies were not identical (e.g., times samples were obtained after
LMWH administration, blood sample collecting procedures, and delay
from sampling to analysis) and the analytic methods and reference
levels differ among laboratories. Moreover, the reporting of measured
anti-Xa activity concentrations in the studies varied (e.g., median,
mean or AUC), making data interpretation difﬁcult. Fifth, the secondary
outcomes should also be considered a study limitation because the
deﬁnitions of these adverse events (e.g., DVT, symptomatic DVT, PE,
symptomatic PE, and minor or major bleeding) varied across studies.
Sixth, the literature searchwas updated inMay 2015; thus, more recent
data may be missing.
5. Conclusion
No deﬁnite conclusions can be drawn regarding target anti-FXa levels
in critically ill patients administered LMWHs for thromboprophylaxis. No
recommendations can be made on the timing of anti-FXa monitoring or
for dose adjustments for individual patients.
Acknowledgments
AV, SV, VP and AK planned and designed the study. AV and AK
acquired and reviewed the data and assessed risk of bias. All authors re-
vised themanuscript criticallywith a contribution and gaveﬁnal approval
of the version to be published. No external funding was received.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.thromres.2015.12.016.
References
[1] D. Cook, M. Crowther, M. Meade, et al., Deep venous thrombosis in medical-surgical
critically ill patients: prevalence, incidence, and risk factors, Crit. Care Med. 33
(2005) 1565–1571.
[2] W.H. Geerts, D. Bergqvist, G.F. Pineo, et al., Prevention of venous thromboembolism:
American College of Chest Physicians evidence-based clinical practice guidelines
(8th edition), Chest 133 (2008) 381S–453S.
Table 2
Down and Black checklist.
Study Total
score
(27)
Reporting
(10)
External
validity
(3)
Internal
validity-bias
(7)
Internal
validity-confounding
and power (7)
[15] 8 6 1 0 1
[32] 15 8 1 4 2
[27] 20 10 1 6 3
[28] 13 7 2 4 0
[16] 19 9 1 5 4
[17] 15 6 1 5 3
[31] 19 8 1 5 5
[18] 22 10 3 5 4
[19] 17 7 3 4 3
[20] 20 9 1 5 5
[21] 16 7 1 5 3
[29] 14 8 0 4 2
[23] 26 10 2 7 7
[22] 23 9 1 7 6
[30] 21 10 1 5 5
[24] 14 8 0 4 2
[33] 20 11 1 5 3
[26] 20 10 1 5 4
Median (IQR) 19 (15–20) 8.5 (7–10) 1 (1–2) 5 (4–5] 3 [2–5)
IQR indicates interquartile range.
Reporting
1. Is the hypothesis/aim/objective of the study clearly described?
2. Are the main outcomes to be measured clearly described in Sections 1 and 2?
3. Are the characteristics of the patients included in the study clearly described?
4. Are the interventions of interest clearly described?
5. Are the distributions of principal confounders in each group of subjects to be com-
pared clearly described?
6. Are the main ﬁndings of the study clearly described?
7. Does the study provide estimates of the random variability in the data for the main
outcomes?
8. Have all important adverse events that may be a consequence of the intervention
been reported?
9. Have the characteristics of patients lost to follow-up been described?
10. Have actual probability values been reported (e.g. 0.035 rather than b0.05) for the
main outcomes except where the probability value is less than 0.001?
External validity
1. Were the subjects asked to participate in the study representative of the entire popula-
tion from which they were recruited?
2. Were those subjects who were prepared to participate representative of the entire
population from which they were recruited?
3. Were the staff, places, and facilities where the patients were treated, representative of
the treatment the majority of patients receive?
Internal validity — bias
1. Was an attempt made to blind study subjects to the intervention they have received?
2. Was an attempt made to blind those measuring the main outcomes of the intervention?
3. If any of the results of the study were based on “data dredging”, was this made clear?
4. In trials and cohort studies, do the analyses adjust for different lengths of follow-up of
patients, or in case–control studies, is the time period between the intervention and
outcome the same for cases and controls?
5. Were the statistical tests used to assess the main outcomes appropriate?
6. Was compliance with the intervention/s reliable?
7. Were the main outcome measures used accurate (valid and reliable)?
Internal validity — confounding (selection bias) and power.
1. Were the patients in different intervention groups (trials and cohort studies) or were
the cases and controls (case–control studies) recruited from the same population?
2. Were study subjects in different intervention groups (trials and cohort studies) orwere
the cases and controls (case–control studies) recruited over the same period of time?
3. Were study subjects randomized to intervention groups?
4. Was the randomized intervention assignment concealed fromboth patients and health
care staff until recruitment was complete and irrevocable?
5. Was there adequate adjustment for confounding in the analyses from which the main
ﬁndings were drawn?
6. Were losses of patients to follow-up taken into account?
7. Did the study have sufﬁcient power to detect a clinically important effect where the
probability value for a difference being due to chance is less than 5%?
15A. Vahtera et al. / Thrombosis Research 139 (2016) 10–16
[3] M. Sivula, V. Pettila, T.T. Niemi, M. Varpula, A.H. Kuitunen, Thromboelastometry in
patients with severe sepsis and disseminated intravascular coagulation, Blood
Coagul. Fibrinolysis 20 (2009) 419–426.
[4] R.M. Van H, T. CM, V. EJ, et al., Hypercoagulability after burn injury, J. Trauma Acute
Care Surg. 75 (2013) 37–43.
[5] F. Lauzier, J. Muscedere, E. Deland, et al., Thromboprophylaxis patterns and determi-
nants in critically ill patients: a multicenter audit, Crit. Care 18 (2014) R82.
[6] J. Attia, J.G. Ray, D.J. Cook, J. Douketis, J.S. Ginsberg, W.H. Geerts, Deep vein
thrombosis and its prevention in critically ill adults, Arch. Intern. Med. 161 (2001)
1268–1279.
[7] G.P. Patel, J. Liberman, D. Gurka, E. Elpern, R.A. Balk, Complications of critical illness:
rationale for prophylactic strategies, Clin. Pulm. Med. 12 (2005) 258–268.
[8] S.R. Kahn, W. Lim, A.S. Dunn, et al., Prevention of VTE in nonsurgical patients.
Antithrombotic therapy and prevention of thrombosis, 9th ed: American College
of Chest Physicians evidence-based clinical practice guidelines, Chest 141 (2012)
e195S–e226S.
[9] P.F. Leyvraz, F. Bachmann, J. Hoek, et al., Prevention of deep vein thrombosis after
hip replacement: randomised comparison between unfractionated heparin and
low molecular weight heparin, BMJ 303 (1991) 543–548.
[10] D.A. Garcia, T.P. Baglin, J.I. Weitz, M.M. Samama, Parenteral anticoagulants: anti-
thrombotic therapy and prevention of thrombosis, 9th ed: American College of
Chest Physicians evidence-based clinical practice guidelines, Chest 141 (2012)
e24S–e43S.
[11] D. Cook, M.Meade, G. Guyatt, et al., Dalteparin versus unfractionated heparin in crit-
ically ill patients, N. Engl. J. Med. 364 (2011) 1305–1314.
[12] F. Fraisse, L. Holzapfel, J.M. Couland, et al., Nadroparin in the prevention of deep vein
thrombosis in acute decompensated COPD, Am. J. Respir. Crit. Care Med. 161 (2000)
1109–1114.
[13] L. Bara, A. Planes, M.M. Samama, Occurrence of thrombosis and haemorrhage,
relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients
receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent
deep vein thrombosis after hip surgery, Br. J. Haematol. 104 (1999) 230–240.
[14] S.H. Downs, N. Black, The feasibility of creating a checklist for the assessment of the
methodological quality both of randomised and non-randomised studies of health
care interventions, J. Epidemiol. Community Health 52 (1998) 377–384.
[15] T.W. Costantini, E. Min, K. Box, et al., Dose adjusting enoxaparin is necessary to
achieve adequate venous thromboembolism prophylaxis in trauma patients,
J. Trauma Acute Care Surg. 74 (2013) 128–133 discussion 134.
[16] G. Gouya, S. Palkovits, S. Kapiotis, et al., Bioactivity of enoxaparin in critically ill
patients with normal renal function, Br. J. Clin. Pharmacol. 74 (2012) 806–814.
[17] C.E. Haas, J.L. Nelsen, K. Raghavendran, et al., Pharmacokinetics and pharmacody-
namics of enoxaparin in multiple trauma patients, J. Trauma 59 (2005) 1336–1344.
[18] S.Y. Lim, K. Jeon, H.-J. Kim, et al., Antifactor Xa levels in critically ill Korean patients
receiving enoxaparin for thromboprophylaxis: a prospective observational study, J.
Korean Med. Sci. 28 (2013) 466–471.
[19] D. Malinoski, F. Jafari, T. Ewing, et al., Standard prophylactic enoxaparin dosing leads
to inadequate anti-Xa levels and increased deep venous thrombosis rates in critical-
ly Ill trauma and surgical patients, J. Trauma 68 (2010) 874–879.
[20] A.J. Mayr, M. Dünser, S. Jochberger, et al., Antifactor Xa activity in intensive care pa-
tients receiving thromboembolic prophylaxis with standard doses of enoxaparin,
Thromb. Res. 105 (2002) 201–204.
[21] U. Priglinger, D. KG, G. A, et al., Prophylactic anticoagulation with enoxaparin: is the
subcutaneous route appropriate in the critically ill? Crit. Care Med. 31 (2003)
1405–1409.
[22] S. Robinson, A. Zincuk, T. Strom, T.B. Larsen, B. Rasmussen, P. Toft, Enoxaparin,
effective dosage for intensive care patients: double-blinded, randomised clinical
trial, Crit. Care 14 (2010) R41.
[23] S. Robinson, A. Zincuk, U.L. Larsen, et al., A comparative study of varying doses of
enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded,
randomised controlled trial, Crit. Care 17 (2013).
[24] E.J. Rutherford, W.G. Schooler, E. Sredzienski, J.E. Abrams, D.A. Skeete, Optimal dose
of enoxaparin in critically III trauma and surgical patients, J. Trauma 58 (2005)
1167–1170.
[25] J.L. Vincent, R. Moreno, J. Takala, et al., The SOFA (Sepsis-related Organ Failure
Assessment) score to describe organ dysfunction/failure. On behalf of the working
group on sepsis-related problems of the European Society of Intensive Care
Medicine, Intensive Care Med. 22 (1996) 707–710.
[26] Z. Zenáhlíková, J. Kvasnicka, Z. Kudrnová, M. Sudrová, R. Brzezková, J. Mazoch, I.V.J.
Malíková, D. Erhart, L. Pecen, FXa inhibition and coagulation changes during DVT
prophylaxis by enoxaparin over the course of a 15-day follow-up in septic patients,
Clin. Appl. Thromb. Hemost. 16 (2010) 584–590.
[27] J. Douketis, D. Cook, M. Meade, et al., Prophylaxis against deep vein thrombosis in
critically ill patients with severe renal insufﬁciency with the low-molecular-
weight heparin dalteparin: an assessment of safety and pharmacodynamics: the
DIRECT study, Arch. Intern. Med. 168 (2008) 1805–1812.
[28] M.E. Droege, E.W. Mueller, K.M. Besl, et al., Effect of a dalteparin prophylaxis proto-
col using anti-factor Xa concentrations on venous thromboembolism in high-risk
trauma patients, J. Trauma Acute Care Surg. 76 (2014) 450–456.
[29] C.G. Rabbat, D.J. Cook, M.A. Crowther, et al., Dalteparin thromboprophylaxis for crit-
ically ill medical-surgical patients with renal insufﬁciency, J. Crit. Care 20 (2005)
357–363.
[30] M.K. Rommers, N. Van DL, E. TCG, P.M.L.A. van DB, Anti-Xa activity after subcutane-
ous administration of dalteparin in ICU patients with and without subcutaneous
oedema: A pilot study, Crit. Care 10 (2006).
[31] S. Jochberger, V. Mayr, G. Luckner, et al., Antifactor Xa activity in critically ill patients
receiving antithrombotic prophylaxis with standard dosages of certoparin: a pro-
spective, clinical study. Critical care (London, England), Crit. Care 9 (2005)
R541–R548.
[32] J.D.J.E. Dörfﬂer-Melly, A.C. Pont, J. Meijers, M.B. Vroom, H.R. Büller, M. Levi, Bioavail-
ability of subcutaneous low-molecular-weight heparin to patients on vasopressors,
Lancet 359 (2002) 849–850.
[33] P.D. Vincent, M. Albert, M.-C. Champagne, et al., Factors inﬂuencing enoxaparin anti-
Xa activity in surgical critically ill patients, J. Crit. Care 26 (2011) 347–351.
[34] E. Young, T.J. Podor, T. Venner, J. Hirsh, Induction of the acute-phase reaction in-
creases heparin-binding proteins in plasma, Arterioscler. Thromb. Vasc. Biol. 17
(1997) 1568–1574.
[35] W. Alhazzani, W. Lim, R.Z. Jaeschke, M.H. Murad, J. Cade, D.J. Cook, Heparin
thromboprophylaxis in medical-surgical critically ill patients: a systematic review
and meta-analysis of randomized trials, Crit. Care Med. 41 (2013) 2088–2098.
[36] M.N. Levine, A. Planes, J. Hirsh, M. Goodyear, N. Vochelle, M. Gent, The relationship
between anti-factor Xa level and clinical outcome in patients receiving enoxaparine
low molecular weight heparin to prevent deep vein thrombosis after hip replace-
ment, Thromb. Haemost. 62 (1989) 940–944.
[37] M. Laposata, D. Green, E.M. Van Cott, T.W. Barrowcliffe, S.H. Goodnight, R.C. Sosolik,
College of American Pathologists Conference XXXI on laboratory monitoring of an-
ticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-
weight heparin, danaparoid, hirudin and related compounds, and argatroban,
Arch. Pathol. Lab. Med. 122 (1998) 799–807.
[38] G. Bragadottir, B. Redfors, S.E. Ricksten, Assessing glomerular ﬁltration rate (GFR) in
critically ill patients with acute kidney injury-true GFR versus urinary creatinine
clearance and estimating equations, Crit. Care 17 (2013) R108.
[39] W. Lim, F. Dentali, J.W. Eikelboom, M.A. Crowther, Meta-analysis: low-molecular-
weight heparin and bleeding in patients with severe renal insufﬁciency, Ann. Intern.
Med. 144 (2006) 673–684.
[40] I. Mahe, M. Aghassarian, L. Drouet, et al., Tinzaparin and enoxaparin given at pro-
phylactic dose for eight days in medical elderly patients with impaired renal func-
tion: a comparative pharmacokinetic study, Thromb. Haemost. 97 (2007) 581–586.
[41] H. Lin, I. Faraklas, J. Safﬂe, A. Cochran, Enoxaparin dose adjustment is associated
with low incidence of venous thromboembolic events in acute burn patients, J.
Trauma 71 (2011) 1557–1561.
16 A. Vahtera et al. / Thrombosis Research 139 (2016) 10–16

Contents lists available at ScienceDirect
Thrombosis Research
journal homepage: www.elsevier.com/locate/thromres
Full Length Article
Plasma anti-FXa concentration after continuous intravenous infusion and
subcutaneous dosing of enoxaparin for thromboprophylaxis in critically ill
patients. A randomized clinical trial☆
Annukka Vahteraa,⁎, Miia Valkonenb, Heini Huhtalac, Ville Pettiläb,d, Anne Kuitunena
a Tampere University Hospital, Critical Care Medicine Research Group, PO Box 2000, 33521 Tampere, Finland
b Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki and Helsinki University Hospital, Helsinki,
Finland
c Faculty of Social Sciences, University of Tampere, Tampere, Finland
d Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
A R T I C L E I N F O
Keywords:
Heparin
Low-molecular-weight
Anticoagulants
Enoxaparin
Critical care
Pharmacokinetics
Drug monitoring
A B S T R A C T
Introduction: In intensive care unit (ICU) patients, subcutaneous low-molecular weight heparin thrombopro-
phylaxis results in lower plasma anti-factor Xa (anti-FXa) levels compared to general ward patients. The aim of
this study was to examine whether enoxaparin thromboprophylaxis given as a continuous intravenous infusion
(CII) results in more constant and predictable anti-FXa concentration than standard subcutaneous bolus (SCB)
administration.
Materials and methods: This was a prospective, single-blind, multicenter, randomized controlled trial where ICU
patients requiring thromboprophylaxis received enoxaparin either 40 mg as a SCB once daily or 40 mg as a CII
over 24 h for three consecutive days.
The primary outcome was maximum serum anti-FXa concentration (Cmax24 h) within the ﬁrst 24 h; the sec-
ondary outcome was anti-FXa area under the curve (AUC)(0–24 h). Trough level was measured at 72 h.
Results: Thirty-nine patients were included in the intention to treat analysis. The median anti-FXa Cmax24 h was
0.05 (interquartile range, IQR, 0.05–0.18) IU/ml in the CII group and 0.18 (IQR, 0.12–0.33) IU/ml in the SCB
group (p= 0.05). Median anti-FXa AUC(0–24 h) was 1.20 (IQR, 0.98–2.88) in the CII and 1.54 (IQR, 1.22–4.12) in
the SCB group (p= 0.095). After 72 h, 66.7% of patients in the CII group had a detectable anti-FXa con-
centration of> 0.1 IU/ml, compared with 16.7% in the SCB group (p= 0.019).
Conclusions: Continuous infusion of enoxaparin led to lower anti-FXa Cmax24 h than standard SCB administration.
No diﬀerence in anti-FXa AUC0–24 h was detected.
1. Introduction
Despite pharmacologic thromboprophylaxis, venous thromboem-
bolism (VTE), including deep vein thrombosis (DVT) and pulmonary
embolism (PE), are common complications of critical illness, and sub-
stantially increase morbidity and mortality [1,2]. Low-molecular-
weight heparins (LMWHs) have become the drug of choice for throm-
boprophylaxis, as they have a more predictable and reproducible dose
response than low-dose unfractionated heparin. The monitoring of an-
ticoagulant eﬀect is not generally recommended when using LMWHs
[3]. Nonetheless, the measurement of plasma anti-factor Xa (anti-FXa)
concentration has been described, although its eﬃcacy as a means of
monitoring therapeutic eﬀect and association with clinical
thromboembolic events is thought to be inadequate [4].
There is growing evidence that critically ill patients have lower anti-
FXa concentration than general ward patients after the initiation of
standard LMWH thromboprophylaxis [5,6]. It has been proposed that
the bioavailability of subcutaneous LMWH is impaired in critically ill
patients, due to low cardiac output, impaired peripheral blood ﬂow,
concomitant use of vasoconstrictors [6] and subcutaneous edema [7].
In support of this hypothesis, subcutaneous LMWH thromboprophylaxis
in ICU patients receiving vasopressor therapy has been shown to result
in substantially lower anti-FXa activity than in patients not receiving
vasoconstrictors [6].
To investigate whether the current practice of subcutaneous bolus
(SCB) LMWH thromboprophylaxis is suitable for critically ill patients,
http://dx.doi.org/10.1016/j.thromres.2017.08.014
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we compared SCB therapy with a continuous intravenous infusion (CII)
in this randomized clinical trial (RCT).
2. Materials and methods
2.1. Trial design
This prospective, randomized, single-blind clinical trial was con-
ducted in two Finnish university hospital mixed ICUs at Tampere
University Hospital and Meilahti University Hospital. The trial was
conducted in accordance with the amended Declaration of Helsinki.
The study design was approved by the local ethics committee of
Pirkanmaa, Finland and the Finnish Medicines Agency, and it was re-
gistered in the Clinical Trials database (ClinicalTrials.gov;
NCT02095509). Before enrolment, written informed consent was ob-
tained from each patient, or his or her legal representative.
2.2. Study population
Adult ICU patients aged between 18 and 80 years with an indication
for pharmacologic thromboprophylaxis, a body mass index (BMI)
18–30 kg/m2 and an expected ICU stay≥72 h were eligible. Exclusion
criteria were: indications for anticoagulant therapy other than throm-
boprophylaxis; intracranial hemorrhage or central neurosurgical op-
eration within 3 months of ICU admission; diagnosis of disseminated
intravascular coagulation according to International Society on
Thrombosis and Haemostasis criteria [8]; known heparin-induced
thrombocytopenia (HIT); hypersensitivity to enoxaparin or heparin;
blood platelet count< 20 × 109/l, prothrombin time (PT)< 20% or
International Normalized Ratio (INR)> 1.7; major hemorrhage within
the last week unless deﬁnitively treated; glomerular ﬁltration rate<
50 ml/min/1.73 m2 estimated from serum creatinine concentration by
applying the Cockcroft-Gault equation [9] or chronic dialysis; known
HIV, hepatitis B or hepatitis C infection; pregnancy; and known liver
disease. A patient who had received LMWH thromboprophylaxis within
24–72 h of ICU admission could be included if measured anti-FXa
concentration was< 0.1 IU/ml at the time of randomization. Basic
patient characteristics, comorbidities and Acute Physiology and
Chronic Health Evaluation (APACHE II) score were also recorded at
baseline.
2.3. Study intervention
Patients were randomized to receive 40 mg enoxaparin (Klexane®,
Sanoﬁ-Aventis, Helsinki, Finland) either as an SCB every 24 h or as a CII
over 24 h for three consecutive days. Block randomization into two
groups was performed using sequentially numbered, sealed envelopes
that were stratiﬁed according to the use of a vasopressor (yes or no).
The SCB dose was administered once daily from a preﬁlled single-dose
syringe containing 40 mg enoxaparin. The CII (40 mg enoxaparin di-
luted in 100 ml 0.9% sodium chloride solution) was prepared by a
pharmacist or ICU nurse, divided in two syringes of 50 ml and infused
intravenously (via either a central or peripheral venous catheter) over
24 h via an automatic pump. Any discontinuations of the study drug
were recorded; if the infusion was stopped for> 2 h, the patient was
excluded from the ﬁnal analysis. Mechanical thromboprophylaxis was
undertaken according to normal clinical practice. The study period was
72 h, after which thromboprophylaxis was continued according to
routine clinical practice in the ICUs.
Plasma anti-FXa concentration was determined at 0, 3, 6, 9, 12, 15,
18, 24, 27, 48, 51 and 72 h after the beginning of the study, where 24,
48 and 72 h samples represented trough concentrations and 27 and
51 h peak concentrations for SCB dosing. Additional samples were ob-
tained from patients in the CII group at 1.5 and 4.5 h. The total dose of
norepinephrine was documented daily. Blood chemistry, serum C-re-
active protein concentration, platelet count, INR and PT were checked
daily. All blood samples were drawn from an arterial catheter that did
not contain any heparin. Anti-FXa activity was measured in fresh blood
samples in the core laboratory of each study hospital using a validated
chromogenic assay (STA-Liquid anti-Xa, Diagnostica Stago, Asnières-
sur-Seine, France).
2.4. Outcome measurements
The primary outcome measure was maximum plasma anti-FXa
concentration within 24 h after initiation (Cmax24 h). The secondary
outcomes were maximum anti-FXa Cmax within 72 h (Cmax72 h), area
under the time-concentration curve at 24 and 72 h (AUC(0–24 h) and
AUC(0–72 h)) determined by standard pharmacokinetic procedures. The
trough level was evaluated by anti-FXa concentration after the study
period at 72 h. The inﬂuence of norepinephrine infusion (yes/no) and
total norepinephrine dose on anti-FXa Cmax24 h and AUC0–24 h were also
examined.
Clinically relevant complications were deﬁned as follows: major
hemorrhage (requiring> 2 units transfusion of red blood cells, in-
tracranial bleeding, or bleeding requiring major therapeutic interven-
tion, causing hemodynamic compromise or resulting in death), minor
hemorrhage (any other bleeding), DVT (conﬁrmed by compression ul-
trasound, if clinically suspected), PE (conﬁrmed by chest computed
tomography angiography if clinically suspected) and HIT [10]. During
the study period, the duration of mechanical ventilation and daily Se-
quential Organ Failure Assessment score were recorded, as well as the
length of ICU stay and all-cause mortality at day 90 after ICU admis-
sion.
2.5. Statistical analysis
Standard sample size calculations indicated that at least 20 patients
would be needed in each group to detect a clinically meaningful 33%
reduction (from 0.30 to 0.20, standard deviation 0.11) in peak anti-FXa
concentration, assuming a power of 80% and a signiﬁcance level of 5%.
The distribution of data was assessed with the Shapiro-Wilk test.
Non-normally distributed data are presented as the median (inter-
quartile range, IQR). All comparisons between the study groups were
performed with the Mann-Whitney U test, the χ2 test, Fisher's test and
Spearman's correlation coeﬃcient as appropriate. All statistical ana-
lyses were performed using the SPSS statistical software program
(version 23.0; IBM, Armonk, NY).
3. Results
Forty patients were randomized between March 2014 and July
2016. One patient did not receive the study drug because of infusion
pump failure, and was excluded from the modiﬁed intention to treat
(ITT) analysis. There were four randomization errors and three protocol
violations, leaving 32 patients in the per protocol (PP) analysis (Fig. 1).
Baseline characteristics and laboratory values are shown in Table 1; the
study groups were well balanced.
3.1. Outcomes
In the ITT analysis, the median Cmax24 h was 0.05 (IQR, 0.05–0.18)
IU/ml in the CII group and 0.18 (IQR, 0.12–0.33) IU/ml in the SCB
group (p= 0.05). The median AUC(0–24 h) was 1.20 (IQR, 0.98–2.88)
IU/l/h in the CII group and 1.54 (IQR, 1.22–4.12) IU/l/h in the SCB
group (p= 0.095). Per protocol analysis did not change the results
(Table 2). After the study period of 72 h, the trough anti-FXa con-
centration was 0.12 (IQR, 0.05–0.17) IU/ml in the CII group and 0.05
(IQR, 0.01–0.05) IU/ml in the SCB group (p= 0.021), leaving only
16.7% (two out of 10) patients with detectable anti-FXa concentra-
tion > 0.1 IU/ml in the SCB group compared with 66.7% (10 out of
15) in the CII group (p= 0.019).
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No correlations between the ﬁrst ICU day total norepinephrine dose
and Cmax24 h or AUC(0–24 h) were observed: Spearman's correlation
coeﬃcients were −0.176 for Cmax24 h (p= 0.291) and −0.171 for
AUC(0–24 h) (p= 0.305). Norepinephrine infusion at randomization did
not aﬀect signiﬁcantly the anti-FXa concentration: Cmax24 h was 0.05
(IQR, 0.05–0.20, p= 0.93), mean diﬀerence + 0.001 [95% conﬁdence
interval, CI, −0.08, +0.008] and 0.13 (IQR, 0.05–0.28, p= 0.174),
mean diﬀerence + 0.08 [95% CI −0.03, +0.20] in the CII and SCB
groups, respectively. And 0.13 (IQR, 0.05–0.28, p= 0.174) in the CII
and SCB groups, respectively. The eﬀect of the baseline norepinephrine
infusion on AUC(0–24 h) is shown in Fig. 2.
The follow-up data are provided as Supplementary material (Supp.
1). Three PEs were diagnosed; two in the CII group and one in the SCB
group. Four patients (three in the CII group and one in the SCB group)
had minor bleeding. None of the adverse events were assessed to be
associated with the anti-FXa concentration (data not shown). The 90-
day mortality was 12.8% (n= 5); all deaths were judged to be in-
dependent of the study drug.
4. Discussion
We found that continuous intravenous enoxaparin infusion as
thromboprophylaxis therapy resulted in lower plasma anti-FXa con-
centration than standard subcutaneous administration during the ﬁrst
24 h. No associations between anti-FXa concentration and clinical
endpoints (bleeding or thromboembolic complications) were detected.
This result supports our previous ﬁndings [4].
In medical and surgical patients, the recommended peak anti-FXa
concentration for thromboprophylaxis is 0.1–0.3 IU/ml [11], but there
are no recommendations on adequate anti-FXa concentration in
Fig. 1. Diagram of enrollment. One patient from the CII
group was excluded prior the study start due to infusion
pump failure leaving 39 patients in the ITT group. From the
ITT group 7 patients were excluded (3 erroneous study drug
dosing, 3 BMI over 30 kg/m2 and 1 GFR under 50 ml/min/
1.73 m2) leaving 32 patients in the PP group.
Abbreviations: ITT, intention to treat; CII, continuous in-
travenous infusion; SCB, standard subcutaneous bolus; BMI,
body mass index; GFR, glomerular ﬁltration rate; PP, per
protocol analysis.
Table 1
Baseline characteristics and laboratory values according to route of enoxaparin administration.
Patient characteristics Continuous intravenous infusion n= 23 Standard subcutaneous bolus
n= 16
p-Value
Male sex 13 56.5 14 87.5 0.076
Age, years 52 45–59 56 42–64 0.646
BMI, kg/m2 26.8 22.9–29.5 26.5 23.9–29.6 0.940
Active cancer 2 8.7 2 12.5 1.000
Diabetes 4 17.4 2 12.5 1.000
Smoking 13 56.5 5 31.3 0.119
Alcohol abuse 11 47.8 8 50.0 0.894
Hypertension 9 39.1 6 37.5 0.918
APACHE II 16.0 14–20 17.5 11.3–25.8 0.536
Creatine clearance, ml/min 121.4 83.5–152.0 121.5 94.3–162.0 0.848
Norepinephrine 8 34.8 7 43.8 0.571
Sepsis/septic shock
Sepsis 7 30.4 7 43.8 0.692
Septic shock 2 8.7 1 6.3
Primary admission diagnosis 0.991
Cardiovascular 1 4.3 0 0.0
Respiratory 10 43.5 6 37.5
Gastrointestinal 7 30.4 6 37.5
Neurologic 1 4.3 0 0.0
Infection 2 8.7 2 12.5
Trauma 1 4.3 1 6.3
Metabolic 1 4.3 1 6.3
LMWH prophylaxis before inclusion 11 47.8 5 31.3 0.301
Length of ICU stay before LMWH, h:mm 18:56 10:18–26:47 17:33 13:55–24:55 0.471
Mechanical ventilation 15 65.2 12 75.0 0.726
Platelet count, 109/l 195 153–319 142 122–192 0.135
WBC count, 109/l 13.4 7.6–16.5 11.6 9.9–21.3 0.848
CRP mg/l 236 140–295 262 190–393 0.848
Hct% 0.36 0.30–0.38 0.34 0.29–0.43 0.399
Bilirubin μmol/l 12 7–20 13 9–15 0.646
Data are presented as n (%) or median (interquartile range).
Abbreviations: BMI, body mass index; APACHE, Acute Physiology and Chronic Health Evaluation; VTE, venous thromboembolism; LMWH, low-molecular weight heparin; WBC, white
blood cell; CRP, C-reactive protein.
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critically ill patients, nor is it known whether peak or trough con-
centration should be measured. In previous studies, ICU patients have
had lower peak anti-FXa concentration than ward patients [5,6].
However, when administering enoxaparin 40 mg once daily or 30 mg
twice daily subcutaneously, peak anti-FXa concentration reportedly
reaches the lower target concentration of 0.1 IU/ml [7,12–19], con-
sistent with our ﬁndings in the SCB group. In the CII group, Cmax24 h
remained< 0.1 IU/ml and the target concentration was not reached
until 72 h. This could likely have been avoided by giving a loading
dose.
To our knowledge this is the ﬁrst RCT to have examined continuous
dosing of thromboprophylactic LMWH in ICU patients. Previous studies
have found that trough anti-FXa concentration tends to be low in these
patients [14,17,18,20]. In this trial, anti-FXa concentration remained
low in the CII group, but by the end of the study period (at 72 h) most of
the patients in the CII group had a measurable anti-FXa concentration,
whereas the concentration in the SCB group was comparable with those
reported in previous trials. This supports our hypothesis that CII could
oﬀer more consistent anticoagulation; however, the clinical relevance
of this ﬁnding is unclear. Furthermore, there is no consensus whether
the laboratory target for LMWH prophylaxis should be a high peak anti-
FXa concentration or a constant anti-FXa concentration.
The ﬁndings of previous trials suggest that suboptimal anti-FXa
concentration in ICU patients could be explained by reduction in the
bioavailability of subcutaneous LMWH, due to subcutaneous edema [7]
or concomitant vasopressor therapy [6]. Moreover, the procoagulant
eﬀect of exogenous epinephrine is well established in historic trials, and
there is some evidence that norepinephrine infusion (0.15–0.75 μg/kg/
min) promotes platelet aggregation [21]. Johansson and colleagues
have demonstrated that even though higher endogenous nor-
epinephrine concentration was associated with increased endothelial
activation and ﬁbrinolysis, exogenous norepinephrine infusion did not
further potentiate these changes in patients with septic shock [22]. Our
trial did not identify any signiﬁcant eﬀect of norepinephrine infusion on
anti-FXa concentration in either of the study groups. However, it must
be remembered that the choice and dose of LMWH used here diﬀered
from the study design of Dörﬄer-Melly and colleagues, who used na-
droparin 2850 IU instead of enoxaparin 40 mg [6]. In a more recent
trial in which the enoxaparin dose was similar to ours, norepinephrine
did not have any eﬀect on peak or trough anti-FXa concentration [23].
Additionally, despite lacking statistical signiﬁcance our ﬁndings cannot
refute a clinically meaningful eﬀect size (upper conﬁdence interval for
diﬀerence in means antiFXa 0.20) of norepinephrine in subcutaneous
dosing of enoxaparin.
The clinical relevance of anti-FXa concentration to bleeding or VTE
is unclear; however, in one study a low trough anti-FXa concentration
increased the risk of DVT [13]. In this trial, three patients were diag-
nosed with PE irrespective of the anti-FXa concentration; screening
ultrasound was not undertaken in these patients in line with current
guidelines [24]. The therapeutic beneﬁts of mechanical thrombopro-
phylaxis for these thrombotic events are uncertain. Nearly all our pa-
tients had compression stockings and/or pneumatic compression de-
vices.
Our study had some limitations. First, the PP group was smaller than
planned. Nevertheless, the results of the ITT and PP groups were
broadly comparable. Second, our decision to stratify groups with nor-
epinephrine administration in two diﬀerent study sites led to diﬀerent
number of patients in each study group. However, diﬀering numbers in
the study groups do not compromise statistical testing and we con-
sidered it important to stratify according to norepinephrine dosing due
to preliminary reports suggesting marked confounding inﬂuence of
norepinephrine [6]. Third, as the study period was only 72 h, it is
possible that we missed the opportunity to observe enoxaparin accu-
mulation and its consequences. Fourth, we excluded patients with acute
kidney injury and obesity to avoid bias. Fift, the sample size was not
designed to detect clinically relevant endpoints. Finally, we acknowl-
edge that anti-FXa concentration is only a surrogate marker for
thromboprophylaxis, and ignores the anticoagulant eﬀect of enoxaparin
on other plasma proteins (such as thrombin and platelet factor 4).
5. Conclusions
Continuous intravenous infusion of enoxaparin as thromboprophy-
laxis led to lower 24 h anti-FXa Cmax compared with standard SCB ad-
ministration. No diﬀerence in anti-FXa AUC0–24 h was detected. Our
ﬁndings could not conﬁrm or refute a clinically relevant eﬀect of nor-
epinephrine infusion on antiFXa levels using subcutaneous dosing of
Table 2
Maximum enoxaparin concentration and area under the curve by route of administration.
Pharmacological parameters Continuous intravenous infusion Standard subcutaneous bolus p-Value
Median Q1–Q3 Median Q1–Q3
ITT Anti-FXa Cmax 24 h 0.05 0.05–0.18 0.18 0.12–0.33 0.005
Anti-FXa Cmax 72 h 0.14 0.05–0.22 0.23 0.20–0.38 0.009
AUC(0–24 h) 1.20 0.98–2.88 1.54 1.22–4.12 0.095
AUC(0–72 h) 5.37 3.60–10.90 7.74 5.89–11.67 0.427
PP Anti-FXa Cmax 24 h 0.05 0.05–0.16 0.19 0.11–0.34 0.008
Anti-FXa Cmax 72 h 0.11 0.05–0.19 0.22 0.18–0.34 0.006
AUC(0–24 h) 1.20 0.79–2.67 1.61 1.26–4.77 0.113
AUC(0–72 h) 4.10 1.83–7.91 5.70 3.06–7.98 0.506
Abbreviations: FXa, activated Factor X; Cmax, maximum concentration; AUC, area under the curve; ITT, intention-to-treat; PP, per-protocol.
Fig. 2. The eﬀect of the baseline norepinephrine infusion on anti-FXa AUC(0–24 h).
Abbreviations: AUC, area under the curve; CI, continuous intravenous infusion; SC,
subcutaneous bolus.
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enoxaparin. Further studies scrutinizing enoxaparin infusion with a
loading dose in critically ill patients are warranted.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.thromres.2017.08.014.
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Activation of Blood Coagulation After Aneurysmal Subarachnoid Hemorrhage: A
Prospective Observational Trial of Rotational Thromboelastometry
Annukka S. Vahtera1, Eija K. Junttila2, L. Ville Jalkanen1, Heini S. Huhtala5, Ksenia V. Katanandova3, Pauli T. He´len4,
Anne H. Kuitunen1
-OBJECTIVE: Aneurysmal subarachnoid hemorrhage
(aSAH) has been reported to actuate blood coagulation.
Rotational thromboelastometry (ROTEM) is a dynamic he-
mostatic test that can differentiate various coagulation
abnormalities. For example, increased coagulation activity
can be detected as a wider amplitude of tracing (maximal
clot firmness [MCF]). ROTEM had not been used to evaluate
coagulation changes after aSAH. We evaluated the on-
going coagulation process in patients with aSAH in a
prospective, observational study to compare their ROTEM
assay results with the control values obtained from pa-
tients undergoing clipping of nonruptured aneurysms.
-METHODS: ROTEM analyses were performed at 12, 24,
48, and 72 hours after the onset of aSAH and compared with
the preoperative analyses from the control group. A total of
17 patients with aSAH treated in the intensive care unit and
16 control patients were enrolled.
-RESULTS: At 72 hours, EXTEM-MCF was significantly
greater in patients with aSAH compared with the baseline
values of the control group (68.0 mm [interquartile range
(IQR), 66.0e71.0] versus 64.5 mm [IQR, 59.5e66.8];
P [ 0.024). This was mainly due to increased fibrin for-
mation and fibrin polymerization. The same comparison in
the FIBTEM-MCF analysis yielded similar results (aSAH
group, 23.0 mm [IQR, 19.0e25.0] vs. control group, 15.4 mm
[IQR, 12.5e17.8], respectively; P [ 0.001).
-CONCLUSIONS: Blood coagulation is activated at 72
hours after aSAH onset, which can be detected by ROTEM
EXTEM-MCF analysis. Also, the FIBTEM-MCF was elevated,
implying that the relative contribution of fibrin formation
and fibrin polymerization is essential.
INTRODUCTION
The annual incidence of aneurysmal subarachnoid hemor-rhage (aSAH) has been decreasing1,2; however, its 1-yearmortality has remained at nearly 50%.3 Among the
survivors of aSAH, both early brain injury (EBI) and delayed
cerebral ischemia (DCI) are major risk factors for poor
neurological outcomes4,5 and increased mortality.6 EBI is
deﬁned as early neurological deterioration caused by transient
direct toxic effects from an initial hemorrhage.7 In contrast, DCI
is delayed brain injury presenting as either clinical deterioration
or cerebral infarction.8 However, the pathophysiology of these 2
entities is not fully understood.9,10
Blood coagulation and ﬁbrinolytic systems seem to activate
during the acute phase of aSAH,11 and increased coagulation can
be detected within minutes after the initial hemorrhage.12
However, the association of cerebral microthrombosis with EBI
or DCI has not been unequivocally determined in the clinical
setting.9
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Viscoelastic point-of-care coagulation tests (e.g., rotational
thromboelastometry [ROTEM]) are thought to be advantageous
compared with conventional laboratory tests when analyzing the
increased coagulation.13 No studies have investigated the ongoing
coagulation process after aSAH using ROTEM. Our main aim was
to assess the ROTEM measurements after aSAH and analyze the
role of platelets and ﬁbrinogen on clot formation. We also
examined the association of ROTEM assay results with clinical
events such as EBI and DCI.
METHODS
The present prospective, observational clinical study was con-
ducted in the intensive care unit (ICU) and neurosurgical depart-
ment of Tampere University Hospital (Tampere, Finland) from
October 2015 to June 2016. The trial was conducted in accordance
with the amended Declaration of Helsinki. The local ethics com-
mittee of Pirkanmaa approved the study design (approval no.
230215-1), and the study was registered in the ClinicalTrials.gov
database (ClinicalTrials.gov identiﬁer, NCT02540005). All the pa-
tients or their next of kin provided written informed consent
before study enrollment.
Study Subjects
Consecutive patients with acute aSAH who were admitted to the
ICU within 12 hours of the onset of aSAH symptoms (deﬁned as a
sudden severe headache or loss of consciousness) and expected to
stay in the ICU for 72 hours, were considered eligible. Sub-
arachnoid bleeding was diagnosed from the nonecontrast-
enhanced computed tomography scan ﬁndings of the brain. A
ruptured aneurysm as a source of hemorrhage was conﬁrmed by
either computed tomography angiography or digital subtraction
angiography. The exclusion criteria were age <18 years, preg-
nancy, anticoagulant medication in regular use, and known active
cancer. Only acetylsalicylic acid (<150 mg daily) was allowed as an
antithrombotic medication. Patients undergoing elective non-
ruptured intracranial aneurysm clipping were chosen as the con-
trol group because they had the same disease entity and thus
offered the closest surrogate values for the bleeding state before
the occurrence of aSAH. The control group also served as a local
reference group for ROTEM.
Clinical Management
All patients with aSAH received neurointensive care in accordance
with international guidelines.14,15 The therapy included thrombo-
prophylaxis therapy (tinzaparin, 4500 IU subcutaneously, once
daily) after occlusion of the ruptured aneurysm by either endo-
vascular coiling or surgical clipping.16 After tinzaparin was started,
no mechanical thromboprophylaxis was used.17 All control
patients were treated in accordance with perioperative protocols.
In addition to our standard neurointensive care, bilateral
compression ultrasonography of the lower extremity veins was
performed to exclude asymptomatic deep venous thrombosis
(DVT) by the radiologist once within days 3e5. When necessary,
computed tomography pulmonary angiography was performed to
rule out pulmonary embolism (PE).
Blood Sampling
Blood samples for ROTEM analysis were retrieved from patients
with aSAH at 12, 24, 48, and 72 hours after the onset of aSAH
symptoms and compared with the preoperative samples of the
control group (i.e., baseline). Complete blood, platelet, and
leukocyte counts, serum C-reactive protein, and international
normalized ratio concentrations were measured daily during the
study period. All blood samples from the aSAH and control groups
were taken from a heparin-naive arterial line.
Thromboelastometry
All ROTEM assays were performed in the central laboratory of
Tampere University Hospital using a ROTEM delta analysis system
(TEM Innovations GmbH, Munich, Germany). The following pa-
rameters were measured: clotting time (CT; which represents the
interval to initiation of clot formation), clot formation time (CFT,
which represents stabilization of the clot), and maximum clot
ﬁrmness (MCF, which represents the maximum clot strength).
Each analysis was performed using single-use reagents. The
EXTEM (tissue factor activated, citrated, and recalciﬁed) analysis
measures coagulation activated by the extrinsic pathway. The
FIBTEM (tissue factor plus platelet inhibitor cytochalasin
D-activated, citrated, and recalciﬁed) analysis measures formation
of ﬁbrin-based clots after platelet inhibition by cytochalasin D to
block the function of glycoprotein IIb/IIIa receptor. The INTEM
(contact-activated, citrated, and recalciﬁed) analysis measures clot
formation via the contact phase. In general, a hypercoagulable
state can be detected if the MCF is elevated.18 Using different
reagents, the effect of platelets and ﬁbrinogen (EXTEM-MCF)
and ﬁbrin formation and its polymerization (FIBTEM-MCF) on
clots can be distinguished.
Our primary outcome was the EXTEM-MCF value in the aSAH
group compared with the baseline value from the control group.
The secondary outcomes were other ROTEM parameters (i.e.,
EXTEM-CT, EXTEM-CFT, FIBTEM-MCF, INTEM-MCF, INTEM-
CT, and INTEM-CFT) compared with the baseline values from
the control group. To identify the platelet contribution to clot
strength, the difference between EXTEM-MCF and FIBTEM-MCF
was calculated.
Clinical and Outcome Measures
The clinical severity of aSAH at admission was reviewed retro-
spectively using the HunteHess grade, from which the EBI
severity was classiﬁed as severe (HunteHess score, 4e5) or mild
(HunteHess score, 1e3).19 The severity of bleeding was evaluated
from the primary head computed tomography scan using the
Fisher scale20 and deﬁned as moderate to severe if the scale
score was 3. Moreover, DCI was evaluated retrospectively from
the ICU database (Centricity Critical Care Clinisoft; GE
Healthcare, Barrington, Illinois, USA) at 24 hours to 14 days
from the onset of aSAH symptoms using the criteria presented
by Vergouwen et al.8 In brief, DCI was deﬁned as neurological
deterioration (a reduction in the Glasgow coma scale score by
2 points) for 1 hour, a new neurological symptom for
1 hour that could not be explained by other features, or a new
ischemic episode on neuroimaging data that was not related to
the primary aSAH or neurosurgery.
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Clinically signiﬁcant events representing the hypercoagulable
state were evaluated (e.g., venous thromboembolism [VTE],
including DVT and PE). The extended Glasgow outcome scale
score,21 including mortality, was registered on day 90.
Statistical Analysis
Statistical analyses were performed using the SPSS statistical
software program, version 23.0, released 2015 (IBM Corp.,
Armonk, New York, USA). Depending on the distribution of the
variables, comparisons between the continuous variables were
performed using either the Mann-Whitney U test or Student t test.
For categorical variables, univariate analysis with Fisher’s exact
test was performed.
Using standard sample size calculations, 16 patients in each
group were needed to detect a clinically signiﬁcant increase in
MCF, from 65 to 70 mm (standard deviation, 5) using the EXTEM S
reagent, assuming a power of 80% and a signiﬁcance level of 5%.
RESULTS
We enrolled 17 patients with aSAH and 16 control patients. The
groups did not differ in sex, comorbidities, or body mass index.
However, the proportion of smokers was greater and the patients
were younger in the aSAH group (Table 1). Moreover, the ruptured
aneurysm was more commonly located in the anterior
communicating artery in the aSAH group. In contrast, most
aneurysms in the control group were located in the middle
cerebral artery (Table 1). In most of the patients with aSAH,
bleeding was classiﬁed as moderate to severe, and the aneurysm
was repaired by endovascular coiling in 13 of the patients
(76.5%; Table 2). On day 90, nearly 60% of the patients with
aSAH showed good neurological recovery; the mortality was
5.9%. More detailed demographic information on the aSAH
patient group is presented in Table 2.
At 72 hours, the EXTEM-MCF was signiﬁcantly greater in the
patients with aSAH compared with the baseline value from the
control group (68.0 mm [interquartile range (IQR), 66.0e71.0]
versus 64.5 mm [IQR, 59.5e66.8], respectively; P ¼ 0.024).
FIBTEM-MCF was also signiﬁcantly increased at 72 hours
compared with the baseline value from the control group
(23.0 mm [IQR, 19.0e25.0] vs. 15.4 mm [IQR, 12.5e17.8],
respectively; P ¼ 0.001). The difference between EXTEM-MCF and
Table 2. Characteristics of Patients with Aneurysmal
Subarachnoid Hemorrhage
Parameter Value
HunteHess score 2.4  1
1 2 (11.8)
2 10 (58.8)
3 1 (5.9)
4 4 (23.5)
Fisher scale score 3  0.9
1 0 (0)
2 6 (35.3)
3 5 (29.4)
4 6 (35.3)
Treatment
Clipping 4 (23.5)
Coiling 13 (76.5)
TXA 1 (5.9)
LMWH during ICU 15 (88.2)
GOSe score at 90 days 6.7 1.9
Death 1 (5.9)
Vegetative state 0 (0)
Lower severe disability 0 (0)
Upper severe disability 0 (0)
Lower moderate disability 1 (5.9)
Upper moderate disability 3 (17.6)
Lower good recovery 3 (17.6)
Upper good recovery 7 (41.2)
Data presented as mean  standard deviation or n (%).
TXA, tranexamic acid; LMWH, low-molecular weight heparin; GOSe, Glasgow outcome
scale, extended.
Table 1. Baseline Patient Characteristics
Characteristic
aSAH Group
(n [ 17)
Control Group
(n [ 16) P Value
BMI (kg/m2) 30 (25e33) 28 (25e31) 0.363
Age (years) 49 (40e60) 62 (56e67) 0.037
Male sex 6 (35.3) 7 (43.8) 0.728
Smoking 10 (58.8) 6 (37.5) 0.003
Alcohol abuse 2 (12.5) 0 (0) 0.227
HTN 7 (41.2) 11 (68.8) 0.166
Diabetes 0 (0) 3 (18.8) 0.103
Cancer in remission 1 (5.9) 1 (6.3) 1.000
Low-dose aspirin 1 (5.9) 5 (31.3) 0.085
Aneurysm location
ACA 6 (35.3) 0 (0)
BA 2 (11.8) 0 (0)
ICA 4 (23.5) 0 (0)
MCA 4 (23.5) 15 (93.8)
PCA 1 (5.9) 0 (0)
PA 0 (0) 1 (6.3)
Data presented as median (quartile 1 to quartile 3) or n (%).
aSAH, aneurysmal subarachnoid hemorrhage; BMI, body mass index; HTA, hypertension;
ACA, anterior communicating artery; BA, basilar artery; ICA, internal carotid artery;
MCA, middle cerebral artery; PCA, posterior cerebral artery; PA, pericallosal artery.
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FIBTEM-MCF represents the platelet contribution to clot forma-
tion. This decreased signiﬁcantly during the ﬁrst 72 hours (from
48.5 mm [IQR, 46.3e50.8] to 44.0 mm [IQR, 41.0e48.0];
P ¼ 0.027) compared with the baseline values from the control
group (Figure 1). The absolute platelet concentration remained
unchanged (221  66 109/L at 72 hours vs. 244  88 109/L at
baseline for the control group; P ¼ 0.426). Compared with the
aSAH value at 72 hours, the EXTEM-CFT had decreased signiﬁ-
cantly from the baseline value for the control group (96.5 seconds
[IQR, 81.3e120.5] vs. 74.0 seconds [IQR, 65.0e89.0]; P ¼ 0.015).
No differences in INTEM-MCF, EXTEM-CT, INTEM-CT, or
INTEM-CFT were observed at 72 hours compared with the baseline
values from the control group (Table 3). Other time comparisons
(12, 24, and 48 hours after the onset of aSAH symptoms) with the
baseline values of the control group are shown in Table 3.
Furthermore, DCI was observed in 7 of the 17 patients with
aSAH (41%). At 72 hours, the FIBTEM-MCF was signiﬁcantly
greater in the patients who developed DCI compared with those
who did not (25.0 mm [IQR, 24.8e26.8] vs. 19.0 mm [IQR,
16.5e22.5]; P ¼ 0.012; Figure 2). No differences were detected in
EXTEM-MCF (68.5 mm [IQR, 66.8e69.8] vs. 67.0 mm [IQR,
64.5e71.5]; P ¼ 0.698) or INTEM-MCF (66.0 mm [IQR,
36.0e70.5] vs. 68.0 mm [IQR, 65.5e71.5]; P ¼ 0.606). Four pa-
tients had severe EBI. In these patients, FIBTEM-MCF was
signiﬁcantly greater at 72 hours compared with those patients with
mild EBI (26.0 mm [IQR, 25.0e26.0] vs. 22.0 mm [IQR,
18.3e24.8]; P ¼ 0.031; Figure 2). EXTEM-MCF was unchanged at
72 hours (data not shown).
Two DVTs were detected in patients with aSAH, and both pa-
tients also developed a PE. In these patients, EXTEM-MCF was not
greater compared with that of the other patients with aSAH at 72
hours (61.5 mm [IQR, 57.0e61.5] vs. 69.0 mm [IQR, 66.5e71.5];
P ¼ 0.076). No thromboembolic complications were observed in
the control group.
DISCUSSION
The present clinical, observational trial examined the ongoing
coagulation process after aSAH using ROTEM analysis. We
observed that at 72 hours after the onset of aSAH, the strength of
the formed blood clot had increased, as shown by the greater
EXTEM-MCF and FIBTEM-MCF values. Greater FIBTEM-MCF
levels were associated with the incidence of DCI and EBI. To the
best of our knowledge, our study is the ﬁrst to use ROTEM to
examine the changes in coagulation after aSAH.
In the present study, EXTEM-MCF was increased at 72 hours after
the onset of aSAH, suggesting overall coagulability was increased.
In previous trials, the hemostatic changes after aSAH were investi-
gated by another viscoelastic point-of-care coagulation test, such as
thromboelastography (TEG), in which the overall coagulation state
is evaluated by themaximumamplitude (MA), which is analogous to
the MCF value in ROTEM.22,23 The results of these studies are
consistentwith ours for patientswithmoderate to severe aSAH,with
onset of the hypercoagulable state observed at 3 days after bleeding,
with the greatest MA levels found on day 10.24When themonitoring
period was shorter than 72 hours, no change in the MA value was
observed in the overall aSAH population.22,23 Interpretation of
these previous results is difﬁcult,22,23 because the exact timing of the
blood samples is not known. Moreover, because blood coagulation
has been activated by different reagents in previous trials, a direct
comparison between results would be challenging. We chose to use
the extrinsic pathway because it most accurately mimics rupture of
an aneurysm and the release of tissue factors to initiate blood
coagulation. However, these data suggest that the hypercoagulation
state develops gradually after aSAH and can be detected by visco-
elastic point-of-care coagulation test 3 days after the bleeding event.
We noted that at 72 hours after the onset of aSAH bleeding, the
FIBTEM-MCF levels had signiﬁcantly increased. This implies that
ﬁbrin formation and polymerization exert a major contribution on
clot strength. To the best of our knowledge, no previous trials have
investigated ﬁbrin function after aSAH. In general, FIBTEM-MCF
is a surrogate marker for plasma ﬁbrinogen concentration, and
they are both known to increase the recovery phase of many acute
illnesses (e.g., severe sepsis).25 When measured at the early phase
of aSAH, the ﬁbrinogen concentration will reportedly be within
normal limits11,23,26-29 or slightly elevated.24 However, we have
not found any trials in which the change in ﬁbrinogen
concentration has been studied. It is known that higher values
Figure 1. Change in rotational thromboelastometry (ROTEM) analysis from
baseline value of the control group to 72 hours after the onset of aneurysmal
subarachnoid hemorrhage symptoms. (A) EXTEM-maximal clot ﬁrmness
(MCF): baselinemedian, 64.5mm (interquartile range [IQR], 59.5e66.8); at 72
hours, 68.0 mm (IQR, 66.0e71.0; P ¼ 0.024). (B) FIBTEM-MCF: baseline
median, 15.0 mm (IQR, 12.5e17.8); at 72 hours, 23.0 mm (IQR, 19.0e25.0;
P ¼ 0.001). (C) Difference between EXTEM-MCF and FIBTEM-MCF
represents the effect of platelets on clot formationBaselinemedian, 48.5mm
(IQR, 46.3e50.8); at 72 hours, 44.0 mm (IQR, 41.0e48.0; P ¼ 0.027). Black
diamonds indicate statistical signiﬁcance (P < 0.05).
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of the ﬁbrin degradation product, D-dimer, after aSAH are
associated with poor neurological outcomes.30 This is in
accordance with our results, because a greater D-dimer value
implies that ﬁbrin formation is increased, as does a higher
FIBTEM-MCF. Additional studies are needed to conﬁrm these
results and determine whether FIBTEM-MCF continues to increase
after 3 days.
We noticed that the absolute and relative differences between
EXTEM-MCF and FIBTEM-MCF both decreased after 72 hours and
the absolute platelet concentration remained unchanged. This
shows that the functional effect of platelets on the formation of
clot strength declines and outlines the functional effect of ﬁbrin.
In previous TEG trials, the clot strength was solely evaluated by the
MA, and thickening of the clot was concluded to reﬂect activation
of platelets only.22,24 In a recent trial, activation and aggregation of
platelets was observed after aSAH.31 Nevertheless, it is known that
both platelet activation and ﬁbrin formation and crosslinking are
needed for clot formation. The relative contribution of platelets
and ﬁbrin to clot strength in patients with aSAH is unknown. In
healthy individuals, ﬁbrinogen accounts for 25% of clot
strength, and in trauma patients, the contribution increases
44% after 72 hours of insult.32,33 From our results, it appears
that the relative contribution of ﬁbrinogen also increases after
aSAH, from 23.5% to 33.3% at 72 hours after the onset of aSAH.
We found signiﬁcantly greater FIBTEM-MCF at 72 hours in
patients who had severe EBI or further developed DCI. We did not
observe any association between DCI and EXTEM-MCF, although
the absolute increase in EXTEM-MCF was statistically signiﬁcant.
To the best of our knowledge, no trial has investigated this pre-
viously. Fujii et al.26 found that greater ﬁbrinogen levels predicted
the incidence of DCI at 6 days after aSAH; however, the baseline
ﬁbrinogen concentration has not shown an association with poor
neurological outcomes.34 From the results of previous TEG trials,
the association of MA levels with EBI or DCI has been
Table 3. Laboratory Results and Rotational Thromboelastometry Assays
Parameter
Reference
Range
Baseline of Control
Group
From Onset of aSAH (hours)
12 24 48 72
Median Q1-Q3 Median Q1-Q3 Median Q1-Q3 Median Q1-Q3 Median Q1-Q3
EXTEM
MCF (mm) 50e72 64.50 59.5e66.8 64.0 62.0e69.5 68.0 63.0e70.0 66.0 65.5e69.0 68.0* 66.0e71.0
CT (seconds) 38e79 48 45e58 53 48e57 54 45e61 51 47e62 52 45e61
CFT (seconds) 34e159 96.50 81.3e120.5 100.0 71.5e109.5 101.0 68.5e111.5 86.0y 69.0e92.0 74.0z 65.0e89.0
INTEM
MCF (mm) 50e72 65.50 61.3e68.0 65.0 62.5e71.5 68.0 64.0e71.5 67.0 65.5e70.0 67.5 65.8e71.3
CT (seconds) 100e240 158 149e170 142 129e167 145 129e167 149 138e167 149 143e159
CFT (seconds) 30e110 66.00 58.5e78.5 72.0 51.5e82.5 65.0 51.0e74.5 61.0 52.5e79.0 59.0 50.5e66.8
FIBTEM
MCF (mm) 9e25 15.40 12.5e17.8 15.00 13.5e21.5 16.00 14.5e22.5 19.0x 16.5e23.0 23.0{ 19.0e25.0
Platelet count (109/L) 150e360 244  88 NA NA NA 240  50 NA 217  66 NA 221  66 NA
Leukocyte count (109/L) 3.3e8.2 7.2  1.6 NA NA NA 13.7  3.9 NA 13.5  3.9 NA 12.3  3.5 NA
Hemoglobin (g/L) 134e167 145  13 NA NA NA 132  15.2k NA 124  12.5# NA 127  12.6** NA
CRP (mg/L) <10 23.7 13.0e36.8 NA NA 8.3 3.7e13.2 19.5 9.2e45.5 34.0 6.2e88.5
Data presented as median and first to third quartile or range and mean  standard deviation.
All statistical comparisons were between baseline values of control group and different evaluation points for aSAH group.
aSAH, aneurysmal subarachnoid hemorrhage; Q1, first quartile; Q3, third quartile; MCF, maximum clot firmness; CT, clotting time; CFT, clot formation time; NA, not applicable; CRP; C-reactive
protein.
*P ¼ 0.024.
yP ¼ 0.023.
zP ¼ 0.015.
xP ¼ 0.004.
{P ¼ 0.001.
kP ¼ 0.010.
#P < 0.001.
**P < 0.001.
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inconsistent. Some studies have reported that greater MA levels
increase the likelihood of severe EBI and the risk of developing
DCI.22 In contrast, others did not observe any association with
DCI, although hypercoagulability was associated with poor
neurological outcomes.24
These inconsistent results might be due to the widely varied
deﬁnitions used for DCI.8 Moreover, the pathophysiology of DCI is
complex and not completely understood. It is known that
aneurysm rupture causes platelet activation, which results in
thrombin generation, additional ﬁbrin cleavage from ﬁbrinogen,
and formation of cerebral microthrombi. Ultimately, this might
contribute to the pathophysiology of DCI.35 From our results, it
seems that increasing ﬁbrin formation and polymerization might
play a role in the pathophysiology of DCI. In clinical setting,
antiplatelet therapy has failed to prevent this increased ﬁbrin
formation or reduce the incidence of DCI or mortality after
aSAH.36 Nonetheless, a recent retrospective trial showed
promising results when dual antiplatelet therapy was used.35
The overall incidence of VTE in our study was high: 11.8% for
both DVT and PE. In previous trials, the incidence of DVT among
patients with aSAH varied from 2% to 24%, depending on whether
a screening method was used.37,38 Although weak evidence exists
that the earlier onset of clot formation might increase the risk of
DVT,23 in our present trial, we did not observe shortened
EXTEM-CT or elevated EXTEM-MCF among the 2 patients with
VTE. Moreover, EXTEM-CT and INTEM-CT remained unchanged
during the study period for the whole aSAH group, indicating that
initiation of clotting and thrombin formation and the start of
ﬁbrin polymerization were unaffected. In general, the predictive
value of TEG for VTE diagnostics is highly inconsistent.39 Thus, a
much larger trial is required to show any association between the
changes in coagulation factors and the incidence of VTE after
aSAH. Altogether, this supports the current practice to start
pharmacological thromboprophylaxis as early as is safe.15
The present study had limitations. First, we had a 12-hour
delay from the onset of initial bleeding to the ﬁrst ROTEM
measurement. However, this delay would be inevitable when
performing clinical research on this patient population. Second,
we monitored ROTEM measurements for only 72 hours. In pre-
vious TEG trials, coagulation continued to increase from day 3 to
day 10, with a clear hypercoagulability state identiﬁed on day 5.24
Third, although neurosurgical patients undergoing elective
aneurysmal clipping represent the same patient population, the
patients with aSAH were younger and the proportion of
smokers was higher. This is unsurprising, because smoking is
known to be 1 of the major risk factors for aneurysm rupture.40
However, it is not known whether smoking would affect the
ROTEM results. Fourth, a decrease in the hemoglobin level
after aSAH might have paradoxically increased the measured
EXTEM-MCF. However, the magnitude of this would have most
likely been minimal.41 Also, the precision of FIBTEM-MCF
measurement is known to be better in anemic patients.42 Fifth,
our sample size was underpowered for some clinical endpoints
(e.g., DCI, EBI, and VTE). Thus, these results must be
interpreted with caution. Furthermore, owing to small sample
size, we were unable to perform multivariate testing on other
clinically relevant confounders (e.g., HunteHess or Fisher
score), which might have inﬂuence on the incidence of EBI and
DCI. Finally, with the present trial design, we were unable to
differentiate the effects of the different operative interventions on
blood coagulation.
CONCLUSIONS
Our study has shown that blood coagulation appears to increase at
72 hours after the onset of aSAH, and for the ﬁrst time, this
change can be detected by ROTEM EXTEM-MCF analysis. At the
same time, the FIBTEM-MCF was also elevated, suggesting that
Figure 2. Association with ﬁbrin formation and
polymerization (FIBTEM-MCF) during 72 hours after
onset of aneurysmal subarachnoid hemorrhage
symptoms with the incidence of early brain injury (EBI)
and delayed cerebral ischemia (DCI). (A) In patients
with severe EBI (n ¼ 4), FIBTEM-MCF was signiﬁcantly
greater at 72 hours compared with that in patients with
mild EBI (26.0 mm, [interquartile range (IQR), 25.0e26.
0] versus 22.0 mm [IQR, 18.3e24.8]; P ¼ 0.031). (B) In
patients with DCI (n ¼ 7), FIBTEM-MCF at 72 hours
was 25.0 mm (IQR, 24.8e26.8) compared with 19.
0 mm (IQR 16.5e22.5) for patients without DCI (n ¼
10; P ¼ 0.12). Diamonds indicate statistical signiﬁcance
(P < 0.05).
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the relative contributions of ﬁbrin formation and ﬁbrin polymer-
ization to clot strength are essential. Furthermore, FIBTEM-MCF
was greater in patients with DCI and EBI. Thus, it seems that
formation and polymerization of ﬁbrin might inﬂuence the path-
ophysiology of DCI and EBI. Further clinical trials are warranted to
conﬁrm these results.
ACKNOWLEDGMENTS
We thank Liisa Pyysalo M.D., Ph.D., for the neurosurgical follow-
up data; Antti Valanne, Ph.D., for establishing the ROTEM system
in the central laboratory of Tampere University Hospital; Rachel
James, Ph.D., from the Edanz Group (available at: www.
edanzediting.com/ac) for editing a draft of our report.
REFERENCES
1. de Rooij NK, Linn FH, van der Plas JA, Algra A,
Rinkel GJ. Incidence of subarachnoid haemor-
rhage: a systematic review with emphasis on re-
gion, age, gender and time trends. J Neurol
Neurosurg Psychiatry. 2007;78:1365-1372.
2. Korja M, Lehto H, Juvela S, Kaprio J. Incidence of
subarachnoid hemorrhage is decreasing together
with decreasing smoking rates. Neurology. 2016;87:
1118-1123.
3. Korja M, Silventoinen K, Laatikainen T,
Jousilahti P, Salomaa V, Kaprio J. Cause-speciﬁc
mortality of 1-year survivors of subarachnoid
hemorrhage. Neurology. 2013;80:481-486.
4. Ahn SH, Savarraj JP, Pervez M, Jones W, Park J,
Jeon SB, et al. The subarachnoid hemorrhage
early brain edema score predicts delayed cerebral
ischemia and clinical outcomes. Neurosurgery.
2018;83:137-145.
5. Frontera JA, Fernandez A, Schmidt JM, Claassen J,
Wartenberg KE, Badjatia N, et al. Deﬁning vaso-
spasm after subarachnoid hemorrhage: what is
the most clinically relevant deﬁnition. Stroke.
2009;40:1963-1968.
6. Broderick JP, Brott TG, Duldner JE, Tomsick T,
Leach A. Initial and recurrent bleeding are the
major causes of death following subarachnoid
hemorrhage. Stroke. 1994;25:1342-1347.
7. Fujii M, Yan J, Rolland WB, Soejima Y, Caner B,
Zhang JH. Early brain injury, an evolving frontier
in subarachnoid hemorrhage research. Transl
Stroke Res. 2013;4:432-446.
8. Vergouwen MD, Vermeulen M, van Gijn J,
Rinkel GJ, Wijdicks EF, Muizelaar JP, et al. Deﬁ-
nition of delayed cerebral ischemia after aneu-
rysmal subarachnoid hemorrhage as an outcome
event in clinical trials and observational studies:
proposal of a multidisciplinary research group.
Stroke. 2010;41:2391-2395.
9. Macdonald RL. Delayed neurological deteriora-
tion after subarachnoid haemorrhage. Nat Rev
Neurol. 2014;10:44-58.
10. Rowland MJ, Hadjipavlou G, Kelly M,
Westbrook J, Pattinson KT. Delayed cerebral
ischaemia after subarachnoid haemorrhage:
looking beyond vasospasm. Br J Anaesth. 2012;109:
315-329.
11. Ettinger MG. Coagulation abnormalities in sub-
arachnoid hemorrhage. Stroke. 1970;1:139-142.
12. Ji Y, Meng QH, Wang ZG. Changes in the coag-
ulation and ﬁbrinolytic system of patients with
subarachnoid hemorrhage. Neurol Med Chir (Tokyo).
2014;54:457-464.
13. Park MS, Martini WZ, Dubick MA, Salinas J,
Butenas S, Kheirabadi BS, et al. Thromboelas-
tography as a better indicator of hypercoagulable
state after injury than prothrombin time or acti-
vated partial thromboplastin time. J Trauma. 2009;
67:266-275 [discussion: 275].
14. Diringer MN, Bleck TP, Claude Hemphill J III,
Menon D, Shutter L, Vespa P, et al. Critical care
management of patients following aneurysmal
subarachnoid hemorrhage: recommendations
from the Neurocritical Care Society’s Multidisci-
plinary Consensus Conference. Neurocrit Care. 2011;
15:211-240.
15. Steiner T, Juvela S, Unterberg A, Jung C,
Forsting M, Rinkel G. European Stroke Organi-
zation. European Stroke Organization guidelines
for the management of intracranial aneurysms and
subarachnoid haemorrhage. Cerebrovasc Dis. 2013;
35:93-112.
16. Nyquist P, Bautista C, Jichici D, Burns J,
Chhangani S, DeFilippis M, et al. Prophylaxis of
venous thrombosis in neurocritical care patients:
an evidence-based guideline: a statement for
healthcare professionals from the Neurocritical
Care Society. Neurocrit Care. 2016;24:47-60.
17. Lilly CM, Liu X, Badawi O, Franey CS,
Zuckerman IH. Thrombosis prophylaxis and
mortality risk among critically ill adults. Chest.
2014;146:51-57.
18. Akay OM, Ustuner Z, Canturk Z, Mutlu FS,
Gulbas Z. Laboratory investigation of hypercoag-
ulability in cancer patients using rotation throm-
belastography. Med Oncol. 2009;26:358-364.
19. Hunt WE, Hess RM. Surgical risk as related to
time of intervention in the repair of intracranial
aneurysms. J Neurosurg. 1968;28:14-20.
20. Fisher CM, Kistler JP, Davis JM. Relation of ce-
rebral vasospasm to subarachnoid hemorrhage
visualized by computerized tomographic scan-
ning. Neurosurgery. 1980;6:1-9.
21. Wilson JT, Pettigrew LE, Teasdale GM. Structured
interviews for the Glasgow outcome scale and the
extended Glasgow outcome scale: guidelines for
their use. J Neurotrauma. 1998;15:573-585.
22. Frontera JA, Provencio JJ, Sehba FA, McIntyre TM,
Nowacki AS, Gordon E, et al. The role of platelet
activation and inﬂammation in early brain injury
following subarachnoid hemorrhage. Neurocrit
Care. 2017;26:48-57.
23. Miao W, Zhao K, Deng W, Teng J. Coagulation
factor hyperfunction after subarachnoid hemor-
rhage induces deep venous thrombosis. World
Neurosurg. 2018;110:e46-e52.
24. Ramchand P, Nyirjesy S, Frangos S, Doerﬂer S,
Nawalinski K, Quattrone F, et al.
Thromboelastography parameter predicts
outcome after subarachnoid hemorrhage: an
exploratory analysis. World Neurosurg. 2016;96:
215-221.
25. Sivula M, Pettilä V, Niemi TT, Varpula M,
Kuitunen AH. Thromboelastometry in patients
with severe sepsis and disseminated intravascular
coagulation. Blood Coagul Fibrinolysis. 2009;20:
419-426.
26. Fujii Y, Takeuchi S, Sasaki O, Minakawa T,
Koike T, Tanaka R. Serial changes of hemostasis
in aneurysmal subarachnoid hemorrhage with
special reference to delayed ischemic neurological
deﬁcits. J Neurosurg. 1997;86:594-602.
27. Ilveskero S, Juvela S, Siironen J, Lassila R. D-
dimer predicts outcome after aneurysmal sub-
arachnoid hemorrhage: no effect of thrombopro-
phylaxis on coagulation activity. Neurosurgery.
2005;57:16-24 [discussion: 16].
28. Larsen CC, Sørensen B, Nielsen JD, Astrup J.
Reduced clot-stability during the ﬁrst 6 hours af-
ter aneurysmal subarachnoid haemorrhage—a
prospective case-control study. Thromb Res. 2012;
129:e229-e232.
29. Nina P, Schisano G, Chiappetta F, Luisa Papa M,
Maddaloni E, Brunori A, et al. A study of blood
coagulation and ﬁbrinolytic system in sponta-
neous subarachnoid hemorrhage: correlation with
Hunt-Hess grade and outcome. Surg Neurol. 2001;
55:197-203.
30. Juvela S, Siironen J. D-dimer as an independent
predictor for poor outcome after aneurysmal
subarachnoid hemorrhage. Stroke. 2006;37:
1451-1456.
31. Perez P, Lukaszewicz AC, Lenck S, Nizard R,
Drouet L, Payen D. Platelet activation and aggre-
gation after aneurysmal subarachnoid hemor-
rhage. BMC Neurol. 2018;18:57.
32. Harr JN, Moore EE, Chin TL, Ghasabyan A,
Gonzalez E, Wohlauer MV, et al. Platelets are
dominant contributors to hypercoagulability after
injury. J Trauma Acute Care Surg. 2013;74:756-762
[discussion: 762].
33. Kornblith LZ, Kutcher ME, Redick BJ, Calfee CS,
Vilardi RF, Cohen MJ. Fibrinogen and platelet
contributions to clot formation: implications for
trauma resuscitation and thromboprophylaxis.
J Trauma Acute Care Surg. 2014;76:255-256 [discus-
sion: 262].
34. Turner CL, Budohoski K, Smith C, Hutchinson PJ,
Kirkpatrick PJ, Murray GD, STASH Collaborators.
Elevated baseline C-reactive protein as a predictor
of outcome after aneurysmal subarachnoid hem-
orrhage: data from the simvastatin in aneurysmal
subarachnoid hemorrhage (STASH) trial. Neuro-
surgery. 2015;77:786-792 [discussion: 792].
e340 www.SCIENCEDIRECT.com WORLD NEUROSURGERY, https://doi.org/10.1016/j.wneu.2018.10.035
ORIGINAL ARTICLE
ANNUKKA S. VAHTERA ET AL. ROTEM FOR COAGULATION MONITORING AFTER ASAH
35. Nagahama Y, Allan L, Nakagawa D, Zanaty M,
Starke RM, Chalouhi N, et al. Dual antiplatelet
therapy in aneurysmal subarachnoid hemorrhage:
association with reduced risk of clinical vaso-
spasm and delayed cerebral ischemia. J Neurosurg.
2018;129:702-710.
36. Dorhout Mees SM, Rinkel GJ, Hop JW, Algra A,
van Gijn J. Antiplatelet therapy in aneurysmal
subarachnoid hemorrhage: a systematic review.
Stroke. 2003;34:2285-2289.
37. Siironen J, Juvela S, Varis J, Porras M, Poussa K,
Ilveskero S, et al. No effect of enoxaparin on
outcome of aneurysmal subarachnoid hemor-
rhage: a randomized, double-blind, placebo-
controlled clinical trial. J Neurosurg. 2003;99:
953-959.
38. Ray WZ, Strom RG, Blackburn SL, Ashley WW,
Sicard GA, Rich KM. Incidence of deep venous
thrombosis after subarachnoid hemorrhage.
J Neurosurg. 2009;110:1010-1014.
39. Dai Y, Lee A, Critchley LA, White PF. Does
thromboelastography predict postoperative
thromboembolic events? A systematic review of
the literature. Anesth Analg. 2009;108:734-742.
40. Korja M, Silventoinen K, Laatikainen T,
Jousilahti P, Salomaa V, Hernesniemi J, et al. Risk
factors and their combined effects on the inci-
dence rate of subarachnoid hemorrhage—a
population-based cohort study. PLoS One. 2013;8:
e73760.
41. Nagler M, Kathriner S, Bachmann LM,
Wuillemin WA. Impact of changes in haematocrit
level and platelet count on thromboelastometry
parameters. Thromb Res. 2013;131:249-253.
42. Ogawa S, Szlam F, Bolliger D, Nishimura T,
Chen EP, Tanaka KA. The impact of hematocrit
on ﬁbrin clot formation assessed by rotational
thromboelastometry. Anesth Analg. 2012;115:16-21.
Conflict of interest statement: This work was supported by a
small project grant the CSL Behring Research Grant. The
additional ultrasound scans were provided by a project grant
from the Finnish Intensive Care Society Research Grant.
Received 17 June 2018; accepted 4 October 2018
Citation: World Neurosurg. (2019) 122:e334-e341.
https://doi.org/10.1016/j.wneu.2018.10.035
Journal homepage: www.journals.elsevier.com/world-
neurosurgery
Available online: www.sciencedirect.com
1878-8750/$ - see front matter ª 2018 Elsevier Inc. All
rights reserved.
WORLD NEUROSURGERY 122: e334-e341, FEBRUARY 2019 www.journals.elsevier.com/world-neurosurgery e341
ORIGINAL ARTICLE
ANNUKKA S. VAHTERA ET AL. ROTEM FOR COAGULATION MONITORING AFTER ASAH


